• Welcome to Global Perspectives #2 2025

    HAEi’s CEO and Chairman of the Board, Anthony J. Castaldo, and HAEi’s President, Henrik Balle Boysen

    Dear HAEi Friends,

    We are delighted to welcome you to the second 2025 edition of Global Perspectives – HAEi’s flagship magazine that shares what’s happening in the global HAEi community. Throughout the magazine, you will sense the shared determination of our worldwide HAEi family—people working side by side to bring earlier diagnosis, better care, and lasting change.

    This issue is packed with updates from across our community that include:

    • Country-by-country reports from our RPAs across Europe, the Middle East, and Africa (EMEA), the Americas, and Asia-Pacific (APAC), along with a clear view of what’s next in each region.
    • Record-breaking hae day :-) participation. HAEi Friends logged 211,012,980 steps across 44 countries—a 17% rise over last year—alongside local awareness events that helped more people find their way to diagnosis and care.
    • A feature on LEAP 2025, where 18 students receive specialized advocacy and communication training and mentoring while completing projects designed to help their Member Organizations.
    • Real-world stories of people using HAE TrackR to organize attack and treatment records for clinic visits, and HAE Companion for safer travel—Emergency Cards in 44 languages, ACARE locations, and practical tips.
    • An overview of the US HAEA National Summit, where more than 1,400 people came together to fulfill the meeting’s theme of Embracing a Brighter Future. Sessions focused on disease education, advocating for access to HAE medicines, and ongoing research into new therapies.
    • An HAEi pilot program—the Member Organization Growth & Impact Workshop—launched in Latin America & Mexico. This hands-on meeting brought together leaders from South America and Mexico to set country-specific 12-month plans for increasing diagnosis, awareness, and access. If successful, we’ll conduct this workshop in other parts of the world.
    • An overview of the HAEi/HAEA-sponsored medical journal publication on HAE with normal C1-inhibitor that lays out the current evidence on genetic causes, diagnosis, and therapies.
    • Information about the HAE Insight Series in the Asia Pacific, where expert‑led educational videos are helping healthcare professionals suspect and diagnose HAE earlier.
    • HAEi’s growing presence at major medical congresses in Africa, that is strengthening patient networks and improving diagnosis rates.

    You will also find a lot more information, including clinical trial updates, a roundup of HAE publications, Member Organization news from around the world, and travel guidance.

    In addition, preparations are well underway for the 2025 HAEi Regional Conference EMEA, taking place in Rome, Italy, 10–12 October 2025. We are finalizing details for bringing together 650–700 friends from across the region to connect, exchange knowledge, and strengthen collaboration while enjoying one of Europe’s great cities.

    The content of this Global Perspectives edition reflects a simple principle: Working together across regions, cultures, and experiences enhances the global HAE movement and inspires us to unite and help everyone in our community fulfill their life’s ambitions.

    We are very happy that you are such an important part of the global HAE movement, and we wish you pleasant reading!

    Warmest regards,

    Anthony J. Castaldo


    Chief Executive Officer and Chairman of the Board, HAE International (HAEi)

    Henrik Balle Boysen


    President, HAE International (HAEi)

News from HAEi’s Regional Advocacy team

For our Regional Advocacy team members working with countries in Europe, the Middle East, and Africa, a primary focus over the last few months has been facilitating participation in the 2025 HAEi Regional Conference EMEA. Michal Rutkowski, Patricia Karani, Natasa Angjeleska, Maria Ferron, Fanny Schappler, Jørn Shultz-Boysen, and Fiona Wardman have supported their Member Organizations by answering questions, clarifying procedures, supporting registration and visa queries, and much more to ensure strong representation at one of the main HAEi events of the year. You can read about the non-conference-related activities from our Regional Advocacy team in their updates, and we’ll bring you the full results of their efforts in edition #3-2025 of Global Perspectives.

  • News from Central America and Caribbean

    From Regional Patient Advocate Javier Santana

    Over the last few months, I have had the privilege of continuing to strengthen HAEi’s work in Central America and the Caribbean, collaborating directly with patient group leaders, physicians, health authorities, and representatives of the pharmaceutical industry.

    In Panama, I continued to work closely with HAE Panama’s board of directors, Dr. Olga Barrera, immunologist and advisor to the patient group, and the Ministry of Health (Dr. Cuevas, director of the Department of Rare Diseases), which ultimately approved and authorized the national distribution of the Treatment Guide for Hereditary Angioedema (HAE) in hospitals and emergency centers. The Ministry of Health will make a national announcement to present it to the medical community. Thanks to the efforts of HAE Panama, the country celebrated hae day :-) with educational activities, conferences, and the lighting of government buildings. New patients were also registered.

    Access to medicines is a priority across my region, and I continue to have contact with CSL Bering representatives regarding the official registration process for the Berinert drug in Panama; they advise that significant progress has been made. For Puerto Rico, I met with representatives from CSL Bering and Kalvista to discuss plans and the availability of their medicines on the island.

    A core activity for Regional Patient Advocates (RPAs) is supporting and advising Member Organizations (MOs) with their structure and governance. Recently in Costa Rica, I facilitated a virtual meeting to guide them through a reorganization and the election of a new Board of Directors, and how tools like HAEi Focal Point and HAEi Advocacy Academy can support their advocacy efforts. We have also been working on an effort to update the patient list, in collaboration with immunologists and HAEi, with the goal of establishing an official patient registry in the country. I’ve been able to provide direct guidance to patients regarding specialist physicians and, with the group, celebrated the publication of Tayra Corrales’ book, “Esta también soy yo,” in which she shares her life story as a patient with HAE. We continue to monitor the reduction in government purchases of the drug Berinert, and I met with doctors and pharmaceutical representatives to discuss the issue.

    In the Dominican Republic, our focus is on legislative activities, and we support HAE Dominican Republic on the legislative process, seeking to include HAE in a new national law on rare diseases.

    In my last update, I introduced Trinidad and Tobago as a new member country for HAEi. Since then, we have formally integrated the country as a new Member Organization (MO) and provided access to HAEi’s MO specialist tools and resources, like HAEi Advocacy Academy. We’ve guided Trinidad and Tobago on creating their website, social media platforms, and on how to identify new HAE patients in the country. I also connected them with an HAE-experienced physician who recently arrived in the country from the United Kingdom. I look forward to meeting with this doctor soon.

    This period has been full of challenges, but also important achievements. I am convinced that the collaborative work between patients, physicians, governments, and organizations will continue to bear fruit for the benefit of all people living with HAE in Central America and the Caribbean.

  • News from Central Eastern Europe and Middle East

    From Regional Patient Advocate Michal Rutkowski

    Dear HAE Friends, as we move through 2025, the second quarter has brought significant progress, engagement, and collaboration across the Central Eastern Europe and Middle East regions. Below is an overview of key initiatives and milestones achieved since my last update.

    Continuing earlier outreach efforts, I conducted several one-to-one virtual meetings with patient leads and representatives from numerous HAEi Member Countries, including Armenia, the Czech Republic, Georgia, Hungary, Iran, Kazakhstan, Latvia, Lebanon, Lithuania, Oman, Qatar, Russia, Saudi Arabia, Ukraine, and the UAE. These meetings were an invaluable opportunity to share updates on HAEi tools and resources, gather feedback, and address country-specific challenges.

    To share insights on a couple of these meetings, the discussions with HAE Armenia focused on upcoming clinical trials, LEAP 2025 preparations, and collaboration with health authorities. With HAE Georgia, I heard about their successful HAE & Anaphylaxis Conference in Tbilisi, which over 100 physicians attended and offered guidance on their planning for the 2026 patient meeting.

    Resource localization continues to be a key priority. This quarter, we completed and distributed the “Understanding HAE” patient guide in Armenian and Georgian. Translations of the “Women with HAE” booklet are currently in progress in Hungarian and Latvian. These localized materials play a vital role in increasing awareness and supporting patients at the national level.

    The leads for HAE Saudi Arabia and I collaborated on the content for their newly developed, MO-oriented website hosted by HAEi. I’m pleased to share that our efforts have paid off; you can now visit the website at haesaudiarabia.haei.org.

    In May and June, the Regional Patient Advocates (RPAs) coordinated the second round of the Regional Medical Advisory Panel (RMAP) questionnaire. I worked with the medical advisors across Central Eastern Europe and the Middle East on this. Access to medicines is a high priority, and we supported pharmaceutical research efforts in identifying potential clinical trial sites and advising on relevant trial details in the region. Additionally, I participated in meetings with various pharmaceutical companies, including a Patient Council meeting hosted by Pharvaris and virtual meetings with Astria Therapeutics, CSL Behring, and Takeda.

    In May, as RPA, I was delighted to join HAE Latvia to celebrate hae day :-) during a national virtual patient event. It was an honor to present alongside local physicians, promote stronger advocacy, and introduce HAEi and its global support for MOs. This event led to a closer partnership with the local patient group, and we are now working together on a new website and an advocacy plan for the remainder of the year.

    In June, HAE Poland organized a regional HAE conference in Kraków for patients and their families, which gathered nearly 90 participants. It was gratifying to support the organizers in delivering the meeting. It was the second regional conference held in 2025 and the 20th anniversary of HAE Poland, a significant milestone.

    The past months have highlighted the strength and diversity of our HAEi community. From localization projects and strategic consultations to regional event planning, our collective efforts continue to help expand access, raise awareness, and empower HAE patients.

    I want to thank all Member Organizations for their ongoing collaboration. I look forward to seeing many of you at the 2025 HAEi Regional Conference EMEA in Rome this October!

  • News from East Asia

    From Regional Patient Advocate Yong Hao Lim

    My goal for hae day :-) 2025 was to continue the focus on mental health from last year’s Global Leadership Workshop in Copenhagen, by encouraging patients and caregivers to engage in healthy activities, reconnect with loved ones, and inspire others to do the same. I had #active4HAE wristbands made in purple for some patients and caregivers across the region as a simple and meaningful way to encourage participation and foster belongingness.

    Between April and June, patients, caregivers, and friends across Asia Pacific (APAC) joined the #active4HAE challenge. We logged 277 activities and took around 4.3 million steps, marking a milestone for APAC participation. I am already thinking about 2026 and exploring regional or multi-country events to build on this momentum.

    In recent months, I had the honor of presenting at 2 very different platforms, 1 primarily for doctors and 1 for patients and caregivers.

    On behalf of HAEi, I travelled to Dhaka, Bangladesh, for the 7th International Conference of the Bangladesh Academy of Dermatology. My presentation focused on what patient organizations and healthcare professionals can do to support patients, introduced HAEi, and highlighted recent work showing the impact patient groups have made across APAC. During the meeting, I connected with HAE Bangladesh’s leader and met with local patients and physicians eager to learn about the condition. A conversation with a pediatric dermatologist stood out. She asked if I knew of any HAE training programs, and I shared details of the upcoming EAACI Hong Kong Allergy School in August.

    A month later, I attended the National HAE Annual Meeting in Beijing. During the planning of the meeting, we provided information and any guidance we could on sponsorships. In Beijing, I joined a pre-meeting sharing session with patients and caregivers, gave a short opening address, and took part in a roundtable discussion on improving HAE care and management in China.

    The passionate specialists at Peking Union Medical College Hospital delivered valuable talks on a variety of HAE subjects. It is impressive to have over 20 HAE-knowledgeable physicians at a single institution. Still, for patients spread across a vast country like China, the goal is to have trained professionals in many provinces, and a key point for discussion at the roundtable. The hospital team and HAE China, with HAEi, can work to raise physician awareness nationwide.

    A conversation with Professor Zhi Yuxiang left a deep impression. She commented that many outside China remain unaware that there are at least 1,000 diagnosed HAE patients in the country. Many assume China has no HAE patients at all. This example reinforced my belief that connection is only the beginning. What matters next is what flows from it: the need to know and to share. This dynamic plays out across every level of our work, from individual patients to Member Organizations to Regional Patient Advocates; connecting and sharing is fundamental to advocacy:

    • For example, at the individual level, in Mongolia, a caregiver asked how to get a diagnosis when few HAE-knowledgeable doctors exist. In Singapore, someone relocating wanted to know where to find a physician familiar with HAE. These small, personal questions are crucial first steps toward better care, and providing a lead or contact can change someone’s path entirely.
    • In Hong Kong, the local patient group wanted their work accurately represented and information easily accessible on their website and Facebook page. In Japan, leadership was keen to learn from more mature organizations on strengthening advocacy and to share experiences despite language barriers.
    • Interacting with fellow RPAs, I am exploring how HAE India organizes its community and whether any learnings could help HAE China, and Bangladesh’s Heat Map model sparked Indonesia’s Heat Map idea.

    These past months have reinforced that progress is not just about what we know or do, but also about what we share and how open we remain to learning from each other. By fostering this spirit of curiosity and generosity, we can continue to raise the standard of care for HAE across our region and beyond.

  • News from Mediterranean, North Africa, Benelux and British Isles

    From Regional Patient Advocate Maria Ferron

    The period since the last Global Perspectives magazine has been really exciting, with a lot of activities, advocacy, and awareness efforts taking place.

    Here are some of the top news stories from my region during this period:

    I am thrilled to report that the 1st HAEi Workshop took place in Tunis, Tunisia, on 26 April. Following the foundation of the Tunisian association ANAOH, the number of patients diagnosed has been increasing, and we felt the time was right to bring patients together to introduce HAEi, raise awareness and increase education on HAE, and allow participants to share their experiences. HAEi worked hard on the logistics of the meeting and prepared an engaging agenda, including patient testimonies. We were delighted to welcome around 70 patients, caregivers, and health care professionals. The atmosphere was buzzing. We thank Prof Bouillet from France, who could not attend the meeting but recorded videos to be presented during the meeting, on HAE Modern Treatments & HAE in Pregnancy. The attendees took advantage of all opportunities to ask questions to get more information and clarify any doubts. They had their chance to share their personal experiences, and they contributed new ideas to implement locally to improve the local situation. A huge success!

    After the meeting, Mohamed Osman (HAEi Advocacy Facilitator MENA) and I met with the Member Organization (MO) leads to demonstrate HAEi Connect and the different web designs that HAEi offers through our Hosted Websites resource. The Tunisian MO has now joined HAEi Connect, and they are starting to work on a new website that will help them to share more information with their members and increase their visibility to the public.

    Patricia Karani (RPA for Sub-Sahara Africa) and I had the opportunity to attend the 9th Biennial African Society for Immunodeficiencies (ASID) Congress that took place in Nairobi, Kenya. We presented our experiences of living with HAE, an overview of the current HAE situation in African countries, and HAEi’s advocacy efforts in the African continent. You can read more in the ‘News from MOs’ section from Kenya.

    For other countries in my region, HAEi’s website solutions continue to be popular and successful. I’ve been supporting Meryam Jennane, the Secretary of the Moroccan association (AMMAO), to develop a more sophisticated website and working with Yolaine Nemery (the lead for HAE Belgium) on web2go for Belgium as one of the first steps of boosting the patient group locally (check them out here). Yolaine recently took over as the lead and is building from the ground up.

    Following our HAEi vision, “To unite and strengthen the HAE global community, achieve a world free of barriers where effective treatments are accessible everywhere, and provide a higher quality of life for people with HAE,” I have been supporting Libya in accessing modern HAE treatments. We’ve sent HAEi Board-authored letters to local institutions with a description of the impact of HAE on individuals and their caregivers, and the recommendations for treatment of this disease. To date, there has been no reaction to the letters, but I will continue to insist until we achieve our objective.

  • News from South America and Mexico

    From Regional Patient Advocate Fernanda De Oliveira Martins

    The major news in my region over the past few months was the Member Organization Growth and Impact Summit (MOGIS): South America and Mexico, held in São Paulo at the end of May. It was a significant opportunity for us to connect and share experiences, and support the MOs in my region with training to continue the vital work they do in their countries.

    After the event, more MOs are now using and showing interest in HAEi tools such as HAEi Connect, HAEi Advocacy Academy, and the HAEi Emergency Room poster. Tools like HAEi Connect and the courses on HAEi Advocacy Academy are designed to help MOs build capacity, raise awareness about the disease, and manage their data securely and effectively.

    In recent months, I was able to support physicians treating people with HAE by providing them with more information about the condition and vital connections to other experts. For example, following a message from a doctor in Uruguay who wanted to learn more about HAE and discuss details of a patient, I could connect them with a physician in Argentina who kindly offered to discuss the case with the doctor from Uruguay. This demonstrates the importance of our network and the benefit of having dedicated RPAs in regions!

    Alongside the President of HAE Argentina, Alejandra Menendez, HAEi contributed to a discussion on the assessment of a modern treatment. We provided information about the disease and the importance of having access to modern medicines to prevent and treat HAE attacks. HAEi’s goal is to ensure that all people with HAE have access to medications that improve their quality of life.

    We also welcome Antonio López Huesca to the leadership of HAE Mexico.

  • News from South Asia, Germany, Austria, Switzerland, and Israel

    From Regional Patient Advocate Fanny Schappler

    In the last few months, my focus has been on strengthening collaboration with the Member Organizations (MOs) in my region.

    In South Asia, all MOs are working hard on getting HAEi resources translated into their local languages to reach and help more people living with HAE in their communities. India and Bangladesh are working on an upgraded website, which will enable their members and potential individuals affected by HAE to find life-saving information, tailored locally. A key activity for Regional Patient Advocates (RPA) is supporting local meetings. I was honored to attend the second in-person meeting for patients & caregivers in India, which took place on 18 May in Calcutta. The meeting room was packed with families and physicians alike, which shows the eagerness to connect and learn more about HAE. My presentation highlighted our HAEi patient resources, which are available on our website in several languages

    In Europe, at the end of May, I completed a round of meetings with the MO leaders of the countries I support: Switzerland, Germany, and Austria. These meetings are essential to ensure I understand their operational challenges and how I can best help them. In these three countries, the groups are mature and longstanding organizations. Therefore, the focus is to ensure their sustainability and continuation through established board member roles, digital literacy, and other support as appropriate. Again, in my role as their RPA, I had the privilege to speak at the annual Swiss patients/caregivers meeting held in Zurich on 24 May. My presentation provided an “outside of Switzerland” perspective, sharing the work we do at HAEi in India and other countries with limited resources and healthcare systems. There was also the opportunity to reshare our newest HAEi travel & relocation guide with participants, very timely given that summer was just around the corner.

    I’m excited about the continued journey ahead, supporting my region countries the best I can so they become stronger in their advocacy mission: to help as many people living with HAE as possible in their communities.

  • News from South Eastern Europe

    From Regional Patient Advocate Natasa Angjeleska

    Countries in my region supported hae day :-) from the start of the HAEi #active4HAE activity challenge through to the end of May. Member Organizations (MOs) in Turkiye, Croatia, North Macedonia, Serbia, and Greece organized events to raise awareness and advocate for better care for HAE patients, such as meetings of patients and physicians, public gatherings with joint walks or running, and school sports competitions.

    Regional Patient Advocates (RPAs) can support our countries through participation at their patient’ and physicians’ meetings. I was delighted to join meetings in Croatia in mid-May and Turkiye at the end of June to meet new patients and physicians, and to hear presentations on various activities and results that MOs in both countries have accomplished. These kinds of meetings and face-to-face interaction always bring inspiration and motivation to share different resources and opportunities to cooperate and support. In both meetings, I shared country-specific and comparative data regarding access to medications as well as the influence of HAE on patient quality of life from the HAEi 2024 State of Management survey conducted in South Eastern Europe. The presentation also included a case study to showcase differences in QoL where patients have and do not have access to modern medications, as well as a patient experience where their QoL improved considerably from being on a preventive treatment.

    Regarding HAEi tools and resources, we now have “Women with HAE” available in the Romanian language, all SEE countries now use Focal Point, and the Turkish translation option was approved to be added to the hae day :-) web page as well as HAEi Advocacy Academy (previously, the automatic translation wasn’t of high enough quality to support Turkish participants).

    For other countries in my region, we continued to support MOs on their plans and activities in 2025. I met with a new patient and caregiver representative from Bosnia and Herzegovina and provided details about opportunities to support registering a MO. We also discussed possibilities for access to modern medicines for patients and improving the care for HAE patients. They will participate in the 2025 HAEi Regional Conference EMEA in Rome to hear different experiences from other countries and meet with more MO representatives. During an online meeting with the new board members of HAE Greece, I heard about their plans for this year, including a 24-hour telephone line to get support from experts if you live in Greece, or are just visiting, and you need to receive medication and/or any HAE-related information.

    A key aspect of the RPA’s role is to share information across our networks, whether MOs or physicians. I have promoted ACARE educational webinars with doctors in the SEE region and shared the HAEi Regional Medical Advisory Panel (RMAP) questionnaire with the SEE RMAP.

    As part of the resources HAEi promotes to support children, you can find the children’s books I’ve written about a boy with HAE who gets help from a Talkative Little Balloon.

    The third book, “The Rare Boy on a Race: I swell but you cannot tell” is now available in Spanish. As part of the activities to mark hae day :-) I was honoured to speak about the inspirational background of writing children’s stories and the significance of having children’s literature and this kind of resource available for children with HAE, at a webinar organized by a Spanish caregiver who works at the University of Alicante and is a member of AEDAF.

    Reading the book with children makes a good starting point for a discussion about what HAE is all about. You can find the Rare Boy and the Talkative Balloon series, and other wonderful resources for children, on the HAEi Youngsters’ website.

  • News from Sub Sahara Africa

    From Regional Patient Advocate Patricia Karani

    In my region, I have seen an increase in people who do not have a correct diagnosis reaching out to me through our social media pages or through the Member Organizations (MOs) in their countries, to try to get their uncontrolled swellings resolved. We can support these patients through doctors we have trained on HAE in these countries, as they try to establish the correct cause of uncontrolled angioedema. As a result, we’ve seen an increase in new correctly diagnosed HAE patients in the region, and the doctors are working hard to ensure these patients have the right treatment and management plans.

    Sub Sahara Africa is also experiencing an increase in doctors who are interested in being part of the HAE community. HAEi has many resources available to support doctors and patients, and these are available in many different languages. The doctors share their gratitude for resources in local languages, as this helps resolve some barriers, as Africa has a great diversity in languages within different countries. One resource I have shared is the HAEi Emergency Room posters, now available in multiple languages, and they are being well-appreciated. Also important to the doctors is the 2021 revision and update of the global WAO/EAACI guideline on the diagnosis and management of HAE, information on new treatments for patients, and individual efforts on ways to access modern therapies for their patients in their countries.

    Patients from African countries are travelling to secure accurate diagnosis and management plans from 2 ACARE centres in Sub Sahara Africa: Kenya and South Africa. With the care and guidance of Dr Priya Bowry, ACARE, Kenya, and Dr Jonny Peter, ACARE, South Africa, we are greatly assisted in identifying new HAE patients in the region.

    I have been working with MOs who have realized more vibrant patient awareness activities in their countries. This activity has, in turn, helped the MOs to get more assistance from various civil society groups. The result is they can reach a wider audience in their countries and, for HAE Mozambique and HAE Kenya, lead to an increase in diagnosed HAE patients and organization members.

Update from HAEi’s Global Advocacy

  • Fiona Wardman, Executive Vice President and Chief Advocacy Officer

    Advocacy Highlights: A regional focus

    HAE advocacy works best when it is close to the nuances and needs of the people it serves. For that reason, I want to highlight a few recent projects, some of which you’ll read more about in this magazine, that showcase how HAEi continues to advance its advocacy efforts through strategic, community-informed initiatives.

    HAEi listens from the ground up
    The Regional Medical Advisory Panel (RMAP) questionnaire ensures our work remains aligned with the real-world needs of HAE patients and healthcare providers. The second round of the questionnaire to our physician network in countries across the world focused on barriers and needs:

    • What are the common barriers faced by patients in receiving timely HAE treatment?
    • What HAE-related training or information is currently available to healthcare professionals?
    • What support mechanisms are most needed by patients?
    • How prepared are emergency departments to handle acute HAE attacks?

    By gathering these insights, HAEi ensures that our work in education, awareness, and resource development closely aligns with real-world needs. We look forward to sharing the outcomes of this data-driven initiative in the next edition.

    Empowering Member Organizations (MOs), one region at a time
    HAEi has developed a hands-on workshop to empower MOs with tools to drive meaningful, localized advocacy. This engaging and tailor-made pilot project launched with MOs in HAEi’s South America and Mexico region. The immersive workshop addressed specific regional needs, offering hands-on support to strengthen community impact and accelerate advocacy through concrete, actionable plans. It represents a new model of support—grounded in partnership, purpose, and progress—that we aim to expand to other regions.

    Straight to video: HAE Insight Series in Asia Pacific (APAC)
    A new video series, called The HAE Insight Series: Understanding HAE in Asia Pacific, has been developed to support physicians. Our State of Management of HAE survey in our APAC MOs spotlighted the levels of HAE underdiagnosis and misunderstanding in the region. We produced the films to improve awareness, understanding, and diagnosis of HAE by healthcare professionals in the APAC countries. The videos feature HAE Experts Dr Ankur Jindal from India and Prof Philip Li from Hong Kong, who cover essential themes:

    • The impact of HAE
    • Key HAE symptoms
    • Differential diagnosis
    • The difference that early diagnosis and treatment can make
    • Global and local resources for support and education

    There is also a video sharing real-life patient experiences from Indonesia, India, and Thailand, which reflect the human impact of the disease. HAEi acknowledges a grant from Takeda Growth & Emerging Markets (GEM), which made the development of this video series possible.

    You can watch all the films in the series on the HAEi website.

    HAEi’s growing footprint in Africa
    HAEi has welcomed a growing number of new MOs from the African continent in recent years. We are thrilled to witness the expanding presence and influence of HAE advocacy across Africa, which has contributed to an increase in diagnoses and the emergence of new patient communities in multiple countries. To further support all groups in Africa, some fledgling and others established, we were proud to support a dedicated session on HAE at the recent 9th Biennial African Society for Immunodeficiencies (ASID) Congress in Nairobi, Kenya. This activity is part of HAEi’s ongoing commitment to the region and is made possible through collaborative efforts and partnerships with a wide range of stakeholders.

    Overall, these projects reflect HAEi’s ongoing commitment to listening, partnering, and building sustainable impact worldwide. We are always looking to partner on regionally and locally-led programs and projects.

    If you would like to discuss any ideas or opportunities, please don’t hesitate to contact me.

  • The key to better care in HAE

    Latin America’s missing 80% may hold the key to better care in HAE

    The power of advocacy to find, diagnose, and treat all HAE patients

    “Every diagnosis could be a lifesaver for the individual, but it could also save someone else,” Fiona Wardman, HAEi’s Executive Vice President and Chief Advocacy Officer, said as the leaders of Member Organizations (MOs) from across South America and Mexico met in Brazil. She was speaking at the start of a new, regionally-led, action-oriented HAEi meeting. But with the biggest challenge facing the region being access to modern, life-saving HAE treatments, why is diagnosis so important?

    The latest HAEi State of Management research for this region revealed the stark statistic that only 21% of the expected number of HAE patients have a confirmed diagnosis. The power of advocacy, the MO leaders heard, stems from communicating the scale of the need. Every diagnosed patient potentially means more priority, interest, and action from healthcare professionals, politicians, and policymakers. Increasing the focus on HAE with these stakeholders will help address the regional situation where most countries lack access to modern therapies to prevent HAE attacks.

    The 2-day meeting, called the Member Organization Growth and Impact Workshop, was led by Fernanda de Oliveira Martins, Regional Patient Advocate for South America and Mexico. The event focused on practical, hands-on training to implement HAEi tools and grow MO capacity, with interactive, skills-based sessions and action planning. The aim is to drive tool adoption, MO growth, local impact, and accountability. This is vital as we see MOs that use more of HAEi’s tools and resources are significantly more likely to gain access to medications.

    HAEi last conducted our State of Management research in Latin America around 10 years ago. Compared to 2015, there are reasons for optimism within the data; countries in the region had seen increases in the number of people diagnosed and greater treatment availability. Fernanda commented on this: “The momentum for modern treatments in our region is growing, so it is vital to build on this by making sure our MO leaders have the right data, skills, and know-how to get more patients on the modern treatments that will save and transform their lives. This starts with knowing who has HAE.”

    Mechi Menendez and Alejandra Menendez from HAE Argentina captured the spirit of the meeting: “Surely the next time we meet, we’ll all be a little better off and a little closer to the ultimate goal: that no HAE patient in Latin America remains invisible or without access to the treatment they need. Let’s celebrate every victory, every step taken, and every achievement.”

    After hearing the latest regional data, Fernanda facilitated a discussion about the regional and local priorities and how the HAEi’s resources and tools could play a role. The second day focused on how each MO could develop an actionable work plan that would turbo-charge advocacy and drive meaningful change in communities. At every step, Fernanda, Fiona, and Michal Rutkowski, HAEi’s Director, Regional Advocacy Program, were on hand to support the process. Plans included:

    • Identifying the need
    • Defining the objective
    • Outlining the necessary steps to achieve each goal
    • Identifying required resources
    • Selecting HAEi tools that support each step
    • Constructing a 12-month work plan.

    The meeting was well-received by the participants. Speaking after the Summit, Carlos Carvajalino from HAE Colombia, commented: “With a deep understanding of our realities as Member Organizations, you made possible a meeting that was truly transformative. Today, we feel more connected, more prepared, and more hopeful in our work.”

    The Summit is currently a pilot. Early indications from the participant survey are that the event was a success and will deliver impact in the region:

    • 100% of respondents said the Summit was excellent or extremely useful
    • 100% of respondents would attend a future Summit
    • 100% of respondents said they feel more confident and more equipped to advocate as an MO as a result of the Summit

    HAEi will evaluate the sessions using feedback from the participating MOs to refine and strengthen the meeting. Following this, HAEi will explore ways to roll out this important event to more regions, as it complements and builds on the success of HAEi’s global and regional conferences by filling a critical gap with its hands-on, intensive agenda.

  • Start suspecting HAE, doctors told in new educational films

    Like any great detective drama, there’s always a suspect. The same applies to HAE, according to Dr Ankur Jindal: ‘Always keep HAE in your mind. If you see angioedema, suspect HAE,’ he tells his fellow professionals in a new series of HAEi-produced films about the disease.

    These new films have been produced to improve awareness, understanding, and diagnosis of HAE by healthcare professionals in the countries that make up the Asia Pacific region, as the disease remains underdiagnosed and misunderstood. Prof Philip Li, one of the experts featured in the videos, explains: ‘Historically, many countries in the Asia Pacific region faced similar challenges; HAE was largely unknown among healthcare providers and often dismissed as non-existent. This lack of awareness and infrastructure created a sense of inertia that made meaningful progress seem out of reach.’

    The video series, called The HAE Insight Series: Understanding HAE in Asia Pacific, is designed to support physicians by highlighting key symptoms, guiding differential diagnosis, and sharing real-life patient experiences that reflect the human impact of the disease.

    The full series is:

    • Recognizing the Symptoms of HAE: What Physicians Need to Know
    • Diagnosing HAE: Clinical Steps and Considerations
    • Guiding the Way: Information, Resources, and Next Steps
    • The Human Impact of HAE: What Doctors Don’t Always See

    Each video features expert insights from healthcare professionals across the region (Dr Ankur Jindal from India and Prof Philip Li from Hong Kong), as well as powerful patient stories that emphasize the urgent need for earlier diagnosis. Dr Ankur Jindal comments: ‘There is a remarkable lack of knowledge about HAE amongst healthcare physicians in most Asia Pacific countries. I am glad to be a part of this initiative, spreading the word about HAE to the healthcare community. I am sure this will help in improving the diagnostic rates of HAE in this region.’

    Prof Li suggests that the situation in Asia Pacific is improving fast, but there is a lot still to do: ‘Many Asia Pacific countries have not only caught up but in some cases surpassed global standards in HAE care. Given that the region represents half the world’s population, there remains great potential to identify and treat many more undiagnosed individuals, ultimately achieving equitable care for all HAE patients.’

    Awareness of HAE is a vital first step towards timely diagnosis and effective treatment. It is hoped these videos will ultimately help improve outcomes for people living with HAE, which is a key goal of HAEi. Speaking of his own experience in Hong Kong (HK), Prof Li comments: ‘Without HAEi connecting us with international expertise and integrating HAE HK into the broader global community, it’s difficult to imagine how much progress we could have made on our own.’

    You can watch all the films in the series on the HAEi website, here. Please share with your network of patients, caregivers, and healthcare professionals to spread the message as widely as possible.

    HAEi acknowledges a grant from Takeda Growth & Emerging Markets (GEM), which made the development of this video series possible. These videos were produced independently. The opinions and views expressed in these videos do not represent those of Takeda.

  • HAEi advocates at a key African medical congress

    HAEi representatives were recently in Kenya to advocate for people with HAE, during the Biennial African Society for Immunodeficiencies (ASID) and Allergy Society of Kenya (ASOK) Congress.

    Africa is an important focus for HAEi, as there are too few diagnosed cases of HAE, and knowledge of the condition amongst healthcare professionals is low. As a result, when Patricia Karani, the Regional Patient Advocate (RPA) for Sub Sahara Africa, and Maria Ferron, RPA for Mediterranean, North Africa, Benelux, and British Isles, had the opportunity to be part of the Congress, the invitation was gratefully accepted.

    The Congress, held from 25-27 June 2025 in the Kenyan capital, Nairobi, was attended by healthcare professionals from across Africa. The focus was on patient care in the era of personalized medicine, a theme perfectly suited to the aims of HAEi.

    At a special symposium, supported by HAEi, Dr Priya Bowry, a Kenyan allergist and a specialist in HAE, presented on the condition in the context of African countries. She explored the clinical realities of HAE, including data on the disease across the continent. Dr Bowry then invited Patricia and Maria on stage, so the assembled healthcare professionals could hear first-hand about their life with HAE, and the advocacy work of HAEi.

    Maria commented: “During our presentation, we shared with the public our journey to diagnosis, pointing out the differences between countries; how it is to live with HAE in Africa, where the situation in recent years has improved considerably in some North African countries, and the current picture regarding access to modern treatment.”

    Patricia said: “Our presentation aimed to raise awareness of HAE among African healthcare professionals, explain our roles as patient advocates, and the work of HAEi. I think that the positive impact on HAE in Africa will be felt in the future.”

    With rates of diagnosis of HAE low in African countries, there is an urgent need to address healthcare professionals’ awareness and understanding. HAEi is always on the lookout for opportunities to engage and raise the focus of HAE. Michal Rutkowski, Director, Regional Advocacy Program, commented: “We know that healthcare professionals across Africa want to hear the patient voice. Maria and Patricia were able to discuss their own experiences as patients, as well as advocate for everyone with HAE. This combination of personal experience and professional advocacy is a powerful way to raise awareness and increase diagnosis and treatment.”

    There are HAEi Member Organizations (MOs) in many African countries. You can find out more and search for your local MO here. Additionally, Dr Priya Bowry runs 1 of the 2 ACARE-accredited HAE clinics in Africa. You can find out more about ACARE and search for centres here.

  • hae day :-) 2025 is a record breaker

    We’ve collected the activities and counted all the steps, and you – our HAE community – smashed it, putting your best foot forward for HAE awareness with a massive 211,012,980 steps for hae day :-) 2025. A 17% increase from 2024!

    All those step-related activities add up to 4 trips around the world, a new record for hae day :-)

    Fiona Wardman, HAEi Executive Vice President and Chief Advocacy Officer, said: “There’s always so much going on for hae day :-) and this year, our community took even bigger strides! Every event is the power of advocacy in action. When we work together, there’s no limit to what we can achieve.”

    This massive step count resulted from the 8,731 activities logged on the official hae day :-) website, as part of the ongoing physical and wellbeing activity challenge, #active4HAE, now in its third year. In 2025, individuals and groups from 44 countries took part, many answering the call to be #active4HAE in purple. Here are just a few of the images shared.

    You can see the activity tables for the #active4HAE challenge as well as our collective final results at our hae day :-) website, haeday.org.

    You can also see if you can spot yourself in this specially produced photo-mosaic from HAEi’s RPA East Asia, Yong Hao Lim.

    Why purple?

    Purple is 1 of the colors in our hae day :-) logo and has been adopted by many HAE Member Organizations (MOs) as the color they use in their activities for hae day :-) such as releasing balloons or lighting up buildings. It is also a color associated with rare diseases, as it is one of those used by Rare Disease Day.

    Member Organizations’ creative awareness

    Illuminated buildings, books, a concert, and patient days are just some of the examples of creative MO activities that took place during hae day :-) 2025. In Ireland, the medieval Swords Castle, located outside of Dublin, was an imposing sight bathed in purple light to celebrate 16 May. This was the first time a monument had been illuminated in Ireland.

    AEDAF (HAE Spain) collaborated with the Madrid Marine Infantry Symphonic Band on a benefit concert. To the best of Global Perspectives’ knowledge, this is the first time a concert has been held as part of hae day :-). You can watch the whole concert and see how they incorporated #active4HAE in purple.

    Even if you can’t see them, they exist

    Our main mission, as members of AEDAF and as patients diagnosed with HAE, this rare disease, is to spread the word so that it can be known and researched. It’s difficult when these diseases are invisible and they’re invisible, because the percentage of people who suffer from them is so small that it seems as if they don’t exist. The same thing happens with music. Music can’t be seen, but it can move everyone through sounds made by instruments or voices, and they also substantially vary the same melody, just by changing the person playing it. The same thing happens with angioedema. The same disease, the same symptoms, and it affects those who suffer from it in completely different ways.

    With this concert, we at AEDAF wanted to unite these two invisible concepts: rare diseases and music. And through the latter, which has the power to be heard with the heart, we wanted to give visibility to the former.

    May music serve as a platform so that the voices of people who need to be heard, accompanied, and understood can be heard.

    I would like to thank the Spanish Navy, the Madrid Marine Infantry Band, led by its director, Miguel Ángel Mateo Gijón, and the AEDAF partner companies, CSL Behring, BioCryst, and Otsuka, for their support in this project.

    Through it, we have been able to demonstrate that, even if they are not visible, rare diseases do exist.

    Juan Carlos Valera Ramírez, Vice Presidente AEDAF

    In addition, hae day :-) saw patient information events take place in Greece, Portugal, and Italy (to name a few), giving people with HAE and caregivers a chance to meet, share experiences, and have their questions answered by HAE experts. To coincide with hae day :-) 2025, the popular The Rare Boy and the Talkative Little Balloon by Natasa Angjeleska was translated into Spanish, while HAE Costa Rica officially launched another book, this time sharing the experience of a single patient.

    That’s just a snapshot of all the powerful advocacy and awareness activities that took place. Thank you to everyone who took part in making hae day :-) 2025 such a success! If you’re excited for next year, don’t forget to keep an eye on the HAEi website for more details about hae day :-) 2026.

  • LEAP 2025: The students start an incredible advocacy journey

    Unprecedented weather in Dubai may have put LEAP 2024 on pause, but it just made organizers Nevena and Debs more determined. Even floods in the desert can’t stop HAEi’s youth advocacy and education program for long! The LEAP program, which allows young people to learn new skills and develop as individuals and advocates, returned bigger and better than ever for 2025.

    “Classes were so entertaining, including the breaks. I was always excited to learn more and to interact with my classmates.”
    – LEAP 2025 Student

    The postponement meant LEAP could take another step forward. Every Student due to be part of the class of 2024 was offered a spot in 2025, along with a cohort of new students. The in-person seminar grew from 2 days to 3, meaning more time for students to learn, reflect, share experiences, and get to know each other. It also provided an opportunity for HAE expert Dr Carolina Vera to sit down with the students and answer their questions.

    Learn about the LEAP students

    LEAP welcomed 18 students into the class of 2025; sadly, a broken leg meant 1 person had to withdraw just before the kick-off seminar in Copenhagen. Here are some key facts about the student body:

    • 6 out of 10 of the group were people with HAE. The other participants were caregivers to a sibling or another family member
    • Students came from as far apart as Finland in northern Europe and Peru in South America.
    • With attendees from the US and India, and every HAEi conference region represented, participants came from over half the planet.
    • Students ranged in age from 17 to 25. Some were still studying, others were working, and 1 was planning their wedding.

    While at the in-person kick-off seminar in Copenhagen, the students received tailored education to reflect their project proposals, making sure each participant learned what they needed to turn their ideas into a reality, in collaboration with their Member Organization (MO). In addition, the HAEi Board of Directors meeting was taking place at the same time, offering further opportunities to network and share experiences.

    A new aspect of LEAP 2025 was the support of pharmaceutical industry sponsors. Their presence allowed every LEAP student to meet members of the industry and understand more about the process of developing medicines, and to advocate for the needs of their community through networking and focus/advisory groups, building vital relationships.

    “This is fantastic for community-building. I appreciated the way the industry was involved. I believe we de-mystified the industry a bit, and I hope we inspired the Students. We are all working to make the lives of people with HAE better, and I hope we could transmit this.”
    – LEAP 2025 Supporter

    As well as the education, there was time for fun too, with evening events including group dinners, an #active4HAE walk and talk, and the chance to see some of what the beautiful Danish capital has to offer.

    “It was incredibly inspiring to feel the collective passion for advocacy and to gain practical tools that I can apply to improve support and awareness in my own community.”
    – LEAP 2025 Student

    Over the weeks following the in-person meeting, students have been undertaking bespoke online educational sessions that allow them to learn at their own pace. Nevena and Debs have been checking in with every student to ensure they feel supported as they further develop their projects towards completion later this year.

    Nevena told us: “The LEAP Class of 2025 is so inspiring. The young people are so motivated, which made our job even more joyful. We just know that there are going to be so many exciting ideas and projects taking place in the coming weeks and months. Congratulations to everyone!”

    Once the online education is complete, the students will be working with their MO to deliver their project. You can keep up with the latest news from the Class of 2025 here.

    For LEAP 2025, HAEi acknowledges the generous support of diamond supporters BioCryst and Pharming; gold supporters KalVista and Pharvaris; and silver sponsor Astria Therapeutics.

  • App helps people like you take control of your HAE for better care

    Get on the right HAE TrackR

    Life with HAE can feel like it’s all about keeping score. Records of attacks are scribbled on scraps of paper. Forgotten folders full of information on past medications. Despite all of this, doctors can be left unable to see the complete picture, which can get in the way of good care. These are just some of the reasons patients told us they put down the notepad and picked up the phone to download HAE TrackR.

    HAE TrackR is a tremendous support for us. You usually carry your mobile phone with you, so you can document or review your progress at any time. It’s a huge improvement over paper-based documentation. It’s very easy to use and also allows you to add your own comments. It greatly simplifies communication with doctors.”

    Caregiver, Germany

    Both Michal and his son, Louie, have HAE, but finding a pediatrician to supervise Louie’s care was proving tricky without evidence of frequent and severe attacks. Using HAE TrackR, Michal was able to put all the information in one place and crucially share it with a supportive physician to get their help. As a result, Louie receives the regular medication he needs without constant appointments, so the whole family doesn’t have the stress and worry of an attack. 

    Another user told us that HAE TrackR helps them keep better records of attacks. “I would have written them down in notes or somewhere on a calendar, but this way I have a better overview.” The app enables them to track the chronology of attacks and their frequency, allowing them to see any patterns more easily. Another person with HAE, from Nepal, told us that the app has helped them track episodes and email these to their doctor, making their life simpler. 

    HAE TrackRalso allows people to be more proactive. Troyce, from the United States, who lives with HAE and is also a nurse, told us that she can set reminder notifications for her preventative treatments and keep records of the lot numbers of the medicines she has used. She said: “As a patient, I know how it can seem overwhelming with doctors, pharmacy, and drug manufacturers all wanting information about ‘how are you doing’. The app provides an easy and concise place to keep it and share it if I want to. Additionally, as a nurse working to help patients gain access to HAE therapies here in the US, I help patients understand that documentation is so important for continued care.”

    “I truly believe it’s a great tool for better follow-up with our doctors and for assessing the most appropriate medication for us.”

    Patient, Mexico

    Developed by HAE patients for HAE patients, HAE TrackR is available for free from both the Apple App Store and Google Play Store. All data is securely held, with privacy built in, and patient information can only ever be shared by the individual themselves. 

    Patients and caregivers just like you are using HAE TrackR to get better care. Visit haetrackr.org now to learn more and download the app. 

  • An HAEi Postcard from Baltimore

    Global Perspectives invites you behind the scenes of the US HAEA National Summit 2025

    They often say things are bigger in the US. That’s certainly true with the recent US HAEA National Summit. Over three days, 1,400 people with HAE, caregivers, healthcare professionals, and industry personnel descended on Baltimore, Maryland. A small team from Global Perspectives was at the US National Summit to bring back a flavour of one of the largest gatherings of the HAE community. With so much going on across literally dozens of sessions and rooms, this ‘summit diary’ aims to give you a sense of some of the most interesting and exciting developments in US HAE advocacy.

    The theme of the meeting was ‘Embracing a Brighter Future’, as the overall picture for HAE treatment is looking so positive. To date, there are 10 approved treatments available to HAE patients in the US, with a further six currently in development. For some in the global community, it may seem an enviable state of affairs. However, the situation was described as uncertain, with speakers addressing the challenges people with HAE in the US face when securing and maintaining access to effective medicine. Despite the obstacles and the difficulties recounted, those present were reminded of how fortunate they are compared to the situation in other countries. Tony Castaldo, CEO and Chairman of HAEA, used his opening remarks to remind people of the need to ‘protect what matters’ and continue fighting to preserve the gains achieved.

    Thursday – Advance HAE Scientific Registry

    Attendees began arriving on Thursday 10 July 2025, with the program officially starting on Friday. While many of the pharmaceutical sponsors were still building their stands, Global Perspectives avoided the packing crates and found the HAEA team running the Advance HAE Scientific Registry. This program, launched in 2009, is designed to help researchers resolve the remaining mysteries of HAE and accelerate the advancement of future therapies.

    As it was arrivals day, Global Perspectives expected to see a few people completing questionnaires. Instead, we dropped in on a full clinic, with healthcare professionals taking blood samples and processing them. Over the two official days of the Summit, 198 people took part, bringing the total number of participants in the Registry to 1,438. There are now over 9,000 samples in the bioregistry held at the University of California, San Diego. Every individual will be followed in the coming years, so their personal experiences of HAE can be tracked, providing scientists with a better understanding of the condition.

    Friday morning – Professional-Scientific Track

    Welcoming over 200 healthcare professionals and pharmaceutical industry staff, Tony Castaldo told the audience that the overall aim of the Summit and the HAEA is to unite people, whether they are patients, caregivers, healthcare professionals, or industry partners. Tony reminded everyone that the HAEA is highly active in advancing the science of HAE by producing and publishing its own research and supporting knowledge exchange through gatherings like this. He noted that one of the issues for doctors and patients is navigating the US system of health insurance, and that this will be discussed in both scientific and general Summit sessions. Tony encouraged the healthcare professionals present to work with the HAEA, as the organization has the expertise to support doctors in addressing funding challenges.

    Learnings for the global community

    It can be helpful to establish a partnership with HAE specialists for access to HAE medication. Advocacy organizations can help provide data and knowledge about living with HAE, which can help healthcare professionals and people with HAE to make strong arguments to secure funding or reimbursement.

    You can read our summary of the discussion in the scientific sessions here.

    Friday afternoon – The main room takes centre stage

    After lunch, all eyes turned to the giant ballroom that housed the general conference sessions. As the 1,400 representatives of the US HAE Community took their seats, they were welcomed by Tony Castaldo, HAEA CEO and Chairman of the Board, along with HAEA President and Board Member, Henrik Balle Boysen.

    Tony and Henrik began by reinforcing the theme of the conference, Embracing A Brighter Future. The theme demonstrates how far the community has come and how much more opportunity there is ahead to improve the lives of people with HAE. “What is important in the future,” Tony said, “is engagement with as many people as possible, to show the value of being part of an organization that can strongly advocate for their needs.”

    Tony showcased the range of HAEA’s highly successful programs and how HAEA’s support has helped individuals with medication challenges. You can read more about the exceptional work of the HAEA in their latest Annual Report, available for 2024.

    Henrik reminded people that there are still challenges to be faced as a community. He and Tony used the phrase ‘ Protect What Matters’ to rally the conference delegates to be ready. There have been increasing issues with denials and delays. While problems with Medicare have been addressed, they demonstrate the need to avoid complacency. Tony also mentioned the need to participate in research and trials, as there can be no guarantees that future rounds of treatment approvals will be as positive. In conclusion, the two HAEA leaders reminded the participants of the innovation and creativity present in the HAE community and how the HAEA’s history showed what can be achieved when everyone works together.

    What’s next for HAE – What you need to know

    Dr Marc Riedl came up to the stage to discuss what he felt were some hot topics in HAE, broadly categorized into diagnosis and management. Starting with diagnosis, Dr Riedl told the audience how refreshing it is to hear that HAE patients have educated their family doctor or a doctor in the emergency room. This is something he encouraged everyone to do (if you can).

    Recognising the work of both the HAEA and HAEi, Dr Riedl said that diagnosis is a lifesaver. For Type-1 and Type-2 HAE, there are good tests. With HAE-nl-C1INH it is more difficult. There are 6-8 genes that are identified as causing HAE-nl-C1INH, but not everyone with the condition has one of these. One solution is to look at the system in the body that goes wrong in people affected by a form of HAE. This can happen at the very top of a cascade of biochemical reactions, at the bottom, or somewhere in between. To help with this, Dr Riedl referenced the work of Drs Zuraw, Bork, and Maurer in developing a standardized way to try to reach a diagnosis of HAE-nl-C1INH.

    Moving onto management, Dr Riedl noted that HAE Type-1 and Type-2 were only really discovered around 60 years ago, and progress in this time has been remarkable. In the last month alone in the US, there have been two new medicines. There are oral therapies. There are biological medicines that may only need to be given two or four times a year. There are RNA-targeted therapies, and then there’s the possibility of editing out the faulty gene causing the HAE.

    It may seem, Dr Riedl admitted, that there might not be a need for so many options. The need is there because there is so much variability among individuals. What will work for one won’t necessarily work for others.

    Moving on to the importance of clinical research, Dr Riedl reminded people that advances in care come because people with HAE share their experiences. This way, we know about how the condition affects quality of life. He encouraged people present to take part in surveys and trials, and ‘use it as an opportunity to get better for yourself, and for your community.’

    In closing, Dr Riedl told the audience about how hard everyone is working to make HAE as small a thing in people’s lives as possible. He wanted people to know it’s there, but that it doesn’t interfere with life.

    Protecting access to HAE therapies

    The importance of this topic to people with HAE in the US was reinforced by the time dedicated to this subject: this was one of three sessions across the two days of the Summit.

    Although highly specific to the US healthcare system, some of the discussions are relevant to anyone, anywhere, who may be struggling to access effective HAE medication. Here are the top tips from the panel:

    • Communication is one of the most important things. Everyone needs to talk. The patient and the doctor can make a formidable team in challenging decisions.
    • Every patient should understand the power of their personal story. Be prepared to say clearly how vital medication is and how HAE affects your life. Only the person with HAE can do this.
    • Understand that there are (almost) always opportunities to appeal. Never take no for an answer. Talk to your doctor. Work with your HAE organization. Reach out to HAEi. You are never alone.

    HAEA-initiated research programs

    Next on stage were HAEA Research Advisor Deborah Corcoran, along with Christine Selva, HAEi’s Senior Director for Health and Research, and CEO and Chairman Tony Castaldo.

    Ms Corcoran, a self-proclaimed data obsessive, opened the discussion by asking about HAEA’s advocacy research and why it’s vital.

    Tony responded that insurers, and those who make the decisions about access to and reimbursement of medicines, will only consider paying for medicines when presented with real-world evidence demonstrating the horrific burden of HAE and the life-changing benefits brought by modern medicines. This is different from the clinical research that pharmaceutical companies undertake. HAEA research, which is similar in outlook to that done by the HAEi, generates data on how the disease and its treatment impact the everyday lives of patients.

    The following research programs, either ongoing or concluded, were discussed:

    • Work to understand the value of treatments for HAE beyond cost
    • The impact on patients when payors deny or delay access to treatment
    • A new US-validated tool to specifically measure how HAE affects quality of life
    • A shared-decision-making tool
    • An expert consensus update of our understanding of HAE-nl-C1INH and how it is treated. For the first time, this makes clear that treatment is critical following a diagnosis, even in the absence of a known genetic mutation or biomarker.
    • Estimates of the prevalence of HAE in the US
    • The impact of HAE on the lives of caregivers and on pediatric patients
    • A snapshot of the current well-being of the entire US HAE community, led by the HAE Medical Advisory Board
    • A study to understand how HAE changes for people over a 12-month period

    The clinical papers published as a result of the HAEA research are all available for free online. All those on stage encouraged people to read and share the information, and thanked them for their participation in the research projects. ‘We simply cannot do this work without you,’ Tony concluded.

    HAEA – Driven by impact

    A hugely impactful personal story was given by youth advocate Noah Davis. He spoke eloquently and powerfully about the impact of advocacy on his life. He focused the audience on two things that he had learned to date:

    • People care. There are always individuals and groups out there that will help you and support you. You are never alone.
    • There is power in your story and your voice. He told the audience that they have the power to change the world.

    Ask the Experts Q&A

    The final session on Friday was the first of two expert Q&As spread across the Summit. In the first, Dr Bruce Zuraw moderated a panel consisting of Dr Sandra Christiansen, Dr Henry Li, Dr William Lumry, and Dr Timothy Craig. The questions were many and varied, and we present a selection here.

    I’m expecting my first child. When’s the earliest I can get the baby tested?
    It is possible to test the baby still in the womb, either through a tissue sample or from blood in the placenta.

    Since going through the menopause, I’ve had fewer HAE attacks. Will this continue?
    The course of HAE is never entirely constant. For some, it will get better, for others, it will get worse, and for some, there will be no change. What happens to one person, such as the drop in hormones after the menopause, does not mean there will be no more attacks.

    What is the impact of changes in diet on HAE?
    Doctors don’t have the answer to this. For some people, changes in their diet can impact their well-being and the severity of their disease, but this will be completely individual. There is no evidence to suggest any benefit, right now.

    Are there any long-term side effects for children on HAE prophylaxis?
    The doctors felt it reasonable to assume specific medications for HAE are safe, as there is nothing to suggest any long-term side effects. The doctors were keen to stress that long-term use of androgens (steroids) is highly likely to have significant long-term side effects, especially on young children.

    Should family members without symptoms get tested?
    Yes, the doctors said. If you have an attack, anywhere in the world, and you don’t have treatment because you are not diagnosed, you are at risk.

    Does your overall health affect the severity or frequency of attacks?
    As with the question about diet, none of the doctors was aware of any data to confirm if overall health and fitness had any impact. Dr Christiansen suggested that doing all the things which help health, such as getting plenty of exercise, eating a good diet, and avoiding bad things, may minimize the impact of any health condition.

    Youthful antics

    As the Summit came to the end of its first day, Global Perspectives got a peek at what was going on in the Youth Track. The HAEA team was expecting over 200 young people in both the Brady Club (for children aged 4-12) and Youth (13-25 year olds). Dedicated professionals from The Painted Turtle took care of the Brady Club, with workshops, films, and games. The Youth group likewise had fun, learned from each other, and from healthcare professionals.

    Saturday

    It was another early start on the Saturday, with a packed agenda. Some of the session topics were dedicated to sharing knowledge that we’ve covered in our Professional-Scientific Track snapshot (such as HAE-nl-C1INH and pediatric research), so this is a selection of the other topics discussed.

    HAEA grassroots advocacy network

    In the US, the HAEA maintains a powerful network of people with HAE who are committed to engaging with their elected representatives to advocate for the needs of people with the condition.

    Jess Myers, HAEA’s Advocacy and Communications Manager, was joined on stage by a specialist in lobbying policymakers, Dane Christiansen.

    Jess told the audience that it is essential to overcome any sense of ‘imposter syndrome’. Everyone has the power to be an advocate for HAE. Telling someone about HAE is advocacy. You don’t have to speak to a politician. Just being happy to communicate about your condition to anyone outside the community is advocacy.

    Jess outlined some of the HAEA programs underway in the Grassroots Advocacy Network. There is training for people, and pre-prepared templates which can be sent to elected representatives asking for their support. There are also regular updates on important potential new laws that people with HAE should know about.

    Learnings for the global community

    Keeping an eye on what’s going on in your country can help to pre-empt any challenges or opportunities. Developing basic template letters can encourage people to lobby their local politicians effectively.

    While Dane Christiansen’s presentation was inevitably focused on the situation in the US, his advice to anyone about advocacy was universal. He encouraged people to think: ‘Policy not politics’. He said that HAE and its care are not about partisan politics or politicians arguing. It is about advocating for what the community needs, regardless of the political persuasion of any individual.

    Words from HAE International

    Fiona Wardman, HAEi Executive Vice President and Chief Advocacy Officer, and Jørn Schultz-Boysen, HAEi Executive Vice President and Chief Operating Officer, represented HAEi in Baltimore. Their presentation outlined the mission of the HAEi, to ensure that every person with HAE, no matter where they live, can access an accurate diagnosis and life-saving HAE therapies. Key to this was the support programs and tools on offer.

    HAE TrackR was discussed, along with the HAE Companion app and its emergency cards in many global languages. All HAEi resources are free to download and use. HAEi LEAP, a program of training for youth advocates, has included several young people from HAEA, and ACARE is available to ensure people with HAE can access centers offering the best treatment for the condition.

    The forthcoming 2025 HAEi Regional Conference EMEA was mentioned, and on behalf of HAEi, Jørn was happy to announce that the 2026 HAEi Regional Conference Americas will take place in Ottawa, Canada.

    In conclusion, Fiona and Jørn encouraged all people with HAE to work together, nationally and internationally, as this will deliver the best benefits for everyone, no matter where they live.

    Ask the experts Q&A – Part II

    The popularity of the expert Q&A was such that a second session was placed in the diary. This time the panel was moderated by Dr Marc Riedl, who was joined on stage by Dr Aleena Banerji, Dr Paula Busse, and Dr Mark Davis-Lorton.

    With over 70 questions to answer, Global Perspectives offers highlights of the session:

    Will laboratory tests show normal C1 inhibitor levels if a patient is on prophylaxis?
    Not necessarily. The doctors didn’t feel that any such tests would be of much use. There is natural variation in all people, so changes wouldn’t suggest anything.

    Can people with HAE take the latest medications for weight loss?
    The doctors knew of no reason why HAE patients could not use these treatments.

    What are some prodromal symptoms other than rash?
    There is some evidence of numbness or tingling, or even just a general feeling of being unwell.

    Are there studies of geriatric HAE patients?
    Some of the trials of HAE have included older patients, but there’s limited data. The more patients take part in national Registries, the more information will be available on topics like this.

    What work is underway on gene therapies, and what are the expectations in the coming years?
    Studies are ongoing, but as yet we are waiting for more data before we can make predictions. The goal is to be curative or at least attack-free in everyday life.

    If a person is pregnant with a diagnosis of HAE with normal C1 Inhibitor, what’s the likelihood of passing this to children?
    The genetic mutation is dominant, which means there is a 50% chance of a child having the condition if one parent has HAE. If both parents have HAE, then there is a 75% chance that the child will also have HAE.

    Does HAE affect the ability of the body to regulate glucose or manage insulin?
    The doctors were clear and concise: No.

    Is losartan an acceptable medicine for someone with HAE?
    The big concern for HAE and heart medication is ACE inhibitors. Losartan is not one of this class of medicine. There are rare cases of angioedema from the class losartan belongs to, but they are not contraindicated in people with HAE.

    The final question was: Why does having multiple kids make HAE worse?
    Lightheartedly, the medical panel felt that it was down to the additional stress of raising children!

    Dr Riedl brought the session to a close and turned the stage over to Tony Castaldo and Henrik Balle Boysen to close the Summit.

    Close of two fantastic days

    Throughout the Summit meeting, the audience heard presentations from the Platinum sponsors: BioCryst, CSL Behring, Ionis, Kalvista, Pharming, and Takeda. During the closing session, Tony and Henrik thanked all sponsors, Platinum as mentioned, Gold – Intellia, and Friend – Accredo, ADARx, Astria, Orsini, and PharVaris, for their generous continued support of the US HAEA National Summit and the HAEA community.

    Tony and Henrik stressed the importance of community and how every success of the HAEA has been built on a family of individuals coming together. Tony asked that everyone present always stick together. The team at the HAEA will never give up. They will work to protect what matters and continue to build on the foundations laid over 25 years ago.

    Tony and Henrik closed the Summit by thanking everyone present and asking for all to stay unified in the face of opportunities and challenges to come.

    Making Brady bears

    Tony told the audience that some of the HAEA young people had been stuffing teddy bears throughout the Summit. These bears will be sent to newly diagnosed young people, so they know from the first moment that they are not alone. That bear is a symbol of a fellow patient and the care they show.

    Scientific sessions

    Tony welcomed and reminded over 200 healthcare professionals and pharmaceutical industry staff that the HAEA is highly active in advancing the science of HAE by producing and publishing its own research and supporting knowledge exchange through gatherings like this. He noted that one of the issues for doctors and patients is navigating the US system of health insurance, and that this will be discussed in both scientific and general Summit sessions. Tony encouraged the healthcare professionals present to work with the HAEA, as the organization has the expertise to support doctors in addressing funding challenges.

    Over four hours, the attending healthcare professionals heard six presentations and panel discussions. These were:

    1: From SERPING1 to multiple genes: Genetics and the mechanisms of swelling in HAE

    One of the world’s leading experts on HAE genetics, Dr Allen Kaplan, explained to the assembled healthcare professionals that there is now a growing body of knowledge about the genetic mutations at the heart of HAE. He demonstrated that even with normal C1 inhibitor present, it is possible to have angioedema by overwhelming the body’s systems with bradykinin.

    2: The current state of the art for HAE biomarkers

    Dr Huamin Henry Li discussed the ongoing work to identify biomarkers in HAE. The importance of biomarkers, he said, was threefold. Firstly, they provide an essential means of diagnosing HAE properly, which is increasingly important to distinguish between various HAE types, and to individualize treatment. Secondly, biomarkers offer a way to measure the effectiveness of a therapy, even in the absence of HAE attacks, as the underlying levels can indicate how well a treatment is working in an individual, with the opportunity to personalize treatment. Finally, they help to make clinical trials more effective by providing clear ways in which to measure the performance of a potential new medicine. Dr Li also showed the latest work on measuring bradykinin, which may be beneficial to the management of HAE.

    3: Perspectives on HAE-nl-C1INH from a recently published landmark review

    The first of the panel sessions was dedicated to discussing the latest work in diagnosing and treating HAE with normal C1-inhibitor (HAE-nl-C1INH). The panel of Dr Bruce Zuraw, Dr Marc Riedl, Dr Sandra Christiansen, and Dr Aleena Banerji all presented on a different aspect of the condition.

    Opening the session, Chair of the Scientific Committee, Dr Zuraw, presented a potential HAE case of a mother of two with recurrent angioedema but no diagnosis. Depending on how key questions are answered, the diagnosis and treatment received could radically change. Dr. Zuraw reinforced the importance of asking the right questions and doing the right tests.

    Dr Banerji spoke about the history of HAE-nl-C1INH. She reminded the audience that, as a disease, it had only been identified in 2000. She said there was a lack of knowledge about the prevalence of this form of HAE, but it is certainly rarer than HAE Type-1 and HAE Type-2. She also suggested that HAE-nl-C1INH can be very varied from person to person, potentially leading to underdiagnosis or misdiagnosis.

    Returning to the genetics of HAE, Dr Riedl praised the ongoing work to understand the genetics of HAE-nl-C1INH better, as this allows for testing and eventual diagnosis. He expressed caution about the value of family history of angioedema, as some people may not know their family, or symptoms might simply not have been discussed. Several studies of US doctors treating HAE indicated that there is a lot of variability in the approaches used to diagnose and treat people with HAE-nl-C1INH.

    Dr Zuraw showcased a new diagnostic and treatment algorithm for HAE-nl-C1INH. Using a step-by-step approach, the algorithm starts by excluding common diagnoses such as ACE-inhibitor medications leading to angioedema, or HAE due to C1-inhibitor deficiency, before progressing to tests and treatments for HAE-nl-C1INH.

    Finally, Dr Christiansen spoke on treatment. She told the audience that the patients coming to see her don’t expect a miracle, but they do expect better. Dr Christiansen presented data from a survey of physicians treating HAE-nl-C1INH, exploring which medications, in their experience, had seen success in treating HAE-nl-C1INH. The survey indicated the icatibant and on-demand plasma-derived C1 inhibitor offered benefit in treating attacks. Lanadelumab was used in some cases, as was berotralstat, both of which seemed to demonstrate some efficacy. Anabolic steroids were not used, but tranexamic acid looked to have a benefit regardless of the genetic variant of HAE-nl-C1INH.

    Questions to the panel related to concerns about the cost and availability of genetic testing, and how to manage patients with HAE-nl-C1INH who may need surgery or during childbirth. Additionally, there was a discussion of the potential value of prodromes in HAE. The panel expressed scepticism that these could be effectively used to diagnose different forms of the disease.

    4: Considerations for the pediatric population with HAE

    The second panel discussion was composed of Dr Andrew MacGinnitie, Dr Timothy Craig, and Dr Michael Manning. The group focused on the care of children and adolescents with HAE, and the panel was asked a series of questions.

    Dr Craig was asked about the timing of HAE testing in newborn babies. He recommended that this take place in the first month of life. With genetic testing, this can be a challenge, unless the mutation is already known in the parents. There is some reluctance to test for HAE from some parents and families, the panel conceded. But this is best addressed through education on the importance of a diagnosis. The panel was also asked about testing when there is no family history. The impact of puberty and the associated hormonal changes was the topic of another question, and the panel felt that this can be hugely variable, with some patients worsening while others seeing no change. The desire to address the hormones with birth control is understandable, but not the right solution, they said. A common question was asked about sports and activities in children with HAE. One of the panel members recounted that a patient was able to compete internationally in wrestling, so it is important to work with patients to allow them to achieve their goals.

    The panel also rated the value of young people being part of advocacy groups such as the HAEA, where they can see other people in the same situation and not feel isolated by their condition.

    5: Access to HAE treatment: Prior authorizations and eligibility

    An eagerly awaited session was around the health systems in place in the US, especially ‘prior authorizations’, where doctors have to get approval from health insurers before a medication can be prescribed. This is done to control costs, but can lead to US patients struggling to access medication, or losing the access that they previously had.

    On stage was Troyce Venturella from the HAEA, who works with patients and physicians to address issues around medication access. She was joined by a pharmacist who works in the insurance industry, Steven Kheloussi, who, it was said, lightheartedly, would be ‘taking the tomatoes’ as the panel may be hostile to the health insurance industry. Also on stage were HAE experts Dr William Lumry and Kimberly Poarch to give their perspective.

    The panel explained the landscape of health insurers and how prior authorizations are being used. There were examples of how problems had been overcome, and Mr Kheloussi was able to give context and advice on how best to approach the process. In particular, he highlighted the importance of providing the requested information very concisely. He felt that a complete medical history running to many pages is counter-productive as it means more time is spent having to review, when a succinct response would be better.

    6: Update on emerging HAE therapies and current clinical trials

    The final presentations and discussions were around the latest advances in treatment. Speaking first was Dr Christine Radojicic, who discussed advances in oral medicines. She started with sebetralstat, which was extremely recently approved in the US under the brand name Ekterly. She summed up the efficacy data as favorable. She also discussed concerns about side effects in the stomach and digestion, as this is an oral on-demand treatment for HAE attacks. Dr Radojicic showed that there were very few gastrointestinal side effects reported in the trial. The use of the medicine in people with laryngeal attacks was also discussed. In the trial, every patient with a throat swelling was able to swallow the tablet. Moving on to an as-yet still unapproved medicine, deucrictibant, Dr Radojicic confirmed that this medicine is being considered for both on-demand and prophylaxis. Evidence to date is promising.

    Dr Joshua Jacobs was next to speak. His talk focused on the emerging biological therapies, which make use of living cells to treat and prevent HAE. These included garadacimab, which showed an average of 95% reduction in HAE attacks in a trial, and navenibart, which could be given every three or six months to prevent attacks. Dr Jacobs indicated that this looked like an effective agent based on the trials to date.

    The potential gene therapy was also discussed, including the way it works by clipping out the mutated gene causing HAE, replacing it with an effective one.

    Finally, Dr Marc Riedl gave a presentation on potential HAE treatments that harness RNA, which people may remember was used to develop COVID vaccines. Three potential treatments were mentioned: donidalorsen, ADX324, and a third for which little is currently known. These medicines work by interfering with the production of a protein that causes HAE attacks by silencing a mutated gene. For donidalorsen and ADX324, Dr Riedl suggested that the data in trials to date have shown some steep declines in mean attack rates.

    Summary

    In summary, Dr Zuraw returned to the stage. He thanked all presenters and the audience and asked his fellow health professionals to remember that the United States is in a privileged position when it comes to treating HAE. Most of the rest of the world faces greater issues. Finally, he drew attention to the vital role of patient advocacy in delivering the ‘abundance of riches’ in terms of treatments for people with HAE.

    From the Poster Room

    After the Professional-Scientific track, attention turned to over 30 scientific posters. Here we highlight posters related to living with HAE; its impact on mental health; what patients want to see from their HAE treatment; and the challenges of recruiting people into clinical trials.

    Patient perspectives on the importance of HAE treatments
    Kimberly Poarch and colleagues wanted to understand how people with HAE perceived treatment, especially around oral therapies. They found that individuals with HAE see both on-demand and long-term prophylaxis as important aspects of treatment. The majority of study participants were not willing to stop taking long-term prophylaxis, even if oral on-demand treatments exist, because they preferred to avoid attacks altogether or were concerned about more frequent or severe attacks. However, the idea of an oral medication was of interest.

    Recruitment challenges for rare disease clinical trials: A systematic review
    The authors, led by Mindy Demarco, wanted to identify the challenges of recruiting for rare disease clinical trials and explore effective strategies to secure patient participation in clinical studies. The authors concluded that recruitment for clinical trials in rare diseases can be challenging because diagnoses can be complex, and patients are geographically spread. They suggest that addressing structural barriers, such as speeding up diagnosis, and tailoring communications about the trials to suit specific groups of patients, may help lead to better engagement with patients.

    Treatment burden remains in HAE, despite goals to reach ‘normalization’
    The authors of this research, which included Dr Paula Busse as lead author, presented survey data on perceptions of HAE control and the concept of normalization, as well as the emotions associated with HAE and its management. The conclusions reached included:

    • Most respondents reported multiple attacks in the last year, and thought about HAE weekly, despite considering themselves to be well-controlled
    • Lots of reported concerns about the need for lifetime medication use, which meant it was difficult to feel like they lived a ‘normal’ life
    • HAE attacks were associated with negative emotions. The idea of being attack-free was associated with positive emotions, particularly when it was achieved without the need for ongoing medication use

    Hereditary angioedema (HAE) and post traumatic stress disorder (PTSD)
    Dr Sandra Christiansen and colleagues presented a study of people with HAE that investigated how their mental health may be negatively impacted by attacks, risk of not being able to breathe during a throat attack, and the loss of a loved one to HAE. The study asked people questions to identify if they may have post-traumatic stress disorder (PTSD). In conclusion, the authors were able to identify a high prevalence of potential PTSD in people with HAE. People with increased disease burden, higher rates of depression, and lower quality of life were more likely to be considered to have PTSD. Speaking later, Dr Christiansen indicated that the rates of potential PTSD seen in these HAE patients were profound, perhaps being even higher than that seen in military veterans exposed to combat.

    Living with HAE with normal C1-inhibitor: The worry of when
    Kirstie Cline and colleagues presented a visually exciting poster. They found that improved resources are needed to help healthcare professionals communicate about pain and how attacks resolve over time. They also suggest that people with HAE may need mental health support to manage anxiety around HAE attacks.

  • HAEi’s tip for travelling with HAE: Pack HAE Companion before you go!

    Don’t forget your passport, and HAE Companion

    July is here, which brings the prospect of holidays for many of us. But whether you’re off for a week in the sun or a ski trip in New Zealand, we hope you pack HAE Companion before you jet off.

    Why it’s good to pack some protection

    It’s always good to pack the right protection when traveling. For some, wearing sunscreen and a hat is enough, but for people with HAE, it can be a bit more challenging to know what to do and who to contact in the event of an attack. HAE Companion is a free app that tells you all the information you need to travel safely with HAE.

    While it can’t offer reviews of the hottest restaurants, HAE Companion does provide information, including directions, to medical care facilities all over the world, and in the language you speak. The app uses geofencing technology to know when you’re traveling and send you helpful messages. HAE Companion also offers:

    • Direct access to HAEi’s digital emergency cards allows you to store those relevant to the countries you are going to visit. These are currently available in 44 languages.
    • Contact information for HAE knowledgeable hospitals (including ACAREs) and physicians worldwide.

    HAE Companion, developed by HAEi, is the perfect travel partner, so don’t forget to pack it before your next trip. You can download HAE Companion from the Apple App Store and Google Play Store.

    HAEi’s tips for travelling with HAE

    To get everyone a little more holiday-ready, here are a few more travel tips from HAEi to give you that holiday feeling before you’ve even arrived:

    • Always keep your medicine close at hand, ideally in your carry-on baggage or not buried under the suitcases in the boot of the car. This will stop any medication from being lost or not being available in an emergency
    • Have a letter from your doctor and copies of your prescriptions. Often, airport security personnel will want to check people carrying licensed medicines. It’s important they know that it’s medically necessary for you to travel with treatment
    • If stress is a problem for your HAE, travel can be a big trigger. There are lots you can do to manage stress, such as wearing earplugs and eye masks, or having some of your favorite films, books, and music on hand to help you relax
    • Traveling can involve lots of standing, waiting, and queuing. If your HAE is triggered by fatigue or standing too long, don’t be embarrassed to use things like disability lines at immigration. Increasingly, society understands that just because someone doesn’t look ill, they may need additional support
    • Remember to pack the HAE Companion app to be prepared in the event of an HAE attack – it’s free, and that tells you all the information you need to travel safely with HAE
  • Update on ACARE: an HAEi partnership

    From Rachel Annals
    Coordinator, Global Advocacy and ACARE

    ACARE is a joint partnership between HAE International and the non-profit organization Global Allergy and Asthma Excellence Network (GA2LEN). Rachel Annals is our Coordinator, Global Advocacy and ACARE.

    HAEi and ACARE share the goal of strengthening connections between healthcare centers and patient organizations to support the global HAE community. In fact, “Interaction with and support of patient organization(s) including HAEi and its partner organizations” is one of the requirements for centers seeking ACARE accreditation. One way we support this is by raising awareness of HAEi’s mission and activities through regular e-newsletters sent to the ACARE network, highlighting our important work in the field of HAE.

    We know the value of personal contact and making connections both in the country and across borders. To facilitate these, I am writing to all current ACARE centers to introduce HAEi and encourage each center to work closely with us – particularly with our Regional Advocacy team, who live and work in their respective regions and are well-positioned to provide localized support and guidance. By fostering relationships between centers and promoting collaboration through shared learning, we aim to build a more connected and resilient global HAE care community.

    We’re delighted to share that planning is underway for the 2026 Global Angioedema Leadership Conference (GALC), which will take place from 26–29 March in Madrid, Spain. This joint HAEi and ACARE event brings together patient leaders, healthcare professionals, researchers, and industry representatives to participate in separate scientific and advocacy leadership programs, ultimately combining into joint sessions on Saturday afternoon for a truly inclusive experience.

    If you are interested in becoming an ACARE, you can find out more here.

    Spotlight on current ACARE projects

    HAPY: A questionnaire has been developed to retrospectively gather insights from individuals with HAE and their physicians on how pregnancy may influence the condition. The survey looks at the time periods before, during, and after pregnancy – including breastfeeding – and covers topics such as disease activity, medication use, contraception, coexisting conditions, and pregnancy outcomes.

    All data will be collected anonymously and analyzed electronically, with plans for publication once the evaluation is complete.

    ACARE has shared a few updates that make participation even easier. The pregnancy can have occurred at any point in the past, and there is no longer a requirement for physicians to sign the consent form. This change allows doctors who know HAE patients with a history of pregnancy to share the survey more freely, now that it is fully anonymous.

    To understand more about HAPY, click here.

    SHAERPA: The SHAERPA project is an international, multi-center academic study that is both prospective and partly retrospective in nature. This observational, cross-sectional project aims to gather real-world data to help develop practical guidance on how to safely discontinue androgen treatment in patients with HAE. The ultimate goal is to support physicians and improve patient care globally.

    Physicians across the ACARE network, and those outside of it who treat HAE patients, are strongly encouraged to take part.

    The study involves both physician and patient questionnaires and focuses on understanding why, how, and with what outcomes androgens are discontinued in HAE. Specifically, it aims to:

    • Identify the reasons behind stopping long-term androgen prophylaxis
    • Examine the protocols used during androgen withdrawal
    • Assess the consequences of stopping treatment, including the effectiveness of various approaches
    • Use the collected data to generate evidence-based recommendations for safely discontinuing androgens in clinical practice

    To understand more about SHAERPA, click here.

  • Updating expert consensus in HAE with normal C1 Inhibitor - an extraordinary effort

    Behind the scenes of a scientific push to improve care for those with HAE with normal C1 Inhibitor

    Thirty-one authors from 16 countries. 140 separate references. Four rounds of review. Just under 2 years from the first meeting to official publication. These are a few of the statistics from a new consensus paper on HAE with normal C1 inhibitor (HAE-nC1INH), published in March 2025. They show what a marathon effort it was to distill scientific discussion, debate, and decision into 24 pages.

    Considering the detail in the paper, all authors appreciated the positive feedback from the peer review process, which reflected the value of the work. Within the author team, the mood was captured by comments like: “Big congratulations on an important paper which many have been anticipating” and “This is great news, and I think this paper will be extremely useful.”

    To understand why HAEi and the US HAEA supported this initiative from first thought to last word, and why the clinical community was motivated to work so long and so hard, we need to start with HAE-nC1INH. What is it, and what has life been like for people with the condition?

    HAE-nC1INH is rarer even than HAE Type-I and Type-II, and was identified only in the early years of the 21st century. Initially called HAE Type-III, people with the condition suffered from recurrent episodes of swelling without hives, but existing diagnostic tests indicated normal levels and function of the C1 inhibitor protein, which made effective diagnosis and management of the condition very difficult. With the advent of detailed genetic testing, the condition began to be better understood and was eventually renamed HAE-nC1INH. As diagnosis rates increased, the US HAEA, in particular, began hearing from people with the condition, but had no way to answer the many questions asked. Driven by the US HAEA, the last expert consensus review of the science was published in 2012.

    The US HAEA and HAEi understood the need to advocate for this underserved group of patients and, in early 2023, enlisted a group of global HAE experts to synthesize the current knowledge in the area. Anthony J. Castaldo, HAEi Chief Executive Officer and Chairman of the Board, said: “There was no one source of truth in an emerging and highly complex form of HAE. We needed this paper to give practical support to a group of patients who really needed better care.”

    The experts presented their preliminary findings, sharing a best practice approach to the diagnosis and management of HAE-nC1INH at an HAEi/US HAEA-supported symposium held on 1 September 2023 in Germany, ahead of the first 2023 HAEi Regional Conference EMEA. HAEi and the US HAEA represented the patient throughout and worked with the co-chairs to ensure the work reflected the patient’s needs.

    The efforts culminated in a new and comprehensive review and expert opinion on the best practice approach to diagnosing and treating HAE-nC1INH.

    What’s the consensus?

    >> Click here for the full paper

    Here are some of the key points that people with HAE should know:

    • Three critical areas of science were covered:
      • Clinical features, diagnosis, and differential diagnosis
      • Genomics, biomarkers, and pathophysiology
      • Management and treatment
    • C1 tests are normal, so doctors may hesitate to initiate treatment for patients with HAE-nC1INH as they don’t have a test to confirm the diagnosis. Genetic testing to identify a mutation would then confirm the diagnosis, but this isn’t available to everyone. In the meantime, patients are not being treated and living with attacks.
    • In response to this, the paper states:
      • Like HAE due to C1INH deficiency, HAE-nC1INH patients are at risk of serious morbidity and mortality.
      • Proactive management and treatment of HAE-nC1INH patients after an expert physician diagnosis is critically important.
      • Even without an identified mutation, a presumptive diagnosis of HAE-nC1INH made by an expert physician is sufficient. Since these patients are at risk, treatment needs to be available even for a presumptive diagnosis of HAE-nC1INH.
    • In the absence of robust clinical data on treatment, the authors were surveyed to pull together real-world evidence of treatment outcomes from 594 patients in 15 countries.

    The science didn’t stop with this publication either. A further publication, in a Japanese journal, is also planned to bring the consensus paper to a broader audience there. And part of the survey data has subsequently been used in a scientific paper on the management of idiopathic non-mast cell angioedema (INMA).

    Deborah Corcoran, HAEi’s Director, Research, 1 of the combined HAEi and US HAEA team supporting the expert publication, commented: “We are grateful to everyone who contributed to making this publication possible. There was a single-minded focus on practical ways to improve the lives of people with HAE-nC1INH, and we hope to see this translate from the page to improved care very soon.”

    HAEi and the US HAEA extend heartfelt thanks to all the experts involved in this vital publication, in particular Prof Bruce Zuraw, Prof Konrad Bork, and the much-missed Prof Marcus Maurer, who were Co-Chairs for this mammoth project.

Have you wondered how to get your HAE under control? HAE TrackR can help you!

Developed by fellow HAE patients at HAEi, HAE TrackR is an easy-to-use electronic diary designed to record your HAE treatments, HAE attacks, and the impact HAE has on your life and the lives of your loved ones.

HAE TrackR allows you to download a comprehensive report of your treatments and attacks, which can be used as a tool for you and your physician to manage your HAE.

Features of the app:

  • Records your treatments (preventative, on-demand and clinical trial medication)
  • Records attacks and developments/improvements of attacks
  • Has a smart reminder functionality for prophylactic treatments
  • Is endorsed by ACARE for its ease of collecting and using data and comprehensive reporting
  • Is safe and secure, product and company neutral with no commercial interests

News from HAEi countries around the globe

  • From Zoe Steiner, Operations Coordinator, HAE Australasia

    Over the past few months, the HAE Australasia team has been focused on strengthening connection, education, and support for the HAE community across Australia and New Zealand. A recent highlight was our Patient & Carer Meeting in Auckland, which brought together individuals from across New Zealand. We were pleased to welcome HAE specialists from both Australia and New Zealand, who shared valuable insights on current treatments, clinical trials, and assistive technologies—including apps designed to help manage life with HAE more easily. The event also created a meaningful space for local patients and carers to connect, share their experiences, and build ongoing support networks.

    We’re also pleased to have recently welcomed more than 10 new members to our growing community. We’re proud of the work we’re doing to ensure that people living with HAE are seen, heard, and supported.

    As we continue to support members across a wide geographical region—including time zones spanning up to five hours—we’re looking at ways to stay connected more regularly. In the coming months, we plan to hold a series of casual online catch-ups to provide a relaxed space for community connection, updates, and peer support. These informal sessions will help us stay in touch between larger events and ensure everyone has an opportunity to participate, no matter where they’re located.

    We’re also actively exploring funding opportunities to support more face-to-face gatherings in the future. These in-person events are incredibly valuable for strengthening our community, sharing lived experiences, and accessing expert advice—and we’re committed to making them as accessible as possible.

    Thank you to everyone who has joined us so far. We look forward to staying connected and continuing to grow our HAE Australasia community.

  • From Lisa Buchberger, HAE Austria

    HAE Austria Elects New Board
    On Saturday, April 26, 2025, HAE Austria’s annual patient meeting took place in Vienna at the Hotel Superbude. After a welcoming coffee, the general assembly began for all members present. After the quorum was established and the reports from the chair and auditor were presented, the board was discharged, and the election proposals were presented. Lisa Buchberger was unanimously elected as the new secretary of HAE Austria. She succeeds Christian Müllner, a board member since the patient organization’s founding in 2006. He was appointed HAE Austria’s first honorary member during the motions to the general assembly. A heartfelt thank you for your years of dedication!

    After the general assembly, the agenda included exciting presentations by Prof T. Kinaciyan, Dr Clemens Schöffl, and Sabine Altrichter (doctor of public health). A shared lunch on the 7th floor of the hotel, with outstanding views over Vienna (and especially the Vienna Prater), was enjoyed before the afternoon program offered a free choice of two workshops.

  • From Raquel de Oliveira Martins, HAE Brazil/Abranghe

    During the past months, HAE Brazil has participated in several events:

    • On April 23, the Minas Gerais State Legislative Assembly congratulated Abranghe for the work it has done over its 15 years of existence.
    • On April 25 and 26, we had a booth at the Bragid (Brazilian Group of Immunodeficiencies) medical event in São Paulo, celebrating Abranghe’s 15th anniversary.
    • On April 25, we participated in Pint Pharma’s II SPHERE in Campinas, São Paulo. This training event provided training for leaders of invited associations.
    • On May 15, we participated in the event promoted by Gebraeh with the theme: Hereditary Angioedema: Fact or Fake. At the end, the doctors paid tribute to Abranghe’s 15th anniversary.
    • On May 30th and June 1st, we participated in the meeting of leaders from South America and Mexico in São Paulo.
    • On June 23rd, we participated in the event produced by Casa Hunter: 10th Edition of the Rare Disease Scenario in Brazil.
    See images from HAE Brazil
  • From Daphne Dumbrille, HAE Canada

    This spring has been an inspiring season of connection, learning, and advocacy for HAE Canada and our community. From strategic planning sessions to national conferences, local gatherings, and the Global Activity Challenge, here’s a look at the meaningful moments that shaped the last few months.

    Board Retreat: Setting the Stage for a Purposeful Year
    Our annual board retreat took place in Ottawa, where board members and volunteers came together in person and virtually to align on projects rooted in our strategic plan. The energy was high as we brainstormed, built stronger relationships, and mapped out activities for the year ahead. The retreat was both productive and motivating, reinforcing our shared commitment to the HAE community.

    Patient Information Update in Timmins, ON
    On April 5th, Michelle Cooper (HAEC President), Daphne Dumbrille (COO), and our trusty consultant, Heather Dow (Event’s Management Plus), travelled to Timmins, Ontario, to host a hybrid Patient Information Update. Dr William Yang (MD, FRCPC, FAAAAI), along with two members of his clinical team, Stephanie Santucci (RN) and Hazelyn Torres (RPN), joined us virtually from Ottawa to present on the latest HAE treatments and ongoing clinical trials. Attendees benefited from a dynamic Q&A session, gaining valuable insights directly from medical professionals. After the Q&A, we switched gears, and Anne Morin joined us at the podium to tell her inspiring journey as a person with HAE living in northern Ontario. The event also featured Anna Taneburgo (B.S.W.), a fantastic therapist who spoke on self-care and stress management for those living with a genetic condition. She closed her session with a calming guided meditation—an experience that left everyone feeling recharged. Thank you to each of our presenters and to everyone who attended, both virtually and in person. It’s always a highlight to meet new people and see familiar faces at our Patient Updates.

    CORD’s Rare Disease Day Spring Conference
    From April 29–30, HAE Canada staff member Daphne Dumbrille and a volunteer attended the Canadian Organization for Rare Disorders (CORD)’s Rare Disease Day conference in Calgary. Under the theme “Reimagining Rare: Optimizing the Patient Journey from Diagnosis to Treatment,” the event brought together patients, healthcare professionals, and industry leaders. Together, they explored how federal investments can most effectively support Canadians living with rare diseases. It was an important reminder of the power of collaboration in driving change.

    HAEi Global Activity Challenge: Canada Steps Up!
    We’re thrilled to share that Canada placed third out of 43 countries in the HAEi Global HAE Activity Challenge for total step count (as of June 3rd, clocking in at 12,619,567 steps), behind first-place United States and second-place Denmark. Congrats to both those countries for your amazing job! We are also very proud of our second-place finish in two other categories: the number of activities (883) and the number of participants (1,469 people contributed to Canada’s totals)! From April 1 to May 31, our passionate members, along with friends and family, showed up in full force.

    To mark hae day :-) on May 16th, our fabulous HAE Canada volunteers reached out to their local municipalities to request monuments and city signs to light up purple. In the end, ten cities across Canada lit up in purple, including two major landmarks in Ontario: the CN Tower and Niagara Falls. What a powerful show of solidarity! We want to thank all our volunteers who dedicated their time to getting as many cities as possible to recognize hae day :-). We have already started planning how we will increase the number of purple lights next year.

    Patient’s Stories: Raising Awareness Through Video and a Blog
    A few years ago, four HAEC members generously agreed to step forward and share their experiences as a person with HAE living in Canada. Recently, we added two more stories to our website. We’re honoured to share a moving video created by the Daniel family about their young son’s journey with HAE. Created entirely by Charbel, Rebecca, and their son Lucas, the video shines a light on a condition too few people know about and helps foster understanding. Another recent addition to our page comes from Stacy and Amanda (The Unedited Sisters). With help from their family members, they have written a very impactful and meaningful blog about living as a person with HAE with normal C1 in Canada.

    We want to extend a HUGE thank you to the Daniel family and Stacy and Amanda’s family for their enthusiasm and creativity in raising awareness and helping others connect with the lived HAE experience.

    Please visit our website’s Patient Stories page to watch Lucas’s video and read Stacy and Amanda’s blog post.

    ED Poster Initiative: A Practical Tool for Emergency Situations
    People with HAE often face significant challenges when presenting to Emergency Departments (ED). To help address this, HAE Canada – using HAEi’s template and with support from the Canadian HAE Network (CHAEN) – has developed a Canadian-specific ED poster. Designed to be brought by people with HAE to their local hospitals, the poster informs clinicians about HAE and supports faster, more accurate diagnoses during emergencies. If just one person is diagnosed because a physician recognizes their symptoms from this poster, we’ll consider it a huge success. A heartfelt thank you to HAEi and CHAEN for their support in making this project a reality.

    Submission to CDA re: Patient Group Participation
    To help influence how patient perspectives are included in the drug reimbursement review process, HAE Canada responded to Canada’s Drug Agency (CDA-AMC)’s request for feedback on improving the process for evolving patient group input submissions. This consultation marked the first in a series of initiatives focused on enhancing the role and impact of patient group contributions in these critical reviews.

    Attending EAACI’s 2025 Annual Congress
    From June 13 to 16, Michelle and Daphne were in Glasgow, Scotland, to attend the 2025 European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress.

    The event was a huge success, with many sessions dedicated to HAE. It was particularly encouraging to see numerous research posters addressing a broad range of topics, such as the burden of disease and patient preference in HAE and the impact on quality of life, disease management, and sleep health.

    Michelle delivered an excellent presentation of HAE Canada’s poster titled ‘Quality of life and measures of well-being of Canadian patients with HAE C1-INH based on data from the 2020 and 2024 national surveys,’ and we thank her for representing the organization so well.

    We were also pleased to see all of our sponsors represented with exhibitor booths (Astria, BioCryst, CSL Behring, KalVista, Pharvaris, and Takeda), providing attendees with valuable information about current and emerging HAE treatments. It was a privilege to meet and engage with the European representatives from each of our sponsoring organizations. We also had the opportunity to meet with Angela Metcalfe, CEO of HAEUK. We always appreciate meeting with other organizations to learn and connect.

    Letter Writing Campaign: Equal Access to icatibant
    In a previous newsletter, we shared that HAE Canada submitted patient input to CDA-AMC in support of granting people with HAE with normal C1-INH access to icatibant. Following that, CDA-AMC issued its report stating icatibant should be accessible to individuals with all types of HAE.

    In response, HAE Canada, in partnership with the Canadian HAE Network (CHAEN), wrote to every provincial and territorial government urging them to follow CDA-AMC’s advice and update their formularies to include people with HAE with normal C1-INH.

    To amplify our message, we launched a national letter-writing campaign, encouraging our members to contact their provincial representatives and demand equal access to icatibant for all people living with HAE – regardless of type. The response has been amazing, and we know the momentum will continue to grow.

    We are confident that, before long, we will be able to share the good news that equitable access to icatibant has finally been achieved across Canada.

  • News from Central America and Caribbean

    Country updates shared by Javier Sanatana, HAEi’s Regional Patient Advocate, Central America and Caribbean

    Dominican Republic: The group is working to ensure that medications are included in the health system and continues their efforts and meetings with medical professionals to promote HAE. New HAE patients and doctors have been identified.

    Puerto Rico: There have been public discussions about the recently passed Law 9 of 2025, which establishes a new support office for people with rare diseases. Encouraged by follow-up from RPA Javier Santana, the Puerto Rico Department of Health actively participated in the hae day :-)awareness campaign. The group held informational events, continued dialogue with pharmaceutical companies, and participated in local events to further educate about new HAE treatments. The local group also represented Puerto Rico at the 2025 US HAEA National Summit in Baltimore in July.

    Guatemala: More allergist physicians have expressed interest in receiving training on HAE. Dr Emilia Morales, a HAE patient and healthcare professional, has actively collaborated with health centers to raise awareness about Hereditary Angioedema.

    Cuba: Unfortunately, a shortage of specific medications for HAE has emerged again. New physicians have been identified who are providing the necessary care to HAE patients in this country.

  • From Mdm Zhang Nan, HAE China, and Lim Yong Hao, RPA HAEi

    This year’s HAE National Annual Meeting unfolded over two days, from June 27 to 28, at the Tiantan Hotel in the heart of Beijing. Held under the banner “United in Strength, Hope for the Future,” the event brought together nearly 180 patients and family members from across the country, along with leading medical experts and patient organization leaders. Jointly organized by the Chinese Organization for Rare Disorders (CORD) and HAE China (also known as the Yu Yan Angioedema Care Center), the meeting showcased the tremendous strides China has made in the diagnosis, treatment, and community support for patients and caregivers living with HAE.

    This year marked a significant milestone in China’s nine-year journey of officially organizing HAE activities. Reflecting on the humble beginnings, Mdm Zhang Nan, National Contact for HAE China, shared how the initiative began in 2016 with a modest gathering of just 20 patients at Peking Union Medical College Hospital (PUMCH). Today, the annual meeting has grown into a large-scale national event. HAE China’s membership has expanded from 130 to nearly 400, while the number of hospitals capable of diagnosing HAE has increased from just one to more than 100 across the country.

    According to Mr Kevin Huang, founder of CORD, the number of diagnosed HAE patients in China has now surpassed 1,000. He expressed a hopeful vision for the future where patient gatherings are not prompted by illness, but by shared journeys and life experiences. What was once a condition without treatment options has seen a major breakthrough: first-line HAE medications are now included in public health insurance. These achievements reflect a remarkable collaboration between medical professionals, pharmaceutical companies, patients, and caregivers.

    During the meeting, medical experts from PUMCH, led by Professor Zhi Yuxiang, provided timely updates on the evolving landscape of HAE care in China. Topics included the early detection of laryngeal edema, the importance of genetic counseling in family planning, and the ongoing challenge of misdiagnosis. Professor Zhi also mapped out the treatment timeline and discussed the availability and reimbursement of both on-demand and preventive therapies. Domestic pharmaceutical innovation is also gaining momentum, with several Chinese-developed therapies currently in clinical trials.

    The conference also served as a valuable platform for dialogue between doctors and patients. In the Q&A session, medical experts addressed practical concerns such as medication intervals and daily precautions. Patient testimonies, ranging from individuals who endured years of misdiagnosis to advocates who successfully lobbied for local policy changes, offered moving accounts of resilience and determination.

    In a roundtable discussion, Mr Lim Yong Hao, HAEi’s Regional Patient Advocate for East Asia, commended China’s growing leadership in the region. He called for the further development of a tiered diagnostic system to reduce regional disparities and emphasized the importance of increasing the number of HAE-trained healthcare professionals to improve care delivery and disease management. Pharmaceutical partners echoed their commitment to strengthening treatment infrastructure and raising public awareness.

    As the event came to a close, Mdm Zhang Nan acknowledged the challenges that remain, namely, limited awareness of HAE and unequal access to treatments. Still, her message was one of perseverance and solidarity: “Rare does not mean forgotten.” The meeting concluded with a group photo and a shared pledge among participants to meet again in 2026.

    Special thanks were extended to Takeda China, Qualifind Medical, CNBG, and Argo Biopharma for their generous support. Through continued collaboration, the vision of a better future for HAE patients in China is steadily becoming a reality.

  • From Jesús González, Costa Rica

    First Step Toward a National HAE Patient Organization
    Over the years in Costa Rica, we’ve faced many challenges in creating an organization that represents and defends the rights of people living with HAE. Although rare, this condition requires specialized care and much more visibility within the healthcare system.

    After many efforts, conversations, and collaborative work between patients and HAEi’s Regional Patient Advocate in our region, Javier Santana, we are proud to announce that we’ve finally taken the first step toward the formal creation of a patient organization. While it’s just the beginning, it’s a meaningful milestone that allows us to start building a strong foundation for better representation and advocacy.

    This isn’t just a symbolic achievement — it’s a strategic one. It gives us a stronger voice to be heard by health authorities, especially the Costa Rican Social Security Fund (CCSS). Our main goal is to work with institutions to improve the quality of life for people with HAE in Costa Rica, ensuring access to proper treatments, timely diagnoses, and comprehensive support.

    We invite anyone who wants to collaborate or share ideas to do so freely. Every contribution matters and will be welcomed — this project is built by all of us, with the well-being of patients as our shared goal.

  • From Rosa María Pérez González, HAE Cuba

    A Community in Progress Amidst Deep Challenges
    Greetings from Cuba. We send our warm regards from our patient group, which is slowly building a national community. Today, we join you — patients, families, doctors, and advocates around the world — in solidarity and hope. We are united by our shared experience with HAE.

    We face tough challenges, including limited access to both diagnostics and modern treatments. But we find strength in mutual support and in the backing of HAEi, which welcomed us as a member country in 2024. From different provinces and through our virtual groups, we share stories, push for visibility, and work toward a better life.

    This year, we made a major step for our patients: a new pediatric care clinic for suspected HAE cases was launched at the Institute of Hematology and Immunology. This specialized service for children marks a big win for early diagnosis and national HAE care. Now, young patients and their families have a space dedicated to their care and monitoring, with professional support from early childhood.

    However, amid Cuba’s severe economic and social crisis, we’ve made no progress in expanding diagnostic tools for HAE. We also don’t have access to specific treatments like purified C1-INH or icatibant, which are used in other nearby countries. At the moment, we only have extremely limited access to danazol, tranexamic acid, and fresh frozen plasma — and even these are not consistently available for all who need them.

    Despite these shortages, we continue working together to secure dignified care and the support all patients deserve.

  • From Camelia C. Isaic, Czech HAE Junior z.s.

    HAE Junior presented a scientific poster and a new art exhibition in Budapest
    HAE Junior from the Czech Republic participated as a partner organization at the prestigious scientific 14th C1-inhibitor Deficiency & Angioedema Workshop in Budapest, Hungary (29 May – 1 June 2025). This year, our patient organization presented artworks by HAE juniors & friends as well as a poster in the scientific section of the program.

    The poster titled ‘Unmet Needs and Systemic Challenges of HAE Pediatric Patient Families in Europe’ shared the findings of a large-scale AI analysis of data reflecting the experience of patients from 11 European countries. This research project was made possible with the support of AMGEN #RAREis Global Advocacy Grant Program.

    Read more about the study, its methods, and key findings on our website.

    In addition, the new exhibition ‘My Inspiration’ prepared by HAE Junior patient organization, showcased drawings and paintings by children and adolescents with HAE, their siblings & friends. Symbolically, on International Children’s Day, their artworks displayed the everyday challenges, dreams, and sources of inspiration that help them overcome obstacles in life. The scientific conference participants hence had the opportunity to look into the world of HAE juniors through their creativity.

    Learn more about the exhibition and view selected artworks on the HAE Junior website.

    Many tHAEnks to all contributing talented young artists from the HAE patient community!

  • From Caroll and Andry Batista, HAE Dominican Republic

    FUNDAEHER Is Born and Legislation for Rare Diseases Advances
    This year, 2025, has been a significant one in the fight for the rights and care of people living with HAE in the Dominican Republic.

    For the first time, after some meetings with HAEi’s Regional Patient Advocate, Javier Santana, and his advice, the founding members of FUNDAEHER (Dominican Foundation for Hereditary Angioedema) met in person with several patients we’ve been in touch with for some time. This gathering marked a hopeful milestone in building a more united, informed, and empowered community.

    One of the biggest breakthroughs this year was the addition of an allergist with HAE experience to our mission as a medical collaborator. This step brings us closer to providing more specialized and compassionate care tailored to the real needs of HAE patients.

    At the same time, we’ve been actively following a bill introduced in the National Congress that aims to create a legal framework for the comprehensive care of people with rare diseases — including HAE, which remains underrepresented. This legislative proposal offers real hope for better access to specialized services, early diagnoses, and timely treatments for a historically invisible population.

    Finally, we expect that before the end of the year, FUNDAEHER will gain official legal status as a foundation, establishing a formal structure to support those who need it most.

  • From Edison Galarraga, HAE Ecuador

    Evaluation of the prevalence of sleep disorders in severe and uncontrolled patients with HAE in Ecuador
    With great satisfaction, the Espiritu Santo University, located in the city of Guayaquil, through the Research Unit directed by Dr Iván Chérrez, celebrates the completion of research on sleep apnea in patients with hereditary angioedema in Ecuador. This achievement represents an important contribution to national scientific knowledge and reaffirms our commitment to the health and well-being of the community. 

  • From Raquel Fuentes, HAE El Salvador

    HAE Awareness Walk Unites Our Community
    In recognition of hae day :-), we organized a symbolic walk in El Salvador. Patients, caregivers, and family members joined together, creating a space for connection and visibility.

    Throughout the day, we shared personal stories and reinforced the need to build support networks and raise awareness about this still-unknown condition.

    Every step we take together strengthens the HAE community in El Salvador and makes the invisible visible.

  • From Maria Hartofilli, HAE Greece

    The HAE Patients’ Association continues its efforts to raise awareness, support patients, and advocate for early diagnosis and access to treatment across Greece.

    On the occasion of hae day :-) (May 16), we successfully organized a public awareness event in collaboration with the basketball club Ethnikos Ellinoroson. The event was a great success and received a warm response from the local community.

    More than 110 children from the basketball academy participated, along with a large number of people from the local community, creating a vibrant and engaging environment of awareness and support.

    A special contribution was made by Dr Fotis Psarros, who provided detailed information to the public about HAE, including symptoms, treatment options, and the importance of early diagnosis. Additionally, representatives from pharmaceutical companies that offer therapies for HAE were present, providing important insights and information on available treatment options.

    Thanks to this initiative, six new patients were informed about our Association and have since joined as members, expanding our growing network of support for people living with HAE.

    On the institutional front, the Association continues to collaborate with governmental authorities, particularly the Ministry of Health, achieving key milestones:

    Distribution of an informative poster to all Emergency Departments (EDs) across the country, helping healthcare professionals recognize and properly respond to HAE attacks.

    Free genetic testing is now offered to HAE patients and their families, supporting early diagnosis, prevention, and appropriate medical care.

    A 24-hour open telephone support line for patients with hereditary angioedema has been established for all of Greece by the scientific team.

    And recently, a major step forward was taken: the establishment of a dedicated HAE clinic at the children’s hospital in the capital. This specialized unit will provide expert care, follow-up, and guidance for young patients and their families. It represents real progress — and real hope.

    Our mission is simple but urgent: to ensure timely diagnosis, access to treatment, and a better quality of life for every person living with HAE in Greece.

    We sincerely thank our members, volunteers, healthcare professionals, organizations, and all partners who contribute to our ongoing efforts.

    For more information or to become a member, please visit our website kaoelladas.gr, or follow us on Instagram @haegreece or contact the Association directly.

  • From Samantha Alvarado, HAE Guatemala

    Limited Diagnosis and Structural Barriers
    Unfortunately, living with HAE in Guatemala means dealing with a healthcare system that still doesn’t fully recognize or understand the condition. Even with doctors willing to help, such as Dr Rigalt, the lack of awareness and resources causes diagnoses to be delayed — or never happen at all.

    Awareness, diagnosis, and treatment access in Guatemala continue to progress very slowly due to a severe lack of nationwide information. While some information is available online, both patients and doctors remain reluctant.

    We’ve tried to support family members and other possible patients, but most labs do not have the capacity to run C1-INH or genetic tests. At this point, only two families, in addition to mine, have been diagnosed with HAE.

    Dr Emilia Morales — who is also a patient — continues her efforts to raise awareness about HAE within the country’s healthcare centers.

    As for treatment, we still don’t have access to specific medications. We rely on limited options such as danazol or tranexamic acid, and unfortunately, the use of steroids — which are known to be inadequate — remains common.

    HAE continues to be underdiagnosed in Guatemala. We hope efforts toward education and awareness will keep moving forward.

  • From Priyanka Meduthuri, HAE India

    HAEIPΑ Patients Meet 2025 in Charnock Hospital, Kolkata: Two days and so many powerful moments.

    On May 17, HAE India’s dedicated state representatives came together at Charnock Hospital, Kolkata, to strengthen our collective mission and drive change for our rare community.

    We discussed how to become stronger, more effective advocates, how to influence policies, and how to reach more doctors and undiagnosed patients across the country. We explored how to leverage powerful tools like HAEi Connect, HAE TrackR, and the HAEi Advocacy Academy to equip ourselves to better support patients and families. A key part of our discussion focused on India’s Rare Disease Policy – its current challenges, opportunities for improvement, and how we can ensure better access to life-saving treatments.

    Most importantly, we outlined clear goals for our states and created a collaborative to-do list for the future of HAE advocacy in India. Because every patient matters, and every voice counts!

    On May 18, 2025, we came together at Charnock Hospital, Kolkata, for the HAE Society of India (HAESI) Patients Meet – a full day of learning, sharing, and uniting as a rare disease community.

    We began with a heartfelt welcome note from President Pravalika Meduthuri and Founder Dr Shaibal Guha, sharing how far we’ve come on India’s HAE journey. Fanny Schappler, our HAEi Regional Patient Advocate, reminded us that we are part of a global family fighting for access, awareness, and care.

    One of the most powerful moments of the day was a one-hour talk by Dr Ankur Jindal, who gave a deep and incredibly helpful overview of HAE in India – from diagnosis to treatment gaps to emergency care. His insights were eye-opening and empowering for patients and caregivers alike. We also had an expert talk by Dr Binay Biswas, who brought clinical clarity and practical information that helped patients better understand their condition.

    The expert panel, featuring Dr Binay Biswas, Dr Suprit, Dr Archan, and Dr Rakesh (all from HAESI), and all the wonderful doctors from Charnock Hospital, offered practical advice and answered patient questions with compassion and clarity.

    After a powerful morning of knowledge-sharing, the afternoon brought heart, connection, and action. Patients and families shared their journeys – raw, real, and deeply moving. We admire their courage to open up, and we’re so grateful they traveled from near and far to attend this meet and be part of something bigger.

    One of the most meaningful parts of the day was seeing the engaging conversations between patients and doctors filled with questions, insights, and genuine connection. Mr. Manoj Kumar guided us through India’s Rare Disease Policy, helping us understand the road ahead and how we can influence change through advocacy.

    We closed with an interactive quiz, shared laughs, and reflections that reminded us – this isn’t just an event. This is the beginning of a stronger, more united HAE community.

  • News from Parichehr Bahraini, HAE Iran

    Hereditary Angioedema (HAE) International Day at the Immunology, Asthma, and Allergy Research Institute (IAARI), Tehran University of Medical Sciences, Iran
    In honor of hae day :-), the Immunology, Asthma, and Allergy Research Institute (IAARI), in collaboration with the Immunodeficiency Patients Advocacy Association (IDPA), hosted a gathering for HAE patients and their families. The event took place on Wednesday, May 14th, 2025, from 10:00 AM to 12:00 PM at the Farhoodi Conference Hall in the Children’s Medical Center in Tehran. The meeting was accessible both in person and virtually.

    The meeting focused on the latest developments in the diagnosis, prevention, and management of HAE, aiming to raise awareness among patients and their families across the country.

    Initially, Ms. Marzieh Salk, CEO of IDPA, mentioned that May 16th is recognized globally as hae day :-). She highlighted various awareness programs held worldwide to educate people and attract attention from society and authorities to this disease. In Iran, similar initiatives have been ongoing for five years – initially exclusive to healthcare professionals, and more recently, from 3 years ago, including programs directly for patients and their families.

    She also shared updates on the institute’s activities, such as disseminating educational content via social media and supporting patient participation in international conferences, and announced details of the upcoming conferences.

    Following her, Dr Mohammad Reza Fazlollahi, an allergist and clinical immunologist at IAARI, gave a lecture on the diagnosis and treatment of HAE. He emphasized the importance of awareness for managing the disease effectively and living actively with HAE. Dr Zahra Alizadeh, PhD in biomedicine, discussed the genetic factors involved in HAE. Dr Parichehr Bahraini, a pharmacist, talked about medications used in HAE and the importance of proper medication use.

    At the conclusion, a patient shared his personal experience of adapting to this chronic condition and leading a vibrant, successful life while managing the illness. The speakers then responded to questions from the attendees.

    For more information, you can visit the news article in Farsi on the IAARI website.

  • From Bettina Carty, HAE Ireland

    Now that we are halfway through 2025, it has been great so far for HAE Ireland.

    In March, we had our first patient meet-up, which was a great success, with patients coming from all over Ireland for the afternoon in Dublin.

    In May, we had hae day :-) – this started on the 16th with Swords Castle being lit up in purple to celebrate, then on the 17th, we had a walk in Phoenix Park in Dublin City. It has been wonderful to meet so many new patients and carers in the last months.

    We are looking forward to the next 6 months and the 2025 HAEi Regional Conference EMEA in October, where a number of new patients from Ireland will be in attendance.

  • From Patricia Karani, President, HAE Kenya

    As president and founder of HAE Kenya, I was invited to attend the 9th Biennial African Society of Immunodeficiencies (ASID) Congress held in Nairobi, Kenya, from June 25th to 27th 2025 in collaboration with the Allergy Society of Kenya, ASOK. The congress, themed “The African Landscape of Primary Immunodeficiencies and Allergies – in the Era of Personalized Medicine” had a special emphasis on the African context.

    The International Nursing Group of Immunodeficiencies (INGID) and the International Patient Organization for Primary Immunodeficiency (IPOPI) also hosted events alongside the congress, including a two-day Africa Patients’ meeting, which HAE Kenya was invited to attend.

    IPOPI is a group of patients living with rare diseases from different countries, and they recognize HAE as rare. We were taken through an interactive skills-building workshop. We learnt ways of how to seek and collaborate with the relevant stakeholders during our awareness and advocacy activities in our individual countries and strategies of good governance within our individual patient organizations. We highlighted our challenges and came up with both long-term and short-term action plans that are achievable within various time limits.

    We were also encouraged to build patient group morale by celebrating our wins whether big or small as we conduct our advocacy work in our individual countries in order to boost group momentum. HAE Kenya was glad to be invited by Martine Pergent (Chairperson of IPOPI France) and Cynthia Oluoch (Chairperson of PID Kenya and member of the IPOPI board.

    The skills covered in the IPOPI workshop are universal to patient advocacy and reflect the courses HAEi offers to Member Organizations in HAEi Advocacy AcademyMember Organizations can obtain their exclusive access code to view course content by speaking with their Regional Patient Advocate.

  • From Meryam Jennane, Secretary, HAE Morocco

    Uniting for change: Building bridges for HAE patients in Morocco
    Promising progress is currently underway for the Moroccan HAE community, thanks to the commitment of local advocates and meaningful international partnerships.

    We are currently developing a brand-new website, which represents the first major step toward building a stronger national presence and providing better access to information. The website will be hosted by HAEi, with technical support from their developers and IT specialists, and built in close collaboration with our regional patient advocate, Ms. Maria Ferron, as well as Ms. Meryam Jennane and Mr. Imad El Aouni, respectively Secretary and President of the Moroccan organization – Association Marocaine des Malades d’Angio-Oedeme (AMMAO). It will feature essential resources in Arabic, English, and French to serve patients, families, and healthcare providers across the country.

    Following this, we aim to become more active on social media to raise awareness, share patient experiences, and foster a more connected and informed community.

    We also translated key HAE guidelines into French to ensure that patients throughout Morocco and Francophone Africa have access to clear, reliable information. These translated materials are being reviewed by Prof Bouillet (National coordinator of the Angioedema Reference Center – CREAK) to guarantee quality and alignment with international best practices.

    As part of our commitment to early diagnosis and access to care, AMMAO is collaborating with Ms. Hajar Kalil, a Moroccan PhD student, who is conducting her thesis on HAE in collaboration with Dr Khadija Moussayer, board member of the Moroccan Association. Together, we are offering free C1 Inhibitor testing for a group of patients, helping to uncover undiagnosed cases and connect families with appropriate treatment pathways.

    In another exciting development, we are working in partnership with South African researchers and a local Moroccan laboratory, the “Centre de Biologie de Casablanca”, led by Dr Hicham Ouazzani, to offer free genetic testing for the first time in Morocco. This project represents a major step forward in confirming diagnoses and expanding access to personalized care.

    These ongoing efforts reflect a united movement toward greater visibility, stronger support systems, and improved care for HAE patients in Morocco — and this is just the beginning.

  • From HAE Mozambique

    In recognition of hae day :-), HAE Mozambique was invited to speak on a national TV platform on May 22, 2025. During a 30-minute live segment on STV’s morning show Manhãs Alegres – one of the most-watched programs in Mozambique – we discussed the basics of HAE, its symptoms, and what it’s like living with a rare disease in the country.

    Our patient lead, Daniella Assa, shared her personal journey with HAE, alongside the work that HAE Mozambique has been doing to raise awareness, identify patients, and promote access to treatment. We also invited the public to reach out to the organization if they suspect they may have HAE or would like to get involved with our cause.

    During the interview, Daniella also made a public appeal to the Ministry of Health to support ongoing efforts aimed at improving access to healthcare for patients with rare diseases in Mozambique.

    The program is available to watch here, in Portuguese.

    Following this appearance, we received three calls from individuals suspecting they may have HAE. These cases were referred to our doctors for further evaluation. Additionally, two people reached out with interest in volunteering for the cause – a very encouraging outcome.

    Due to the positive public response, Daniella was invited for a longer, more in-depth interview on STV’s Vidas em Directo, a show that highlights real-life stories from across the country. This interview was recorded on June 7 and aired on June 11. It generated substantial public interest in HAE and the work being done by our member organization.

    In the one-hour segment, Daniella discussed her diagnostic journey, the challenges of living with a rare disease, and the emotional impact of her experience. She closed the interview with a heartfelt message of solidarity, emphasizing that people with HAE are not alone – and highlighting the community support made possible through HAEi’s efforts globally.

    As a result, we received more than 10 calls. Working in collaboration with our local doctors, we have since begun testing and clinical investigations for at least three suspected patients.

    Daniella shared that her LEAP educational experience has significantly improved her understanding of media engagement and the power of building strong relationships with journalists for advocacy purposes. While awareness of HAE in Mozambique remains limited, the interest sparked by these interviews has been incredibly motivating for our team.

  • From HAE Nepal

    We have a few updates:

    1. All the resources are translated into the local language.
    2. HAE Nepal took part in a Patient Advocacy Program and competed amongst 20 plus countries, secured a top 3 position, won a 1000 euro grant, and received it successfully in the bank.
    3. A new website for HAE Nepal has been launched at haenepal.com
    4. A video awareness project with Dr Dharma is in line.
    5. An MOU signing with the Rare Disease Society of Nepal, RDSN, which is a member of Rare Disease International, has been signed by HAE Nepal and awaits signing from RDSN, where we will be collaborating in future events.
  • From Natasha Jovanovska Popovska, President, HAE North Macedonia

    hae day :-) Marked in North Macedonia with a Children’s Book Promotion
    HAE Macedonia marked hae day :-) by a promotion of the children’s book about hereditary angioedema on May 17.

    The book “Rare Boy at a Race: I Swell, But you Cannot Tell – I Run like Hell!” by the author Natasha Angjeleska is the third sequel of the Rare Boy and the Talkative Little Balloon series and has been translated into 8 languages. It is based on a true story about a young boy, Ognen, who suffered a stomach attack but managed to run a marathon after receiving the treatment and was proclaimed the hero of the day by the media.

    The promotion highlighted the importance of having accessibility to treatment for patients with HAE, as in some patients, the quality of life significantly improves over a short period of time. Ognen Jankovski (16) – the inspiration of the book – addressed the audience and said that despite the obstacles we face in our daily lives, we should always move forward without stopping.

    After the promotion, attendees walked through the city center in order to join the HAEi’s initiative of #active4hae to raise awareness of this rare disease.

  • From HAE Panama

    During the month of May, the Panamanian Association of Hereditary Angioedema Patients carried out various awareness and visibility activities.

    • We began by creating an Instagram campaign and sharing important information and graphics about HAE on Instagram.
    • On May 7, the association’s board of directors and other patients met with representatives from the pharmaceutical company that represents the generic drug icatibant in Panama. They learned about the general information about this medication.
    • On Saturday, May 10, the group of patients met at the Panama Canal administration building to have the building illuminated in the colors of HAE Month. There, they distributed flyers to passersby with information about hereditary angioedema, attacks, symptoms, and where to seek help.
    • On May 16, they had a meeting with the head of the emergency department at the Children’s Hospital. They were accompanied by the state coordinator of rare diseases, Dr Johnny Cuevas. The purpose of the meeting was to verify the availability of medications for pediatric patients and to coordinate training for medical staff on the use of HAE medications.
    • Finally, they concluded this month’s awareness-raising event on May 16 with a training session for medical and nursing students at the International University of Panama. This session focused on the general aspects of HAE, led by Dr Olga Melcina Barrera. Dr Johnny Cuevas, the state coordinator of rare diseases, addressed the topic of rare diseases and explained the program run by the Ministry of Health. He also explained how HAE is being managed in the country. The topic of HAE was also addressed from a psychological perspective. This topic was addressed by the psychologist from the Ministry of Health’s rare disease program. This session featured testimony from two HAE patients, Aleyda Milord and Michelle Coronado. Other patients who are members of the association also attended. It’s worth noting that the students were very interested, asked questions, and the auditorium was at capacity. In addition, various buildings at institutions across the country were illuminated during hae day :-).
  • From Carla María Goachet Boulanger, HAE Peru

    Painting Workshop for Patients and Caregivers: “BRING COLOR TO HAE”
    This is how we experienced our gathering for hae day :-)!

    On Saturday, May 24th, patients, family members, and caregivers came together to share a beautiful day dedicated to Hereditary Angioedema (HAE).

    During the event, we painted tote bags in a creative activity that allowed us to express ourselves and connect with one another.

    It was a space for connection, support, and reflection on the importance of improving the quality of life of those living with HAE and those who support them every day.

    Together, we continue to build community and raise awareness

  • From HAE Poland

    Celebrating 20 years: “A season of education and empowerment”, Regional HAE Conferences by “Swelling Beautifully”.
    Over the past months, the Polish HAE Patient Association “Swelling Beautifully” has taken meaningful steps to strengthen the hereditary angioedema (HAE) community through a series of regional conferences designed to inform, support, connect, and celebrate its 20th anniversary. These gatherings were more than informational sessions; they became safe spaces for patients and families to share experiences, deepen their understanding of the disease, and find strength in a community that truly understands the daily realities of living with hereditary angioedema.

    The series began in Warsaw in March, and it was covered in the previous edition of Global Perspectives magazine. The second regional conference, held on June 7, 2025, in Kraków, demonstrated the growing momentum behind this movement. The event welcomed nearly 90 participants from five southern Polish voivodeships: Lower Silesia, Opole, Silesia, Lesser Poland, and Subcarpathia. Themed “Without Boundaries,” the conference addressed both clinical care and personal empowerment. It placed a strong emphasis on self-management and hands-on learning, including self-administration.

    The Conference in Kraków brought together a distinguished panel of experts whose insights gave the audience not only knowledge but confidence:

    • Michał Rutkowski, President of the “Swelling Beautifully” Association, delivered an in-depth presentation on the evolution of patient care over the past 20 years. His historical perspective reminded the audience how far the field has come, and how much remains to be improved.
    • Dr Marcin Sobiecki, from the HAE National Centre in Krakow, reviewed current on-demand and preventative treatments’ availability and reimbursement rules.
    • Dr Robert Pawłowicz, from HAE Regional Centre in Wrocław, presented ongoing clinical trials in HAE, emphasizing the importance of patient participation in research and a bright future for further development in HAE drug discovery.
    • Prof Ewa Cichocka-Jarosz from the Children’s University Hospital (USD) in Kraków focused on the clinical symptoms and their manifestation observed in children and adolescents with HAE. She presented the diagnostic pathway for these patients at the USD hospital, along with case studies of a group of patients under her care.
    • Dr Anna Dzieża-Grudnik, from HAE National Centre in Kraków, provided an update on treatment strategies for children and pregnant women with HAE, the most vulnerable patient groups.
    • Dominika Słodka, “Swelling Beautifully” Regional Patient Advocate and coordinator of the youth group, emphasized the power of patient engagement and how a supportive community can truly transform lives. She shared examples of various youth-led projects and encouraged participants to involve children with HAE and their siblings in multiple events to be organized by both HAE Poland and HAEi.

    Adding an international dimension to the event, our special guest was Fiona Wardman, HAEi Executive Vice President Global Advocacy and Chief Advocacy Officer, who talked about how our global non-profit network of Member Organizations empowers local patient groups to advocate for better future, and what resources HAEi offers to its’ members, so they can effectively advocate for access to and reimbursement of lifesaving therapies.

    While expert talks anchored the conference in scientific rigor, it was the stories shared in the Patient Panel Discussion and between the sessions that truly captured the spirit of the event. Many patients expressed that it was their first time meeting someone else with HAE. That sense of recognition, of finally being seen and heard, was as valuable as any clinical update.

    By choosing to bring their conferences directly to the regions, the HAE Poland is actively dismantling one of the biggest barriers in rare disease care: access, and attracts more patients. These regional events, therefore, do more than inform; they deliver care where it’s needed, making patients feel seen, included, and empowered in their own hometowns.

    Looking ahead, the “Swelling Beautifully” plans to continue this series, ensuring that no matter where someone lives in Poland, they will have the opportunity to connect with experts, learn about the latest treatments, and most importantly, meet others who share their journey. The next and last regional conference of 2025 will be held on 18 October in the city of Poznań in the Higher Poland voivodeship.

  • From Ana Freitas, HAE Portugal

    hae day :-) event: The Portuguese association (ADAH) organized a symbolic walk, with the active participation of its members, to raise awareness of this rare and often invisible disease.

    Special Event: May 9, at Santa Maria Hospital, Lisbon: At the Hospital de Santa Maria, a meeting for patients with HAE was held in commemoration of hae day :-). The meeting was attended by several specialists and included HAE Portugal/ADAH, who gave a presentation on the association’s bridges, partnerships, and synergies. In addition to the in-person meeting, patients also participated virtually via Zoom. At the end of the meeting, ADAH presented a song about the disease.

    Artistic contribution: Renowned Portuguese musician Fernando Tordo released the song “A Esperança Chegou” (Hope Has Arrived), inspired by real testimonies from ADAH patients. The song, available on Spotify, aims to give voice to invisible pain and promote empathy and understanding⁽¹⁾⁽²⁾⁽³⁾.

    This set of actions aimed to raise awareness of the disease, promote early diagnosis, and sensitize society to the challenges faced by those living with HAE.

  • From Janice Strydom, South Africa

    This year for hae day :-) on May 16, 2025, HAE South Africa launched the first in a new series of illustrated children’s books titled “Siya’s Special Superpower”.

    The story follows a young boy with a love for soccer, who learns to navigate life with HAE with resilience and pride. With our series of books, we hope to empower children and their families to embrace their uniqueness while raising awareness of HAE among our community.

    The book has been positively received by families and healthcare professionals, and we are planning to translate it into additional South African languages to expand accessibility and inclusion. Siya’s story is available on our website.

    Our targeted social media campaign leading up to hae day :-) expanded our digital reach, resulting in a 28% increase in engagement. Overall, our advocacy efforts in the past six months of this year have seen strengthened collaborations with other rare disease advocacy groups and academic institutions.

    A number of new drug trials are now enrolling patients in S.A., offering not only hope for better symptom control and quality of life but also reflecting South Africa’s growing role in the global HAE research community.

  • From Soojin Min, HAE Korea

    I am writing this to celebrate the hae day :-) event, which has achieved amazing results in Korea.

    We are pleased to inform you that hae day :-) steps with more than 130 people have reached 544,890. Our patient association gathered to participate in this event and promote HAE, which was supported by the people.

    The 2025 hae day :-) event was held on Saturday, May 10, 2025, in the conference room near Deoksugung Stonewall-gil in Seoul, Korea, to greet each other and walk along the Deoksugung Stonewall-gil to announce hae day :-).

    And I shared the information by uploading the hae day :-) event on the social media platform.

    Congratulations once again on the successful event, and we will try to make more participants active in 2026.

    Thank you for the participation of HAEi and many other countries around the world, and HAE Korea will also work harder to promote HAE.

  • From Sarah Smith, President, HAE Spain (AEDAF)

    April and May were very busy months for AEDAF, with preparations for multiple events to commemorate hae day :-).

    Benefit Concert
    Our most important event was a Benefit Concert that took place on 25 May in the Teatro Monumental of Madrid, performed by the Madrid Marine Infantry Symphonic Band. It was a magnificent concert, and we thank CSL Behring, Biocryst Pharmaceuticals, and Otsuka Pharmaceutical for their sponsorship, the AEDAF Executive Committee for all their help in the organization, particularly our Vice President, Juan Carlos Valera, who was the driving force behind the Concert, and everyone who participated in and attended the event. Very special thanks go to the Band for selflessly donating their time and superb musical skills to raise awareness and give visibility to HAE, and to their conductor, Lieutenant Colonel Miguel Angel Mateo Gijon, who took a special interest in our cause and carefully selected the musical numbers to reflect the patient journey.

    The video of the Concert can be found on our YouTube channel.

    “Historias Que Cuentan”
    AEDAF collaborated with the CSL Behring-sponsored project, “Historias que Cuentan” (Stories That Matter), which was launched on hae day :-). The project consisted of an online patient survey (116 respondents), followed by in-depth interviews with 12 patients and caregivers.

    This initiative was born from the need to give voice to these stories. Through the various narratives, patients and family members share their experiences with the onset of their first symptoms, the path to diagnosis, and how they have learned to live with the disease. These testimonies are also complemented by the survey results, demonstrating that some of the situations talked about in the individual stories are shared by the patient community.

    To facilitate access to all this information, AEDAF has developed “Hereditary Angioedema. Stories That Matter,” a dedicated website, and has published an informational brochure and a booklet that contains the patients’ personal testimonies.

    This campaign highlights the importance of increasing awareness and education about HAE.

    #somosAEHinchas
    Biocryst Pharmaceutical sponsored an incredibly successful social media campaign to educate and raise awareness about HAE: #somosAEHinchas. Hincha in Spanish means an enthusiastic supporter or fan of a soccer (football) team, but “hincha” also comes from the verb “hinchar”, meaning to swell. The campaign was launched on 10 May in the fan zone of the Metropolitano stadium in Madrid, prior to the Atletico de Madrid-Real Sociedad soccer game. With the support of the Atlético de Madrid Foundation, and on the occasion of Children’s Weekend, fans were asked to score a goal against HAE at the “somosAEHinchas” booth, where inflatables helped to show them the symptoms of this rare disease that causes swelling in numerous parts of the body. Two well-known influencers were there to encourage and animate the visitors to take part in the fun. This was then followed by a social media campaign that succeeded in reaching out to a larger-than-expected audience, with many views, shares, and likes.

    Vigo (Galicia)
    A General Clinical Session was held in the Hospital Alvaro Cunquiero of Vigo (Galicia) on 16 May, where Dr Alberto Rivera, Coordinator of the Multidisciplinary Functional Unit on Rare Diseases in Galicia, explained the Galician Rare Disease Strategy and Dr Carmen Marcos, head of the hospital’s Allergy Department, gave a talk on HAE. This was followed by the inauguration of the itinerant interactive exhibition “Poniendo cara al HAE” (Putting a Face on HAE), sponsored by Biocryst.

    Valencia: Giving Visibility to HAE
    On 16 May, the allergy team of Hospital La Fe of Valencia set up a stand in the main hall of the hospital with information on HAE, AEDAF, and HAEi, to give visibility to this rare disease. The idea was to reach out to other patients and personnel who work in the hospital to inform them about HAE and its symptoms.

    “The Rare Boy and the Talkative Little Balloon”, by Natasa Angjeleska
    In addition, to coincide with hae day :-), there was a presentation of the Spanish translation of HAEi’s Regional Patient Advocate, Natasa Angjeleska’s children’s book, “The Rare Boy and the Talkative Little Balloon” (“El niño raro y el globo parlinchín”). Natasa’s book was translated into Spanish by AEDAF members Patricia Rebe and Ignacio Ballester, and the translation was presented on 15 May during an online session on the YouTube channel of the University of Alicante’s Mario Benedetti Center for Iberoamerican Literary Studies. We thank Natasa for her help and enthusiasm in helping Patricia and Ignacio to translate and present her charming book, and we hope to cooperate with her in the future to continue translating into Spanish the children’s books in her series. The translation is available under Recursos on AEDAF’s website and on the HAEi Youngsters’ website.

    Finally, patients and physicians gathered in other hospitals around Spain, including in Barcelona and Almeria, to commemorate hae day :-) 2025 and to raise awareness and educate about HAE. We hope to continue in future years with this level of activity and commitment to raise awareness and improve the lives of HAE patients in Spain and around the world.

  • From Ernst Greber, HAE Switzerland:

    On Saturday, May 24, 2025, we held our annual patient meeting. After a welcome coffee, the various topics were discussed.

    Various treatment options: Three affected patients and HAE experts shared valuable insights, information, and practical tips for everyday life with the various medications: Prof Dr med. Dr Phil. Walter A. Wuillemin, HAE expert, Lucerne Cantonal Hospital, Dr med. Christina Weber, HAE expert, University Hospital Zurich, and Prof Dr med. Dr Phil. Sascha Zeerleder, HAE expert, Lucerne Cantonal Hospital. There was a lively exchange, and various open or uncertain questions were answered.

    After a coffee break, the discussion continued with the following topics:
    Healthy nutrition: The basis for a strong immune system and a better quality of life at any age by Ms. Ils Antonia, nutritionist.
    International HAE Association: Worldwide activities and goals by our HAEi representative, Fanny Schappler.

    After lunch, we were able to experience an interesting tour of Zurich’s SBB main station, something you don’t usually get to see. Afterwards, we concluded the day with a final aperitif.

    For this year’s international hae day :-)
    For this occasion, we surprised the members with a small gift: a luggage tag – in keeping with our motto “Together on the road.” This gift not only represents greater visibility for HAE while traveling and in everyday life, but also our solidarity with all those affected.

  • From Marijk Beekman-Kortekaas, President, HAE the Netherlands

    Members’ Day: Connection, Laughter & A Fresh New Vibe
    On 15 June 2025, something new sparked within our association: the very first Members’ Day, and what a fantastic day it turned out to be! We traded the usual information-packed agenda for a fresh format; one that put personal connection front and center.

    We met at Mooie Boules in Delft, a cozy venue that helped set a relaxed tone. In previous gatherings, we noticed how much people appreciated simply having time to talk, yet the busy program often left little room for that. So this time, we dialed things down and opened things up, and it truly made all the difference.

    We started the day with a short but meaningful general meeting. Updates were shared and insights exchanged. After that, we enjoyed an extended lunch where conversations flowed effortlessly. What made it extra special was the vibrant mix of attendees: young, older, and everything in between. It really reflected our diverse and engaged community.

    Then came the fun: pétanque, Jenga, Dutch shuffleboard, and plenty of games that sparked laughter and a pinch of playful rivalry. People warmed up quickly and soon every turn, toss, and win was met with cheer and conversation. The energy was light and lively; exactly what we had hoped for.

    It was our first time trying out this format, and it worked surprisingly well. We left with a smile and already some excitement about the next edition.

    Save the Date: November 22 – Information Day in Breukelen
    We’re already looking forward to it: on Friday, November 22, 2025, we’re hosting our Dutch annual Information Day, once again at the familiar Hotel Van der Valk in Breukelen.

    The full program is still taking shape, but we can already share an exciting new feature: this year marks the first-ever youngsters program. With it, we’re creating a space where younger participants can connect, feel seen, and join in their own way.

    The registration link will go live soon via our website. As soon as the full agenda is ready, we’ll keep you updated.

    We hope to see you there. Will you be joining us on November 22?

    Empowering Young Voices: Noa Joins HAEi LEAP 2025
    This year, we’re proud to celebrate a special milestone: Noa’s participation in the HAEi LEAP program.

    Noa joined this year’s cohort with enthusiasm and curiosity, representing our community with warmth and dedication. From workshops on storytelling and leadership to connecting with peers from around the world, Noa embraced every challenge and opportunity. We’re especially excited to see how her project will unfold in the coming months. This project is a reflection of her creativity and commitment to making a difference.

    Programs like HAEi LEAP show how powerful youth involvement can be. They don’t just build skills; they build bridges, confidence, and a stronger future for the HAE community.

    Well done, Noa; we’re cheering you on every step of the way!

  • From Arbia Barhoun, HAE Tunisia

    Hereditary Angioedema Patients’ Meeting in Tunisia
    A meeting of angioedema patients affiliated with the Tunisian Association for Angioedema was held at the Sheraton Hotel in Tunis on April 26, 2025. Many thanks to HAEi for their support and assistance in the success of this meeting, which represents a starting point in the progress of achieving our desired goals.

    Thank you, Ms. Maria Ferron and Mr. Mohamed Osman, for your efforts and dedication to helping us. On behalf of myself as a patient and a patient caregiver in Tunisia, and on behalf of all of them, I want you to know that what you are doing is among the most noble and humanitarian of acts.

    The effects of the meeting were evident from the first hours of it, as the patients got to know each other, which led to a feeling of unity, solidarity, security, and enthusiasm. They learned more about this rare disease and our global organization. They learned that they are not alone in struggling with this disease, that treatment exists, and that it is not impossible to acquire it. They felt like a family, and they believed they could achieve their goal by joining hands and working together.

    A group of patients has started on WhatsApp, and the actual work has begun in writing requests to obtain the medicine, with the support of the medical team in Tunisia, headed by Dr Mustafa Belkahia, who is making a great effort with us.

    In the end, this meeting brought smiles to patients’ faces and hope back into their hearts. We are grateful for what you do for us and for all patients around the world.

  • From HAE Ukraine

    This spring, our association carried out a series of events.

    From April 1 to May 31, we joined the flash mob organized by haeday.org, adding our own activities.

    We translated the brochure “Women with HAE”, which is published on the website of the international organization and is available for reading here.

    HAE specialists conducted educational seminars in April and May to raise awareness among doctors and medical professionals across all regions of Ukraine.
    The patient association, with the support of “Takeda”, the Polish “Healthcare Education Institute”, and the technical organizer “Medical Internet Systems”, held the Second All-Ukrainian Scientific and Practical Conference on HAE – “Understanding HAE to Improve Quality of Life” – with the participation of expert doctors from the Central, Western, and Southern regions.

    The conference took place on May 16–18 in the city of Truskavets, with 72 participants.

    Our beloved experienced doctors – Liudmyla Zabrodska, Anastasiia Bondarenko, Tetiana Bondarenko, Khrystyna Lishchuk-Yakymovych, and Liudmyla Samoilenko – made this meeting rich, valuable, and unforgettable.

    The program included introductions of new association members, speeches by the president of the HAE association, Nataliia Formaniuk, and board members Mariia Matkivska, Liudmyla Mekhed, and a representative of the public organization for primary immunodeficiencies – Oksana Strielnykova.

    An important step was the joint creation of a patient guide about the disease and an action plan for seeking medical care.

    In the form of an interactive role-play, volunteers participated and tried themselves in the role of patient rights defenders at a doctor’s appointment. They practiced safe injection techniques and discussed important questions regarding the disease.

    For the first time, a separate program for children was developed, which included an educational lesson on HAE presented by speakers and quizzes with prizes.

    Educators and animators worked with the children, additionally, leading physical exercises, competitions, games, dancing and singing, drawing, and filling the atmosphere with joyful emotions!

    The conference and events allowed patients and their families to share experiences and receive emotional support.

    Speakers’ presentations contributed to a better understanding of HAE, emphasized the importance of screening family members, keeping diaries, and accessing prophylactic treatment where possible.

    Join local and international events to learn more about HAE and support us! Share information about HAE on social media and follow our updates.

    Together, we can make life for people with HAE better and safer.

  • From HAE UK

    HAE UK CEO at EAACI
    Our CEO, Angela, joined a distinguished panel at the EAACI conference in Glasgow, speaking on bi-directional decision-making alongside Dr. Sorena Kiani, Dr. Danny Cohn, and Dr. Marie Campbell.

    hae day :-) Success
    hae day :-) was a hit! Our social media campaign on Shared Decision Making reached wide audiences, with strong engagement and shares from members and beyond – helping to raise awareness of HAE.

    New Treatments on the Horizon
    We’re working hard to gain approval for two new HAE treatments, which we hope will be available to UK patients soon.

    New Patient Journey Videos
    Our website now features powerful new videos showcasing real HAE patient stories of two of our members, and how Shared Decision Making has transformed their care.

    Looking Ahead
    Next, we’re focusing on improving mental health support and starting preparations for a major Rare Disease Day event in 2026.

  • From Jess Meyers,  Communications and Advocacy Manager, US HAEA

    US HAEA Publishes First-Ever Study Showing the Number of People Diagnosed with HAE in the United States

    The HAEA designed this research project to provide a credible estimate of how many people in the US have been diagnosed with HAE. The often-quoted figure of 1 in 50,000 comes from older European studies and only reflects HAE caused by C1 inhibitor deficiency. Our new analysis offers a broader, U.S.-based estimate that includes all forms of diagnosed HAE—addressing a long-standing gap in understanding the true prevalence of the condition.

    Recently published in a top rated peer-reviewed medical journal, this landmark study featured collaboration with leading HAE experts and specialists in data mining and demographic analysis.

    Our goal was to determine, for the first time, how many people in the U.S. are living with HAE—across all known types. To do this, we had to work around a key challenge: there’s no dedicated diagnosis code for HAE in the U.S. billing system. So we developed and validated a unique model that combined a variety of data sources, including insurance claims for HAE-specific medications. Expert HAE physicians then reviewed anonymized records to confirm whether those cases truly reflected HAE.

    We now estimate that nearly 10,000 people in the U.S. have received a diagnosis of HAE. As noted earlier, this number includes all forms of the condition—not just those caused by C1-INH deficiency—and provides the clearest picture yet of the HAE population in the U.S.

    Getting this study published in a respected medical journal is a major milestone for the HAEA community. It gives us real numbers to back up what we’ve long known—that HAE affects more people than older estimates suggested. With this solid, U.S.-based data, we can show we are a bigger force than anyone previously thought. And that puts us in a much stronger position to protect what matters most to people with HAE and their families.

    You can read the full study in the Annals of Allergy, Asthma, and Immunology here!

    US HAEA Celebrates an Unforgettable 2025 National Summit in Baltimore, Maryland
    The 2025 HAEA National Summit, held in Baltimore, Maryland, was an incredible success! From July 10–13, more than 1,400 HAEA community members, including people with HAE, their caregivers, medical professionals, researchers, and industry partners, came together for an unforgettable weekend of education, empowerment, and connection.

    See the article in this edition of Global Perspectives for a detailed overview of this exciting event.

    HAEA Community Blog
    The HAEA community blog features personal narratives detailing the daily struggles of managing HAE and stories of resilience and advocacy. The HAEA Community blog has empowered people with HAE, their caregivers, and other HAE advocates to navigate their HAE journey with confidence.

    Below are excerpts from some recent Community Blog:

    Ally B: My Experience at the HAEi Leap Program

    “This experience gave me more than advocacy skills. It gave me lifelong friendships with incredible people from across the globe. Some were patients, others were caregivers, but all of us shared a common drive to make a difference in the HAE community”.

    Ohm S: From Mystery to Diagnosis: A Decade of Resilience in the Face of Hereditary Angioedema

    “Despite these difficulties, I’m confident that with more awareness, education, legislation, and advocacy surrounding HAE, there will be developments in this space in the near future. I’m dedicated to supporting others in the community affected by this disease, and I encourage everyone to contribute in their own way, regardless of their illness or condition.”

    Zach N: From Tennessee to DC: Raising HAE Awareness on Capitol Hill

    “Over these next few days, we honed in on specific and pertinent policies vital for the rare disease community, not just for HAE but for all thirty million Americans in the United States diagnosed with a rare illness. With that policy in hand and heart, we took to the Capitol, speaking with our representatives and political leaders and urging them to be leaders in making a better and healthier America.”

    Explore the HAEA Community Blog and discover the heartwarming stories, invaluable insights, and empowering voices that unite us in the journey of living with HAE!

    Access the blog at haea.org / News / Community Blog.

Clinical Trials Update

HAE-Related Scientific Publications

  • In addition to a wide range of case reports, reviews, and small case series, here are summaries of recently published HAE-related scientific papers. Data search was undertaken on 23 June 2025.

    Global frequency, diagnosis, and treatment of hereditary angioedema with normal C1 inhibitor

    Markus Magerl, et al

    A global group of authors sought to find out more about the prevalence of HAE with normal C1-inhibitor (HAE-nC1INH) and its current treatment. They conclude that HAE-nC1INH may be more prevalent than previously reported. Additionally, they indicate that there are differences in the way the disease is diagnosed and treated. They call for more clinical trials to identify biomarkers and treatments.

    (Journal of Allergy and Clinical Immunology, August 2025)

    Hereditary angioedema and venous thromboembolism: Where there’s smoke, there’s fire

    Steven P Grover

    The author reviews the growing body of evidence that there are links between HAE and increased risks of blood clots in the blood vessels (venous thromboembolism). He discusses the potential impact of disease-modifying treatment for HAE on blood clotting.

    (Seminars in Thrombosis and Hemostasis, April 2025)

    Adherence and persistence among patients with hereditary angioedema receiving long-term prophylaxis in the United States

    Bruce L Zuraw, et al

    The authors set out to assess how well patients followed an agreed course of treatment (adherence), and how long they used their medication continuously (persistence). They did this by following up with HAE patients based on their electronic health records. They found that the rates of adherence and persistence were uniformly high for all three long-term prophylaxis treatments evaluated.

    (Allergy and Asthma Proceedings, May 2025)

    Population pharmacokinetic/pharmacodynamic and exposure-response modeling of garadacimab in healthy volunteers and patients with hereditary angioedema

    Ramon Garcia, et al

    The authors wanted to identify how the human body responds to a particular dose of garadacimab (200mg, once a month). The findings, the authors suggest, support the use of garadacimab 200mg once-monthly in patients 12 years or over, with no need for dose adjustments. They also indicate that an initial higher dose may provide the onset of protection from week one.

    (CPT: Pharmacometrics & Systems Pharmacology, May 2025)

    Expert consensus on the diagnosis and treatment of hereditary angioedema in China (2024 edition)

    Yingyan Xu, et al

    The authors updated the previous consensus on how HAE should be diagnosed and treated in China. The authors included specialists in allergy, dermatology, and emergency medicine, amongst others. They conclude that, as this is the first time the guidance has been updated since 2019, it standardizes HAE management across China. It emphasizes early diagnosis to prevent life-threatening attacks and recommends individualized treatment strategies tailored to China’s therapeutic landscape.

    (International Archives of Allergy and Immunology, 10 April 2025)

    Comparison of real-world healthcare resource utilization and costs among patients with hereditary angioedema on lanadelumab or berotralstat long-term prophylaxis

    Nicole Princic, et al

    The authors conducted a health economic assessment to compare the costs of HAE treatment with berotralstat and lanadelumab with the expenditure on healthcare resources (such as hospital visits). The authors concluded that HAE patients treated with lanadelumab may require less care and incur lower treatment and healthcare-related costs than those treated with berotralstat.

    (Journal of Comparative Effectiveness Research, April 2025)

    Hereditary angioedema diagnosis evaluation score (HADES): A new clinical scoring system for predicting hereditary angioedema with C1 inhibitor deficiency

    Ricardo Zweiner, et al

    The authors developed a predictive scoring system in order to improve the diagnosis of HAE patients. This study looked at the effectiveness of this scoring system in practice. The authors conclude that their HADES scoring offers a simple and efficient method for improving testing for suspicion of HAE using clinical parameters such as family history and recurrent edema lasting for 24 hours or more.

    (Journal of Allergy and Clinical Immunology: Global, Jan 2025)

    Th2 predominance and decreased NK cells in patients with hereditary angioedema

    Linda Sundler Björkman, et al.

    The authors studied specific cells in the blood of people with HAE to identify if they were elevated compared to healthy people, and if this indicated a higher risk of autoimmune diseases such as lupus. The authors concluded that blood lymphocyte populations are altered in HAE, which may be an important consideration given the increased risks of autoimmunity and allergy associated with the condition.

    (Frontiers in Immunology, May 2025)

    Can depression and anxiety be predicted in hereditary angioedema? A comprehensive assessment

    Hatice Serpil Akten, et al

    The authors assessed the levels of depression and anxiety in patients with HAE, along with factors that influence them. They concluded that patients who experienced frequent severe attacks or recent throat attacks faced a higher risk of psychological distress.

    (Allergy and Asthma Proceedings, May 2025)

    Hereditary angioedema: Patient health care experiences within underrepresented racial and ethnic groups in the United States

    Timothy Craig, et al

    The authors wanted to better understand the experiences and perspectives of HAE care and treatment among patients from underrepresented racial and ethnic groups in the United States. After their research, the authors conclude that barriers to diagnosis and effective treatment (such as difficulties in getting their healthcare provider to consider their background when making decisions) persist among US patients from underrepresented racial and ethnic groups.

    (Annals of Allergy, Asthma and Immunology, April 2025)

    Long-term safety and efficacy of once-daily berotralstat in patients with hereditary angioedema: APeX-S final results

    Henriette Farkas, et al

    The authors aimed to assess the long-term safety and efficacy of berotralstat in patients with HAE due to C1 inhibitor deficiency. Following their research, in which HAE patients received one of two different doses of berotralstat over 96 weeks in the US and 240 weeks in other countries, the authors conclude that their study supports the long-term safety of berotralstat and its efficacy at preventing HAE attacks and improving quality of life.

    (Annals of Allergy, Asthma and Immunology, June 2025)

    Pharmacokinetics, pharmacodynamics, and safety of subcutaneous and intravenous garadacimab following single-dose administration in healthy Japanese and white adults

    Fiona Glassman, et al

    The authors investigated how the human body responds to doses of garadacimab, both in Japanese people and white participants. They conclude that there were no safety concerns or differences in the safety profile of garadacimab between healthy Japanese and white participants.

    (Journal of Clinical Pharmacology, April 2025)

    A national survey of four decades of hereditary angioedema prophylaxis: Efficacy and safety of old and new drugs

    Hanga Réka Horváth, et al

    The authors aimed to assess the use, efficacy, and safety of various long-term prophylaxis (LTP) therapies among Hungarian HAE patients. They conclude that the use of modern prophylaxis is increasing among Hungarian HAE patients. Both modern and traditional LTP options proved safe and effective in Hungarian patients when used with appropriate monitoring.

    (Clinical Immunology, June 2025)

    Garadacimab improves long-term health-related quality of life in patients with hereditary angioedema

    Mar Guilarte, et al

    The authors’ stated objective was to report on health-related quality of life data collected from a phase-3 study of the HAE medicine, garadacimab. The authors conclude that the data show treatment with garadacimab elicited clinically meaningful long-term improvements in health-related quality of life, work productivity, and treatment satisfaction in patients with HAE.

    (Allergy and Asthma Proceedings, May 2025)

    On-demand treatment of hereditary angioedema attacks: Patient-reported utilization, barriers and outcomes

    Sandra Christiansen, et al

    The authors wanted to investigate how patients with HAE approach treating attacks in the real world, especially barriers and delays to treatment, and the impact of any delays when using on-demand treatment. The authors indicate that their data shows that patients felt they treated their attacks earlier than they did. The reasons for delaying on-demand therapy included treatment-related anxiety, and these delays led to more HAE attack severity, duration, and spread to other sites.

    (Annals of Allergy, Asthma and Immunology, May 2025)

    Hereditary angioedema diagnosis: Reflecting on the past, envisioning the future

    Anete S Grumach, et al

    The authors look at the currently available tools for doctors to use in diagnosing HAE, and look at some of the new options that may aid in HAE diagnosis and support better care for people with the condition.

    (World Allergy Organization Journal, May 2025)

    Elevated level of circulating VEGF in Chinese patients with hereditary angioedema and its correlation with disease status

    Ruoyu Ji, et al

    A substance found in the human body, called VEGF, is involved in problems in the walls of blood vessels. The authors wanted to see the importance of this in people with HAE. The authors said their results showed that levels of VEGF were higher in patients with HAE during attack-free periods, suggesting the involvement of VEGF in the process that leads to HAE attacks. They feel VEGF may be a biomarker for disease monitoring in HAE.

    (Orphanet Journal of Rare Diseases, May 2025)

    Effective long-term prophylaxis with lanadelumab in adolescents with hereditary angioedema: EMPOWER/ENABLE

    Raffi Tachdjian, et al

    The authors drew together a range of data on the use of lanadelumab to prevent HAE attacks in adolescents (12 to <18 years). They conclude that their data support the effectiveness and safety of lanadelumab in adolescents with HAE.

    (Pediatric Allergy and Immunology, April 2025)

    Reductions in medical visits and hospitalizations following berotralstat initiation in patients with hereditary angioedema in the United States

    Sandra C Christiansen, et al

    The authors investigated hospital visits and hospitalizations in people with HAE before and after they started taking the HAE medication berotralstat as a long-term prophylaxis (LTP). The authors reviewed a large healthcare database over a two-year period, including 260 patients. The authors found that prophylaxis with berotralstat led to significant reductions in health resource use, regardless of the cause, including fewer HAE attack-related medical visits and use of on-demand treatment.

    (Journal of Managed Care and Specialty Pharmacy, June 2025)

    Content validation of the Angioedema Quality of Life Questionnaire (AE-QoL) in a population of adult and adolescent patients with hereditary angioedema (HAE)

    Lynne Broderick, et al

    The purpose of this study was to find out if the AE-QoL tool was a fit-for-purpose instrument in capturing the impact of HAE attacks on the health-related quality of life of people with HAE. Their research asked a small number of HAE patients to rate their experience with the tool. The authors conclude that there may need to be some revisions for use among adolescents, in general, people with HAE found it relevant, comprehensive, and comprehensible.

    (Journal of Patient Reported Outcomes, April 2025)

    Cascade screening of hereditary angioedema in Pakistan

    Muhammed Hussain, et al

    The authors aimed to establish cascade family screening of newly diagnosed HAE patients in Pakistan, in order to improve early diagnosis of asymptomatic or mildly symptomatic family members of HAE patients. The authors conclude that their work led to further diagnoses and that these will support better management for patients.

    (Journal of the College of Physicians and Surgeons Pakistan, May 2025)

    Recent advances in clinical research on rare and intractable hereditary skin diseases in Japan

    Masashi Akiyama, et al

    The authors describe their work within the Research Group for Rare and Intractable Skin Diseases in the Project for Intractable Diseases of the Ministry of Health, Labour and Welfare of Japan. They indicate that the Angioedema Activity Score and Angioedema Quality of Life Questionnaire have been established for HAE, and that information on HAE (amongst other diseases) has been shared with academic societies, medical professionals, patients, and the general public.

    (Keio Journal of Medicine, March 2025)

    Sustained Effectiveness, Tolerability, and Safety of Long-Term Prophylaxis with Lanadelumab in Hereditary Angioedema: The Prospective, Phase 4, Noninterventional EMPOWER Real-World Study

    Jonathan A Bernstein, et al

    The authors report final data from a trial of lanadelumab used as a long-term prophylaxis treatment for HAE attacks in patients 2 years and over (in the US) and 12 years and over (in Canada). They conclude, based on a study of 109 patients, that there was a marked reduction in the HAE attack rate up to three years after starting treatment with lanadelumab, with no new safety problems identified.

    (Advances in Therapy, June 2025)

    Becoming attack-free further improves health-related quality of life in patients with hereditary angioedema receiving garadacimb

    Petra Staubach, et al

    The authors demonstrated that patients treated with garadacimab who were attack-free had the greatest improvements in their health-related quality of life, bringing them closer to complete disease control and a normal life.

    (Allergy and Asthma Proceedings, May 2025)

    Hereditary angioedema plasma proteomics following specific plasma kallikrein inhibition with lanadelumab

    Dan Sexton, et al

    The authors looked at the biological consequences of specific plasma kallikrein inhibition with lanadelumab. They looked at the levels of certain proteins found in the blood of people with HAE after they had taken lanadelumab. The authors conclude that their analyses confirmed the known biomarkers for HAE and identified potential new options for further investigation.

    (Frontiers of Immunology, May 2025)

    From anxiety to work productivity and activity impairment: The mediating role of fatigue in hereditary angioedema

    Hugo WF Mak, et al

    The authors looked at the impact of fatigue on the lives of people with HAE, and suggest that it is associated with anxiety, work productivity, and the inability to do activities. The authors believe that addressing the unmet need around fatigue would benefit patients’ quality of life.

    (Clinical and Experimental Allergy, June 2025)

    Prediction of hereditary angioedema during attacks in patients with recurrent angioedema: Awareness at a glance with the hereditary angioedema prediction score

    Semra Demir, et al

    The authors aimed to develop a practical scoring system that can be used by doctors unfamiliar with HAE, to predict HAE in patients with recurrent angioedema attacks. After trialing their tool among patients, the authors conclude that their scoring system, called HAEps, is a valuable tool for diagnosing HAE in patients with recurrent angioedema, with a score of 38 or more indicating a strong likelihood of HAE.

    (Clinical and Translational Allergy, April 2025)

    Subjective assessment of sleep quality in adult patients with hereditary angioedema

    Esra Karabiber, et al

    The authors wanted to understand better sleep disorders, such as insomnia, in people with HAE. After asking 23 HAE patients about their quality of sleep, including questions about difficulty falling asleep and insomnia, the authors were able to conclude that poor sleep quality, taking a long time getting to sleep, and increased awakenings are common in people with HAE. They feel that screening for sleep disorders and providing more care for these could help people with HAE have better disease control and quality of life.

    (Frontiers in Neurology, April 2025)

    Factors contributing to non-compliance with on-demand treatment guidelines in hereditary angioedema

    Stephen D Betschel, et al

    The authors asked 107 people with HAE about their use of on-demand therapy and how they did or didn’t use treatment in the event of an attack. The authors found that 57% of respondents did not treat all attacks. In conclusion, the authors state that many HAE patients do not treat attacks early, despite the guidelines recommending that this happen. They believe that open patient-physician communication could be important to improve guideline compliance and management of HAE.

    (Allergy, Asthma and Clinical Immunology, May 2025)

    Assessment of potential drug-drug interactions in patients with hereditary angioedema from the ITACA cohort: simulations from a real-life dataset considering danazol versus berotralstat.

    Andrea Zanichelli, et al

    The authors looked at HAE patients who were taking medications for unrelated conditions, and investigated how likely they would be to have potentially problematic interactions between those medicines and the HAE treatments danazol or berotralstat. The authors conclude that berotralstat was consistently associated with a reduced risk of interactions between drugs compared with danazol.

    (Frontiers in Pharmacology, April 2025)

    The potential of factor XII inhibitors in preventing hereditary angioedema attacks

    James KY Hooi, et al

    The authors review the role of factor XII (FXII) in HAE and how stopping this could provide a new treatment option for the condition. The authors offer an expert opinion that FXII inhibition represents a promising new strategy for HAE management and may address existing unmet needs.

    (Expert Opinion on Biological Therapy, May 2025)

    Urticaria unveiled in hereditary angioedema with carboxypeptidase N mutation

    Pedro Giavina-Bianchi, et al

    The authors describe a novel form of HAE associated with a genetic mutation that affects carboxypeptidase N (CPN). They describe this as causing episodes of both angioedema and urticaria, which is unusual. They indicate that this has added complexity to the understanding of HAE, and a careful approach to diagnosis and treatment is necessary.

    (Journal of Allergy and Clinical Immunology: Global, January 2025)

    Dominant inheritance in hereditary angioedema associated with carboxypeptidase N deficiency

    Tokimasa Hida, et al

    In a similar article to the one above, the authors describe some novel genetic mutations that cause HAE, including those affecting CPN. The authors found a Japanese family who had HAE as a result of this mutation.

    (Allergology International, April 2025)

    Analyzing social media conversations to gain insights into the experiences of patients with hereditary angioedema

    Julia Braverman, et al

    The authors used a social media listening study to hear the experiences of HAE patients and better understand unmet needs. The authors conclude that using social media listening can be a valuable tool to aid in optimizing HAE management, and that disease burden is still considerable for people living with HAE.

    (Allergy and Asthma Proceedings, May 2025)

    Patient-reported outcomes in the phase-III OASIS-HAE study of donidalorsen for hereditary angioedema

    Marc A Riedl, et al

    The authors report on an analysis of donidalorsen, a potential new treatment for HAE, on quality of life and other patient-reported outcomes. The authors conclude that donidalorsen significantly improved quality of life and other patient-reported outcomes versus placebo in patients with HAE.

    (Allergy, April 2025)

    Establishing a hereditary angioedema prevalence for the United States using a large administrative claim database

    Anthony J Castaldo, et al

    The authors, who included individuals working with the US HAE Association, sought to create the first US prevalence estimate for HAE of all types, by using a database of medical insurance claims. The authors conclude that their calculations exceed the frequently cited HAE with C1 Inhibitor deficiency prevalence estimate of two patients per 100,000 people. For the last year of data examined (2020), the prevalence was 2.43 per 100,000. The authors believe their estimate affords a real-world projected prevalence that encompasses all types of HAE.

    (Annals of Allergy, Asthma and Immunology, May 2025)

    Health care providers’ experiences with genetic testing in patients at risk for hereditary angioedema

    Dawn A Laney, et al

    The authors aimed to assess healthcare providers’ (HCPs) experiences, practices, and comfort levels with genetic testing in patients who might have HAE. The authors conclude that although HCPs consider genetic testing for HAE, many lack confidence in ordering or interpreting results. The authors feel that further education of HCPs is needed and that increased collaboration with genetic experts will further support them.

    (Journal of Allergy and Clinical Immunology: Global, February 2025)

    Safety and pharmacokinetics of long-acting plasma kallikrein inhibitor navenibart (STAR-0215) in healthy adults

    William Lumry, et al

    The authors aimed to evaluate the safety, tolerability, and ways in which the human body processes navenibart, a potential new treatment to prevent HAE attacks. The authors gave the medicine to health volunteers, and in doing so, conclude that up to 1200mg of the medicine was well tolerated and lasted a long time in the human body.

    (Annals of Allergy, Asthma and Immunology, July 2025)

    Clinical validity of dried blood spot assay for the measurement of functional C1 inhibitor in angioedema due to C1 inhibitor deficiency

    Jonathan A Bernstein, et al

    The authors aimed to investigate the value of a new potential way to diagnose HAE, using only a dried spot of blood. The authors conclude that this new method is as sensitive and specific in aiding HAE diagnosis as another commonly used laboratory method of analysis. The authors believe this new method may have extra value in regions where diagnosis is currently hampered.

    (Journal of Allergy and Clinical Immunology: Global, January 2025)

    Substitution of reactive centre loop residues from C1 esterase inhibitor increases the inhibitory specificity of alpha-1 antitrypsin for plasma kallikrein

    Sangavi Sivananthan, et al

    The authors report some early scientific work aimed at developing more effective C1-esterase inhibitors.

    (Journal of Biotechnology, May 2025)

    The impact of COVID-19 on patients with bradykinin-mediated angioedema in the ITACA cohort

    Riccardo Senter, et al

    The authors used a large registry of HAE patients to find out whether they were at greater risk of COVID-19 and/or suffered worse disease. They conclude that HAE patients were not at greater risk of COVID and the clinical course of a COVID infection was not worse in HAE, although the severity of COVID-19 influences the features of acute angioedema attacks.

    (Clinical and Experimental Allergy, May 2025)

    Real-world evidence of the effectiveness and utilization of subcutaneous C1INH long-term prophylaxis in patients with HAE in Spain and Germany

    Marcus Maurer, et al

    The authors reviewed the outcomes of patients with HAE treated with subcutaneous long-term prophylaxis with C1-inhibitor replacement therapy. The authors conclude that emergency room visits and use of rescue medication were reduced, as was the annual rate of attacks in patients on long-term prophylaxis.

    (Frontiers of Immunology, May 2025)

    A call to action to use icatibant down to age 2 for hereditary angioedema

    Aisha Mutch, et al

    The authors suggest that, from their professional practice, it is appropriate to prescribe icatibant for children as young as two years old, as there is a need for therapies for young children with HAE in the United States.

    (Annals of Allergy, Asthma and Immunology, May 2025)

    Lanadelumab for prevention of attacks of non-histaminergic normal C1 inhibitor angioedema: results from the randomized, double-blind CASPIAN Study and CASPIAN open-label extension

    Marc A Riedl, et al

    The authors indicate that there is a lack of clinical trial data in preventing HAE with normal C1-inhibitor. They present the results of 77 patients treated either with lanadelumab, a targeted treatment for HAE, or receiving a placebo. The authors conclude that lanadelumab safety was similar in this patient population to that seen in previous studies. They report that efficacy was inconclusive, although there may be some benefit in symptom control.

    (Frontiers of Immunology, May 2025)

    Inhibition of activated coagulation factor XII by the phosphodiesterase-4 inhibitor roflumilast: In vitro and in silico studies

    Hassan A Madkhali, et al

    The authors are investigating the effect of existing medicines, phosphodiesterase-4 inhibitors, on the function of Factor XII in the human body. This could have potential benefits for HAE as a result of FXII mutations. The authors conclude that one medicine, called roflumilast, could have future potential in preventing HAE.

    (Frontiers of Bioscience-Landmark, May 2025)

HAEi reports on news from the industry

  • 1 May, 2025

    New data on navenibart, a potential HAE medicine, published in the Annals of Allergy, Asthma & Immunology

    The results from a Phase 1a trial of navenibart in healthy subjects have been published in the journal Annals of Allergy, Asthma & Immunology. The pharmaceutical company developing navenibart, Astria Therapeutics, announced that these data supported the medicine’s potential to provide long-acting, safe, and effective attack prevention for hereditary angioedema (HAE), with dosing every 3 and 6 months.

    Christopher Morabito MD, Chief Medical Officer at Astria Therapeutics, said: “We are thrilled by our publication in the Annals of Allergy, Asthma & Immunology and the opportunity to provide additional information that affirms our belief in navenibart’s potential. The Phase 1a trial in healthy subjects laid the foundation for the advancement of navenibart and charted a path toward initiating ALPHA-ORBIT, our currently enrolling pivotal Phase 3 trial. The Phase 3 program, designed to introduce a potentially life-changing HAE therapy to eligible participants around the globe, is underway.”

    Overview of results from the Phase 1a trial of navenibart in healthy subjects:

    • For all doses ≥300 mg, navenibart mean half-life ranged from 82 to 105 days, supporting the potential for administration every 3 and 6 months. Navenibart’s inhibition of plasma kallikrein activity versus placebo was statistically significant (P<0.05).
    • Navenibart was well-tolerated, with similar rates of adverse events between navenibart and placebo, and no serious adverse events were observed.
    • Results demonstrated early proof of concept for navenibart as a potential long-acting therapy for HAE.

    (Source: Astria)

  • 5 May, 2025

    Updates on berotralstat

    A series of updates on berotralstat, also called Orladeyo, which is currently in some countries, were provided by the pharmaceutical company BioCryst. The key updates were:

    • The company has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) to expand the berotralstat label to children with HAE aged 2 to 11 using an oral granule formulation. The company also expects to submit regulatory filings in 2025 in global territories, including Europe, Japan and Canada. Berotralstat would be the first targeted oral prophylactic therapy for children with HAE.
    • HAE patients who describe a strong preference for an oral prophylaxis therapy increased to 70 percent, up from 50 percent in 2023, in the company’s latest market survey of HAE patients.
    • The number of patients treated with berotralstat outside the US continued to grow in new and existing markets.

    Dr Helen Thackray, Chief Research and Development Officer of BioCryst, said: “As we move closer to delivering an urgently needed oral prophylactic therapy to children with HAE, we are simultaneously progressing two clinical-stage programs in Netherton syndrome and DME towards the first patient data later this year.”

    (Source: BioCryst)

  • 14 May, 2025

    Corporate update from company developing NTLA-2002, a potential gene therapy for HAE

    A series of updates were given on NTLA-2002, which is currently being trialled in patients with HAE, by the pharmaceutical company Intellia Therapeutics. The key updates shared with HAEi were:

    • Additional data from the ongoing Phase 1/2 study of NTLA-2002 will be presented in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 on Sunday 15 June in Glasgow, United Kingdom. The presentation will include longer-term durability data from patients in the Phase 1 portion of the Phase 1/2 study.
    • Enrollment is progressing in the global Phase 3 HAELO study, and the Company expects to complete enrollment in the third quarter of 2025.
    • It is expected that new and longer-term data from the Phase 2 portion of the ongoing Phase 1/2 study will be presented in the second half of 2025. The data will include patients who initially received a 25 mg dose or placebo and were subsequently given the 50 mg dose of NTLA-2002 selected for the Phase 3 study.
    • The Company is on track to submit a Biologics License Application (BLA) in the second half of 2026.

    Intellia President and Chief Executive Officer John Leonard MD, said: “Intellia is full steam ahead and making excellent progress across its clinical programs. Upcoming catalysts include longer-term data from the ongoing Phase 1 study of NTLA-2002 at the upcoming EAACI Congress in addition to updated data from the Phase 2 study of NTLA-2002 in the second half of 2025.”

    (Source: Intellia)

  • 14 May, 2025

    Updates provided on navenibart, a potential HAE medicine currently being trialled in patients

    A series of updates on navenibart, which is currently undergoing testing amongst HAE patients, were provided by the pharmaceutical company Astria Therapeutics. The key updates shared with HAEi were:

    • The ALPHA-ORBIT pivotal Phase 3 trial of navenibart in people with hereditary angioedema (HAE) is enrolling patients, with top-line results expected in early 2027. The ALPHA-ORBIT trial is a global, randomized, double-blind, placebo-controlled Phase 3 clinical trial to evaluate the efficacy and safety of navenibart over 6 months and includes both every 3-month (Q3M) and every 6-month (Q6M) treatment arms.
    • The navenibart Phase 3 program consists of the ALPHA-ORBIT Phase 3 trial and the ORBIT-EXPANSE long-term trial, which are designed to support registration globally.
    • Positive final top-line results from target enrollment in the Phase 1b/2 ALPHA-STAR trial of navenibart were announced in December 2024. These showed rapid onset of robust and durable efficacy, favorable safety and tolerability, and pharmacokinetics and pharmacodynamics consistent with sustained plasma kallikrein inhibition for both Q3M and Q6M administration. Final results included reduction in mean monthly attack rate of 90-95% and up to a 67% attack-free rate over 6 months.
    • All of the 16 target enrollment patients from ALPHA-STAR have entered the ALPHA-SOLAR long-term open-label trial. Initial safety and efficacy data from ALPHA-SOLAR, with long-term Q3M and Q6M administration, are expected mid-2025.

    Jill C Milne PhD, Chief Executive Officer at Astria Therapeutics, said: “As a late-stage clinical company, we are focused on delivering on navenibart, a therapy with a trusted mechanism and modality, best-in-class profile, and the potential to change the way that people live with HAE. Our goal is to ensure that navenibart reaches its full potential as the market-leading HAE therapy. We are thrilled with patient and physician enthusiasm for the program as we enroll patients in our trial. With STAR-0310, we anticipate early proof-of-concept results from the Phase 1a trial in Q3, which we expect to be informative on differentiation regarding efficacy, safety, and low treatment burden and next steps.”

    (Source: Astria)

     

  • 14 May, 2025

    Updates provided on deucrictibant, a potential HAE medicine currently being trialled in patients

    A series of updates on deucrictibant, which is currently undergoing testing amongst HAE patients, were provided by the pharmaceutical company Pharvaris. The key updates shared with HAEi were:

    • RAPIDe-3, a pivotal global Phase 3 study evaluating deucrictibant immediate-release capsule (20 mg) for the on-demand treatment of HAE attacks in adults and adolescents (12 years and older), reached target enrollment in March 2025; the study continues to assess HAE attacks in approximately 120 participants.
    • CHAPTER-3 is a randomized, double-blind, placebo-controlled Phase 3 study of orally administered deucrictibant extended-release tablet for the prophylaxis against angioedema attacks in adults and adolescents (12 years and older) with HAE. The study aims to enroll approximately 81 participants and randomize them in a 2:1 ratio to receive deucrictibant extended-release tablet (40 mg/day), which is the intended commercial dosage, or placebo, once daily for 24 weeks. Pharvaris anticipates announcing topline data of CHAPTER-3 in the second half of 2026.
    • Data from a recent food effect study, which further supports that the extended-release tablet can be administered with or without food, will be presented at an upcoming medical congress.
    • Following review of preclinical and clinical data, the U.S. Food and Drug Administration (FDA) has accepted Pharvaris’ TQT (through QT) study waiver requests. These waivers apply to the prophylactic program (IND153097) for deucrictibant extended-release formulation and the on-demand program (IND155872) for deucrictibant immediate-release formulation. Previously, Pharvaris has presented clinical and nonclinical data demonstrating that deucrictibant has no evident effect on cardiovascular parameters.

    Berndt Modig, Chief Executive Officer of Pharvaris, said: “Our interactions with the HAE community combined with the regulatory receipt of orphan drug designation for deucrictibant in both the U.S. and EU, strengthen our belief that deucrictibant has the potential to address unmet needs of people living with all types of bradykinin-mediated angioedema, including those with HAE with normal C1 inhibitor and with AAE-C1INH. We will detail our plans to expand the potential treatment opportunities of deucrictibant beyond people with HAE type 1/2 during an R&D call in June. We are diligently working to achieve our clinical, regulatory, and pre-commercial aspirations for 2025 and bring deucrictibant to people living with bradykinin-mediated angioedema.”

    (Source: Pharvaris)

  • 14 May, 2025

    An oral formulation of berotralstat, a potential treatment for children with HAE, to be considered by Federal Drug Administration (FDA) in United States

    An announcement regarding a potential new oral granules formula of berotralstat, an HAE medicine which is also called Orladeyo, were provided by the pharmaceutical company BioCryst. The key updates shared with HAEi were:

    • US Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for the use of oral, once-daily berotralstat in pediatric patients with hereditary angioedema (HAE) aged 2 to 11 years. The FDA also granted Priority Review of the application, with a Prescription Drug User Fee Act (PDUFA) target action date of 12 September 2025.
    • The NDA was based on positive interim data from the APeX-P clinical trial, the largest trial evaluating a prophylactic therapy for HAE in patients 2 to 11 years of age. Interim results showed berotralstat was well tolerated and demonstrated a very consistent safety profile across this age group, and resulted in early and sustained reductions in monthly attack rates.
    • If approved, berotralstat would be the first targeted oral prophylactic therapy for children with HAE under the age of 12.

    Jon Stonehouse, President and Chief Executive Officer of BioCryst, said: “We are excited to take another step closer to bringing berotralstat to younger pediatric patients with HAE. We consistently hear from patients, caregivers and physicians about their desire for a more convenient therapeutic option to treat young children with HAE, and we now may have the opportunity to bring this to them later this year.”

    Dr Helen Thackray, Chief Research and Development Officer of BioCryst. “As detailed in the results from APeX-P, we observed that participants experienced serious HAE attacks at a very early age, with a median age of HAE symptom onset of two years, which suggests there is a larger burden of disease at an earlier age than has been appreciated thus far. If approved, we believe this oral granule formulation could help children with HAE and their families better manage their condition and avoid the traumatic experience of acute attacks with emergency care or hospital stays.”

    (Source: BioCryst)

  • 22 May, 2025

    New data on sebeltralstat, a potential HAE medicine currently being trialled, to be presented at scientific conferences

    Data on sebeltralstat, which is currently undergoing testing amongst HAE patients, will be presented across ten abstracts at the forthcoming 14th C1-inhibitor Deficiency & Angioedema Workshop in Budapest, Hungary, and the Eastern Allergy Conference (EAC) in Palm Beach, Florida. The abstract details, shared with HAEi, are:

    C1-inhibitor Deficiency & Angioedema Workshop

    • In their own words, patient perspectives on time to feeling in control of an HAE attack (P-18)
    • Time to end of progression of hereditary angioedema attacks treated with sebetralstat (P-25)
    • Impact of injectable HAE on-demand treatments on health-related quality of life: a patient and caregiver interview study (P-29)
    • Effectiveness of sebetralstat for the on-demand treatment of mucosal hereditary angioedema attacks: interim analysis from KONFIDENT-S (O-29)
    • Anxiety associated with hereditary angioedema attacks: results from the phase 3 KONFIDENT trial of oral sebetralstat (O-32)
    • Survey results from Italy, the US, UK, and France: Anxiety in patients using injectable on-demand treatments for hereditary angioedema attacks (P-32)

    EAC

    • Effectiveness of sebetralstat for severe or very severe hereditary angioedema attacks in KONFIDENT-S
    • On-demand treatment of hereditary angioedema attacks with sebetralstat in older adults: Interim analysis from KONFIDENT-S
    • Time to end of progression of hereditary angioedema attacks treated with sebetralstat
    • Long-Term prophylaxis compliance and healthcare resource utilization in hereditary angioedema: A claims database analysis

    Both meetings will take place from 29 May – 1 June 2025.

    (Source: KalVista)

  • 22 May, 2025

    Data from a real-world clinical trial shows effectiveness of berotralstat in reducing rates of HAE attacks in adolescents and people with severe HAE

    The results of two clinical trials, in which berotralstat (Orladeyo) was tested in adolescents and people with severe HAE, were provided by the pharmaceutical company BioCryst. The key updates shared with HAEi were:

    Patients with severe HAE

    • Patients experienced significantly lower HAE attack rates while on berotralstat in each 90-day follow-up period (1.24-1.90 attacks/month) compared to baseline (7.78-8.23 attacks/month).
    • Patients experienced significantly fewer HAE attacks per month following berotralstat initiation during every 90-day follow-up period relative to baseline.

    Adolescents

    • Adolescent patients had significantly lower HAE attack rates while on berotralstat during each 90-day follow-up period (0.36-0.76 attacks/month) compared to the mean baseline rate (2.07-2.30 attacks/month).
    • Compared to baseline, adolescents experienced statistically significant and sustained reductions in HAE attack rates after berotralstat initiation during each 90-day follow-up period.

    Dr. Raffi Tachdjian, Associate Clinical Professor of Medicine & Pediatrics, Division of Allergy & Clinical Immunology, David Geffen School of Medicine, said: “The outcomes detailed in these posters show how Orladeyo is making a difference for people living with HAE, in particular those with very severe disease and those who are adolescents. These two groups experienced far fewer attacks per month compared to baseline after starting Orladeyo. These kinds of real-world results should give physicians as well as their HAE patients the additional confidence to improve control of their attacks.”

    These data were presented in two posters at the 2025 International Society for Pharmacoeconomics and Outcomes Research conference (ISPOR), which was held in Montreal from 13-16 May 2025.

    (Source: BioCryst)

  • 23 May, 2025

    New data on navenibart, a potential HAE medicine currently being trialled, to be presented at scientific conferences

    Two abstracts on navenibart, which is currently undergoing testing amongst HAE patients, will be presented at the forthcoming 14th C1-inhibitor Deficiency & Angioedema Workshop in Budapest, Hungary, and the Eastern Allergy Conference (EAC) in Palm Beach, Florida. The abstract details, shared with HAEi, are:

    • Navenibart for hereditary angioedema (HAE): Analysis of safety, pharmacokinetic, and pharmacodynamic data from Phase 1a and Phase 1b/2 ALPHA-STAR trial
    • Treatment with navenibart (STAR-0215) reduces attack severity and use of rescue medication in patients with hereditary angioedema (HAE): Interim results from the ALPHA-STAR trial

    Both meetings will take place from 29 May – 1 June 2025.

    (Source: Astria)

  • 2 June, 2025

    New data on clinical development of deucrictibant shared at clinical conference in Budapest

    A number of clinical trials of deucrictibant, a potential medicine to prevent and treat HAE, reported new data at the recent 14th C1-Inhibitor Deficiency and Angioedema Workshop in Budapest, Hungary. The pharmaceutical company Pharvaris shared the following summary of the data with HAEi:

    • Deucrictibant data shows single-dose durability without symptom reoccurrence in the majority of HAE attacks treated
    • First-ever bradykinin B2 receptor mechanism-on-mechanism prophylactic/on-demand data supports potential for deucrictibant portfolio
    • Clinically validated biomarker assay has potential to eventually expand treatment opportunities of deucrictibant into additional forms of bradykinin-mediated angioedema
    • Epidemiologic data and cognitive interviews further elucidate the unmet needs in bradykinin-mediated angioedema

    Berndt Modig, Chief Executive Officer of Pharvaris, said: “Additional analyses of deucrictibant data demonstrate consistency in the clinical profile shown in both the prophylactic and on-demand treatment settings. Deucrictibant’s early-onset and durable treatment response in the on-demand setting, the maintenance of attack reduction for over a year and a half in the prophylactic setting, and the potential for deucrictibant to be used together in both the prophylactic and on-demand settings, if needed, provide additional evidence of deucrictibant’s potential in the treatment of bradykinin- mediated angioedema. Pharvaris continues to diligently execute on the deucrictibant clinical program and is planning for two pivotal data readouts in the next 18 months.”

    Peng Lu MD PhD, Chief Medical Officer of Pharvaris, stated: “Deucrictibant remains the only drug in development for bradykinin-mediated angioedema that has the potential to both prevent attacks and treat them when they occur. The data from the ongoing study further bolsters the potential value proposition of deucrictibant as it provides initial evidence that a bradykinin B2 receptor antagonist can effectively manage a breakthrough attack during treatment with a B2 receptor antagonist, if it were to occur. We believe further confirming these post-hoc open-label findings in our ongoing CHAPTER-3 study would provide additional evidence on the potential of deucrictibant to help address unmet needs of people living with bradykinin-mediated angioedema.”

    (Source: Pharvaris)

  • 2 June, 2025

    New data on sebeltralstat to be presented at forthcoming European scientific meeting

    The findings of six abstracts on sebeltralstat, which is currently undergoing testing amongst HAE patients, have been accepted for presentation at the forthcoming European Academy of Allergy and Clinical Immunology (EAACI) Congress. Details of the abstract which will be presented were shared with HAEi:

    • Potential for Sebetralstat to Address Pseudo-allergic Reaction Burden Secondary to Icatibant in HAE
    • Psychological Burden Associated with Injectable HAE On-Demand Treatments: A Patient and Caregiver Interview Study
    • Sebetralstat for Treatment of HAE Attacks in Patients Receiving Berotralstat, Lanadelumab, or C1 Inhibitor for Long-term Prophylaxis: Interim Analysis from KONFIDENT-S
    • Adherence to Long-Term Prophylaxis for Hereditary Angioedema and the Impact on On-demand Treatment Claims in the US
    • Anxiety Associated with Parenteral On-Demand Treatment for Hereditary Angioedema Attacks in Patients from Italy
    • Impact of Delayed Treatment of Hereditary Angioedema Attacks: Insights from Patient Surveys Across France, the United Kingdom, and the United States

    (Source: KalVista)

  • 2 June, 2025

    New data on berotralstat to be shared at 2025 meeting of the European Academy of Allergy and Clinical Immunology

    New data on the use of berotralstat (Orladeyo) for the prevention of HAE attacks will be presented at the European Academy of Allergy and Clinical Immunology (EAACI) meeting, according to an announcement shared by the pharmaceutical company BioCryst.

    Four abstracts will be presented at the meeting:

    • Impact of Berotralstat on Quality of Life among Patients with Hereditary Angioedema: Pooled Analysis of the APeX-2 and APeX-J Trials
    • Patients with HAE Report Positive Perceptions Following Berotralstat Treatment: Results from a Focus Group
    • Assessment of the Effectiveness and Tolerability of Berotralstat for Long-term Prophylaxis in Hereditary Angioedema: Findings from the Berolife Study
    • Berotralstat Use Reduced Number of HAE Attacks Requiring Treatment or Professional Care in Pediatric Patients: Interim Results from APeX-P

    The EAACI meeting will take place in in Glasgow, United Kingdom, from 13-16 June 2025.

    (Source: BioCryst)

  • 2 June, 2025

    New data on sebeltralstat highlights medicine’s potential in HAE management

    The findings of a series of studies on sebeltralstat, which is currently undergoing testing amongst HAE patients, were announced by the pharmaceutical company KalVista and shared with HAEi. The company announced:

    • New sebetralstat findings related to time to end of progression of hereditary angioedema (HAE) attacks
    • The effectiveness of treatment of attacks considered the most debilitating by patients, mucosal attacks, and attacks that have progressed in severity after a treatment delay.

    These data were presented at two congresses taking place concurrently: the 14th C1-inhibitor Deficiency & Angioedema Workshop in Budapest, Hungary, and the Eastern Allergy Conference (EAC) in Palm Beach, Florida, from 29 May – 1 June 2025.

    One of the healthcare professionals conducting these trials, Dr William Lumry MD, Clinical Professor of Internal Medicine at the University of Texas Southwestern Medical School in Dallas and Director at Allergy and Asthma Research Associates, Dallas, Texas, United States, said: “Stopping the progression of an HAE attack as early as possible is paramount to mitigating its impact on patients. In both the KONFIDENT and KONFIDENT-S studies, sebetralstat halted attack progression in a median time of 19.8 minutes. As prior data have demonstrated near-complete plasma kallikrein inhibition 15 minutes after treatment, this analysis reveals that attacks are halted minutes after absorption. The consistency of findings across the KONFIDENT and KONFIDENT-S trials underscores the potential of sebetralstat as an effective and rapid-acting on-demand treatment for HAE attacks.”

    Another of the clinical triallists, Henriette Farkas, M.D., PhD, DSc, Professor of Allergology and Clinical Immunology at Semmelweis University and Head of the Hungarian Angioedema Center of Reference and Excellence, Budapest, Hungary, said: “Mucosal HAE attacks, particularly those affecting the larynx, are a significant concern for patients and clinicians due to the risk of rapid progression and severe consequences, including the possibility of asphyxiation if left untreated. These interim data from KONFIDENT-S demonstrate that sebetralstat provided rapid relief and resolution of both abdominal and laryngeal attacks with a favorable safety profile. Patients were able to self-administer sebetralstat very early in the course of an attack, when most attacks were still mild or moderate in severity.”

    Paul Audhya MD MBA, Chief Medical Officer of KalVista, said: “Even in real-world, high-stakes scenarios—be it mucosal attacks or severe attacks due to delayed treatment—sebetralstat consistently delivered rapid and reliable relief. The uniformity of these results, paired with an oral tablet formulation, solidifies our belief that sebetralstat can empower patients to act swiftly and recover quickly. We remain committed to bringing this innovative therapy to the HAE community as quickly as possible.”

    (Source: KalVista)

  • 6 June, 2025

    Berotralstat to reimbursed in the Netherlands

    The Zorginstituut Nederland has issued a positive recommendation on berotralstat (Orladeyo) for the routine prevention of HAE attacks in patients aged 12 years and over, according to a statement shared with the HAEi.

    The pharmaceutical company BioCryst notes that this means the medicine is now reimbursed in all major European countries.

    Abid Karim, General Manager of Europe at BioCryst, said: “From day one, our mission has been to bring Orladeyo to as many people living with hereditary angioedema as possible. Securing reimbursement in the Netherlands is a proud moment for our team as it means that patients and physicians across all major European countries now have access to a modern, oral prophylactic option to help prevent HAE attacks.”

    (Source: BioCryst)

  • 13 June, 2025

    New data on navenibart, a potential HAE medicine currently being trialled, presented at key European Congress

    Positive results drawn from two long-term, ongoing, clinical studies of navenibart to prevent HAE attacks, were presented at the recent 2025 European Academy of Allergy and Clinical Immunology Congress.

    The data presented was one of four studies showcased at the EAACI Congress. These were:

    • Long-term Safety and Efficacy of Navenibart in Participants with Hereditary Angioedema (HAE): Initial Combined Results from ALPHA-STAR and ALPHA-SOLAR
    • Unveiling the Underlying Mechanism of Differentiation for STAR-0310, an Anti-OX40 Antibody for Atopic Dermatitis
    • Results from the ALPHA-STAR Trial, a Phase 1b/2 Single and Multiple Dose Study to Assess the Safety, Tolerability, Clinical Activity, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Navenibart in Participants with Hereditary Angioedema (HAE)
    • ALPHA-ORBIT: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Navenibart in Participants with Hereditary Angioedema (HAE)

    Christopher Morabito MD, Chief Medical Officer at Astria Therapeutics, said: “We are thrilled to share positive initial results from the ALPHA-SOLAR long-term open-label trial. Results are consistent with navenibart’s best-in-class profile that we saw in the ALPHA-STAR Phase 1b/2 trial. With now 12 to 18 months on navenibart, these ALPHA-SOLAR results support navenibart’s favorable profile and the potential to administer navenibart every 3 and every 6 months. The Phase 3 ALPHA-ORBIT trial is evaluating both every 3- and every 6-month regimens and is actively enrolling patients.”

    Dr William Yang MD PRCPC FAAAAI, Chair of the Ottawa Allergy Research Corporation and Red Maple Trials Inc, said: “The navenibart results in patients to date support the potential for patients to have long-acting protection from their HAE attacks with very low treatment burden. We are excited for the Phase 3 ALPHA-ORBIT trial and believe that navenibart’s profile with infrequent dosing could allow patients to spend less time thinking about their HAE, and more time living their lives.”

    (Source: Astria)

  • 15 June, 2025

    Positive data from trial of potential HAE gene therapy presented at key European congress

    All ten HAE patients who were trialling a potential gene therapy were attack-free and treatment-free after 23 months of follow-up, according to new data presented the recent 2025 European Academy of Allergy and Clinical Immunology (EAACI) Congress. Originally known as NTLA-2002, the potential therapy is now known as lonvoguran ziclumeran or lonvo-z.

    The data, shared with HAEi by the pharmaceutical company Intellia Therapeutics, showed that:

    • With up to three years of follow-up, a single dose of lonvo-z led to a 98% mean reduction in monthly HAE attack rate in all 10 patients
    • All 10 patients were attack-free and treatment-free for a median of 23 months through the latest follow-up, demonstrating the potential of lonvo-z to become the first one-time therapy for most HAE patients
    • Lonvo-z was well tolerated and continues to demonstrate a favorable safety profile

    Intellia President and Chief Executive Officer John Leonard MD said: “Seeing all 10 patients in the Phase 1 portion of this study free from both HAE attacks and chronic therapy at nearly two years of median follow-up is incredibly encouraging. These data fuel our optimism for the outcomes of our ongoing Phase 3 HAELO study, which we expect to report in the first half of 2026.”

    Dr Joshua Jacobs, Medical Director, Allergy and Asthma Clinical Research, Inc, said: “People living with HAE often report a reduced quality of life because they worry about the likelihood of their next attack, either because they still experience attacks or are reminded of it by their use of chronic therapy. Based on the data, it is reasonable to expect lonvo-z could offer patients the potential to be free from both physical HAE attacks and the burden of managing chronic HAE treatment.”

    (Source: Intellia)

  • 16 June, 2025

    New data on efficacy and safety of HAE medicine berotralstat presented at key European congress

    The long-term efficacy and safety of berotralstat (Orladeyo) was examined in a series of new studies, presented at the 2025 European Academy of Allergy and Clinical Immunology (EAACI) Congress.

    Four studies were presented by the pharmaceutical company BioCryst:

    • Berotralstat Use Reduced Number of HAE Attacks Requiring Treatment or Professional Care in Pediatric Patients: Interim Results from APeX-P
    • Assessment of the Effectiveness and Tolerability of Berotralstat for Long-term Prophylaxis in Hereditary Angioedema: Findings from the Berolife Study
      • Impact of Berotralstat on Quality of Life in Patients with Hereditary Angioedema
      • Patients With HAE Report Positive Perceptions Following Berotralstat Treatment: Results from a Focus Group

    Helen Thackray, Chief Research and Development Officer of BioCryst, said: “These data from both clinical trials and real-world settings continue to strengthen the evidence that Orladeyo is an effective and well-tolerated long-term prophylactic treatment for HAE. Importantly, patients report not only fewer and less severe attacks, but also meaningful improvements in daily functioning and emotional well-being. This contributes to the growing body of evidence supporting the use of Orladeyo as a long-term prophylactic option for adolescents and adults living with HAE.”

    (Source: BioCryst)

  • 16 June, 2025

    New data presented on us of sebeltralstat to relieve breakthrough attacks in HAE patients on long-term prophylaxis

    Effective on-demand (OD) treatment for HAE attacks remains extremely important among patients receiving long-term prophylaxis (LTP), according to new data presented at the recent 2025 European Academy of Allergy and Clinical Immunology (EAACI) Congress. The pharmaceutical company KalVista said the data showed that:

    • Less than half (44%) of HAE patients using LTP were adherent based on refill data over 12 months
    • In an analysis of a trial, involving 35 participants receiving berotralstat, lanadelumab, or C1 inhibitor (C1-INH), 382 attacks were treated with sebetralstat

    One of the clinical trialists, Dr Marc Riedl MD, Professor of Medicine and Clinical Director of the US Hereditary Angioedema Association Center at the University of California, San Diego, commented: “Even with advancements in HAE long-term prophylactic treatments, attacks still occur, highlighting the critical need for easily administered, fast-acting, effective on-demand options,” said “These data show the promise of sebetralstat as an effective oral on-demand option that can complement all major long-term prophylaxis treatments, including those acting through plasma kallikrein inhibition, like lanadelumab and berotralstat.”

    Paul Audhya, MD MBA, Chief Medical Officer of KalVista, said: “These data reinforce what we hear from patients and clinicians on an ongoing basis; long-term prophylaxis plays an essential role in HAE management, but it’s not the full story. Attacks still occur, and adherence remains a real-world challenge. Sebetralstat is designed to meet this need: a rapid, reliable oral treatment that empowers patients to act the moment symptoms begin, regardless of their background therapy.”

    (Source: KalVista)

  • 16 June, 2025

    New data on clinical development of deucrictibant shared at clinical conference in key European Congress

    A number of clinical trials of deucrictibant, a potential medicine to prevent and treat HAE, reported new data at the recent European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025.

    The pharmaceutical company Pharvaris shared the key data presentations that were made at EAACI:

    Prophylaxis

    • Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Results of the CHAPTER-1 Open-Label Extension Study
    • Long-Term Prophylactic Treatment with Oral Deucrictibant Improves Disease Control and Health-Related Quality of Life in Participants with Hereditary Angioedema in the CHAPTER-1 Open-Label Extension Study
    • CHAPTER-3 Phase 3 Trial Design: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks
    • Health-Related Quality of Life and Clinical Characteristics in People Living with Hereditary Angioedema Prescribed Long Term Prophylaxis Alone and On-Demand Treatment Alone

    On-demand

    • Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study
    • Safety and Efficacy of Oral Deucrictibant for Treatment of Upper Airway and Laryngeal Hereditary Angioedema Attacks: Results from the RAPIDe-2 Extension Study

    Expansion Beyond HAE

    • Clinical Validation of a Novel Kinin Biomarker Assay for Characterization of Bradykinin-Mediated Pathologies in U.S. Subjects with Hereditary Angioedema
    • Development of a Conceptual Model Supporting a Clinical Outcome Assessment Strategy for Acquired Angioedema due to C1 Inhibitor Deficiency

    Berndt Modig, Chief Executive Officer of Pharvaris, said: “Pharvaris embraced the opportunity to engage in scientific exchange with the HAE thought leader community during EAACI as we presented data supporting the differentiated profile of deucrictibant for the prophylactic and on-demand treatment of bradykinin-mediated angioedema attacks.

    “We shared data demonstrating the potential for deucrictibant to address the unmet needs of people living with bradykinin-mediated angioedema beyond HAE-1/2. Deucrictibant showed sustained attack reduction and improved quality of life measures in the randomized portion of the CHAPTER-1 study, which was maintained in the open-label extension study, as well as early-onset symptom relief and complete symptom resolution in a single dose in most attacks in our ongoing RAPIDe-2 on-demand long-term extension study. Finally, RAPIDe-3 is the first and only phase 3 on-demand study that will explore ‘end-of-progression’ as a new pre-specified endpoint, which is particularly meaningful for people living with HAE. Together with the outcomes from other study endpoints, we will be able to assess the full impact of deucrictibant on an HAE attack from start to end.”

    (Source: Pharvaris)

  • 16 June, 2025

    New treatment for HAE, called garadacimab, approved in USA for the prevention of attacks of hereditary angioedema (HAE)

    Garadacimab, a new HAE treatment to prevent HAE attacks, has been approved by the US Food and Drug Administration (FDA).

    The new medicine, also known as Andembry, is a once a month injection. In clinical trials it reduced HAE attacks by a median of more than 99 percent and a least squares mean of 89.2 percent, compared to placebo, according to information shared with HAEi by the pharmaceutical company CSL.

    CSL confirmed that garadacimab will be launched immediately. Garadacimab is now available in the US, Australia, United Kingdom, European Union, Japan, Switzerland and the United Arab Emirates.

    Bill Mezzanotte MD, Executive Vice President and Head of R&D at CSL, said: “Andembry, the first monoclonal antibody discovered and developed entirely by CSL, offers people living with this life-threatening condition long-term control over their disease along with a convenient administration method. Andembry underscores our long-standing and enduring commitment to better the lives of the patients we serve, including those suffering with HAE. I’d like to thank all the physicians, patients and my colleagues who contributed to this exciting milestone for HAE patients and CSL.”

    Anthony J. Castaldo, CEO and Chairman of the Board, US HAE Association and HAE International, said: “Andembry, a novel once-monthly subcutaneous treatment that inhibits factor XIIa, is a welcome addition to the HAE treatment landscape. People with HAE now have another choice for lessening the burden associated with this lifelong condition and realizing the community’s shared goal of experiencing life to the fullest.”

    (Source: CSL)

  • 26 June, 2025

    Rights to sell potential new medicine for HAE in Canada granted to Montreal-based company 

    The company which has developed sebetralstat, a potential new oral treatment for HAE, has granted Pendopharm the exclusive rights to manage the Canadian regulatory approval process and commercialization of the medicine.

    Ben Palleiko, CEO of KalVista, said: “We look forward to collaborating with Pendopharm, whose deep knowledge of the Canadian market and proven track record make them a strong partner as we work to bring sebetralstat to people living with HAE. This partnership supports our broader goal of making sebetralstat available globally, as the first and only oral on-demand treatment that has the potential to transform HAE care.”

    (Source: KalVista)

  • 27 June, 2025

    New company to take over handling of European business for berotralstat

    An Italian pharmaceutical company, called Neopharmed Gentili, have signed a deal with BioCryst to take over the entire European berotralstat (Orladeyo) business.

    BioCryst has confirmed that Neopharmed Gentili is acquiring its entire European organization, which will enable commercial continuity for people with HAE who use berotralstat to treat their condition.

    Jon Stonehouse, President and Chief Executive Officer of BioCryst, said: “This transaction is consistent with our strategy of making Orladeyo available to patients in Europe through the team we built.”

    Alessandro Del Bono, President and Chief Executive Officer of Neopharmed Gentili, said: “This transaction marks the beginning of a new path for Neopharmed Gentili, projecting the company onto the international stage and rare disease field, leveraging its deep Italian roots and welcoming a successful and experienced European team.”

    (Source: BioCryst)

  • 7 July, 2025

    First and only oral on-demand treatment for HAE approved by US FDA

    A new medicine for HAE, called Ekterly (sebeltralstat), has been approved by the regulatory authorities in the USA, and can begin to be prescribed to people with HAE immediately.

    Ben Palleiko, CEO of KalVista, said: “The FDA approval of Ekterly is a defining moment for people living with HAE. Ekterly enables people to treat attacks the moment symptoms begin, wherever they are. This approval affirms the strength of our science and deep commitment to the HAE community. I am profoundly grateful to the KalVista team for their dedication and perseverance, and to the patients and healthcare providers, as well as the HAEA and HAEi, for making this possible.”

    Anthony J. Castaldo, Chief Executive Officer of the US Hereditary Angioedema Association, said: “As the first orally administered on-demand therapy for HAE attacks, Ekterly provides patients and physicians with an important and welcome advance in HAE treatment options.”

    (Source: KalVista)

  • 7 July, 2025

    New data on navenibart, a potential HAE medicine currently being trialled, will be presented at the 2025 US HAEA Summit

    The pharmaceutical company developing navenibart have announced that they have had four posters accepted for presentation at the 2025 US Hereditary Angioedema Association National Summit (HAEA).

    The poster presentations will be:

    • ALPHA-ORBIT – a Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Navenibart in Participants with Hereditary Angioedema (HAE).
    • Long-Term Safety and Efficacy of Navenibart in Participants with Hereditary Angioedema (HAE): Initial Combined Results from ALPHA-STAR and ALPHA-SOLAR.
    • Recruitment Challenges for Rare Disease Clinical Trials: A Systematic Review.
    • Treatment with Navenibart (STAR-0215) Reduces Attack Severity and Use of Rescue Medication in Patients with Hereditary Angioedema (HAE): Interim Results from the ALPHA-STAR Trial.

    (Source: Astria)

  • 10 July, 2025

    Announcement of new data for key clinical trial of deucrictibant expected in late 2025

    The pharmaceutical company developing a potential new HAE medicine, called deucrictibant, has provided an update on when it will be able to share some new clinical trial data. The company, Pharvaris, expects this announcement will take place in the fourth quarter of 2025. Subject to the data being positive, the company expects to submit a New Drug Application to the US Food and Drug Administration (FDA) in the first half of 2026.

    Berndt Modig, Chief Executive Officer of Pharvaris, said: “The attack data in RAPIDe-3 have continued to accrue following the achievement of target enrollment in the study; we now estimate that our RAPIDe-3 topline data announcement will be in the fourth quarter of this year. Our phase 3 data may provide evidence of immediate-release deucrictibant’s potential to address the desire of people living with HAE for an on-demand therapy that combines efficacy—from rapid end of progression to fast and complete resolution—and a favorable safety profile, with the convenience of a single-capsule oral dose.”

    Peng Lu MD PhD, Chief Medical Officer of Pharvaris, added: “We aim to confirm the findings from our Phase 2 studies in a larger Phase 3 trial, RAPIDe-3. Importantly, this study is assessing the effects of deucrictibant for people with high unmet need beyond adults with HAE type 1 and 2, such as participants with HAE with normal C1 inhibitor and adolescents between 12 and 17 years and will be evaluating the effects of deucrictibant in treating laryngeal attacks. We want to thank the clinical trial participants, the investigators and their study site collaborators for their ongoing commitment to this important trial.”

    (Source: Pharvaris)

  • 15 July, 2025

    First and only oral on-demand treatment for HAE approved by regulatory authorities in the United Kingdom

    A new medicine for HAE, called Ekterly (sebeltralstat), has been approved by the regulatory authorities in the United Kingdom.

    After this approval, sebetralstat will continue to be available through the Early Access to Medicines Scheme (EAMS) from the Medicines and Health Regulatory Agency (MHRA) for the treatment of HAE attacks. This scheme enabled healthcare professionals to prescribe the treatment prior to marketing authorization. This situation will continue until KalVista receives a decision from the National Institute for Health and Care Excellence (NICE) for use of sebetralstat under the UK’s National Health Service (NHS). A decision is anticipated in the first half of 2026.

    Ben Palleiko, CEO of KalVista, said: “The approval of Ekterly in the United Kingdom builds on our recent FDA approval and advances our global commitment to bring this innovative treatment option to people living with HAE. This approval holds particular significance for KalVista as Ekterly was discovered in our Salisbury, UK labs — making it even more exciting that now we will be able to offer this therapy to people living with HAE in the UK. More broadly, this is another example of the incredible skills of our entire team in pursuing what we expect to be the fastest global launch of an HAE therapy ever.”

    Dr Sinisa Savic, Professor of Clinical Immunology at St James’s University Hospital Leeds and a sebetralstat investigator, said: “The MHRA approval of Ekterly brings us one step closer to having an oral on-demand treatment available to patients in the UK for the first time. I look forward to seeing the impact this new treatment option will have on the HAE community in the UK.”

    (Source: KalVista)

  • 29 July, 2025

    Positive opinion on sebetralstat from key regulatory committee in European Union

    A new medicine for HAE, called Ekterly (sebetralstat), has received a positive opinion from the European Union regulatory authorities, opening the way for it to receive a license in the EU later in 2025.

    This positive opinion, from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), recommends that sebetralstat receive marketing authorization. A final decision on this will be made by the European Commission by early October 2025.

    Ben Palleiko, CEO of KalVista, said: “This positive CHMP opinion is an important step forward for people living with HAE in Europe, where there remains a high need for effective, easy-to-administer on-demand treatments. Sebetralstat is expected to become the first and only oral on-demand treatment for HAE available in Europe, bringing forward a new treatment approach that enables adherence to guidelines and empowers people to treat attacks quickly, wherever they occur.”

    Dr Emel Aygören-Pürsün MD, Assistant Professor, Internal Medicine and Hemostaseology, Department for Children and Adolescents, University Hospital Frankfurt, said: “Access to on-demand treatments that offer easy self-administration and rapid symptom relief is critical for patients living with HAE. Until now, on-demand therapies for HAE attacks required parenteral administration via injections. The positive CHMP opinion for sebetralstat is an essential move toward a novel, long-awaited oral on-demand option that could help patients treat attacks early and independently, as advocated by guidelines, with the goal of improving outcomes and normalizing lives.”

    (Source: KalVista)

  • 4 August, 2025

    Updates provided on berotralstat, an HAE medicine currently being prescribed

    A series of updates on berotralstat (brand name: Orladeyo), which is currently being used by people with HAE in many countries around the world, were provided by the pharmaceutical company BioCryst. The key updates shared were:

    • New real-world data from over 350 patients with HAE with normal C1 inhibitor showed substantial reductions in attack rates with berotralstat, reinforcing its value for a historically underserved patient segment and providing strong evidence to close both treatment and reimbursement gaps.
    • The Prescription Drug User Fee Act (PDUFA) goal date for the company’s new drug application for berotralstat granules in children with HAE aged 2 to 11 is 12 December 2025. Berotralstat would be the first targeted oral prophylactic therapy for children with HAE.

    Jon Stonehouse, Chief Executive Officer of BioCryst, said: “In the fifth year since approval, Orladeyo revenue and demand have never been stronger, and this is driven by outstanding execution and increasing confidence in the product.”

    (Source: BioCryst)

  • 7 August, 2025

    Updates provided on lonzo-z (also known as NTLA-2002), a potential HAE medicine currently being trialed in patients

    A series of updates on lonzo-z, which is currently undergoing testing amongst HAE patients, were provided by the pharmaceutical company Intellia. The key updates shared were:

    • Recruitment ended earlier than expected during the second quarter, and the Company now expects to complete randomization in the global Phase 3 HAELO study during the third quarter of 2025.
    • Intellia presented three-year follow-up data from the Phase 1 portion of the ongoing Phase 1/2 study after receiving a single dose of lonvo-z. Results were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 on June 15 in Glasgow, United Kingdom. At the time of the 12 February 2025 data cutoff, all 10 patients were attack-free and treatment-free for a median of nearly two years. With up to three years of follow-up, a single dose of lonvo-z led to a mean reduction in monthly HAE attack rate of 98% over the study period, compared to the pre-treatment baseline. Across all three dose levels, lonvo-z was generally well tolerated and showed a safety profile consistent with earlier data presented.
    • Intellia expects to present additional data from the ongoing Phase 1/2 study in the second half of 2025.
    • The Company is on track to submit a Biologics License Application (BLA) in the second half of 2026

    John Leonard MD, Intellia President and Chief Executive Officer, said: “We are exceeding many of our internal expectations. The enthusiasm from both patients and physicians for Intellia’s late-stage programs has resulted in strong enrollment numbers that allow us to plan to accelerate completion of the Phase 3 HAELO study in HAE ahead of our original plans. We are full steam ahead in achieving our mission of getting one-time therapies to more patients.”

    (Source: Intellia)

  • 12 August, 2025

    Updates provided on deucrictibant, a potential HAE medicine currently being trialed in patients

    A series of updates on deucrictibant, which is currently undergoing testing amongst HAE patients, were provided by the pharmaceutical company Pharvaris. The key updates shared were:

    • Topline results for RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, expected in 4Q2025
    • Enrollment continues in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline results expected in 2H2026
    • Startup activities for CREAATE, a pivotal Phase 3 study of deucrictibant for the prophylactic and on-demand treatment of acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH) attacks, on track; study is expected to initiate by YE2025

    Berndt Modig, Chief Executive Officer of Pharvaris, said: “Halfway through 2025, an important executional year for the company, Pharvaris is making meaningful progress in our ambition to address unmet needs of people living with bradykinin-mediated angioedema. The readout of RAPIDe-3 topline results, which is estimated to be in the fourth quarter of this year, is anticipated to be an important inflection point for our stakeholders. CHAPTER-3 continues to progress with topline results expected in the second half of 2026, and we are on track to initiate CREAATE in 2025.”

    (Source: Pharvaris)

  • 12 August, 2025

    Updates provided on navenibart (also known as STAR-0215), a potential HAE medicine currently being trialed in patients

    A series of updates on navenibart, which is currently undergoing testing amongst HAE patients, were provided by the pharmaceutical company Astria. The key updates shared were:

    • Astria has exclusively licensed development and commercialization rights in Japan to Kaken Pharmaceutical for navenibart.
    • The navenibart Phase 3 program consists of the ALPHA-ORBIT Phase 3 trial and the ORBIT-EXPANSE long-term trial, which are designed to support registration globally. ALPHA-ORBIT is a randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of navenibart over a 6-month treatment period, with dosing arms every 3 months (Q3M) and every 6 months (Q6M). Enrollment is ongoing and top-line results are expected in early 2027. After completing ALPHA-ORBIT, eligible patients may continue into the open-label ORBIT-EXPANSE study, which includes 6 months of additional treatment followed by a patient-centric flexible dosing phase.
    • Positive initial results from the ongoing ALPHA-SOLAR long-term open-label trial of navenibart were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress. All 16 ALPHA-STAR target enrollment participants continued into ALPHA-SOLAR and the results are highly consistent with ALPHA-STAR – showing robust overall reduction in monthly attack rates (92% mean and 97% median) and a well-tolerated safety profile.

    Jill C Milne PhD, Chief Executive Officer at Astria Therapeutics, said: “Delivering on navenibart’s potential is our top priority, and enrollment in the global Phase 3 ALPHA-ORBIT trial is well underway with active sites across the US, UK, Canada, Hong Kong, and South Africa. We are encouraged by the strong enthusiasm from patients and physicians, including at the recent HAEA conference, where we had the opportunity to engage with the HAE community. We were also thrilled to announce a strategic partnership with Kaken. Their expertise supports our ongoing Phase 3 enrollment, and may ultimately help expand global patient access to navenibart.”

    (Source: Astria)

HAEi Around the World

Currently, there are HAE Member Organizations in 105 countries. You will find a great deal of vital information on the HAE representations around the globe at haei.org, and the world map will provide you with contact information for the Member Organizations, ACARE centers, hospitals, and physicians.

The information on haei.org is updated as soon as HAEi receives fresh data from the national Member Organizations.

Global Perspectives · Issue 2/2025 · August 2025

Magazine Staff: Henrik Balle Boysen, President; Deborah Corcoran, Director Research; Stuart Mayell, Editor in Chief, Global Perspectives; Rikke Sørensen, Manager, Communication, Design, and Graphics

Subscription: If you would like to subscribe to our magazine, please send an email to info@haei.org or register directly at haei.org

PDF version of the magazine is available on our website – click here to see PDFs and earlier editions of Global Perspectives.

*Google Translate powers the translations on the Global Perspectives website. Google Translate is constantly improving but is not perfect. Not all text may be translated accurately, and some text may not be translated at all. HAEi is not responsible for the quality of translations. The translation should not be considered exact and is an approximation of the English language content. HAEi does not accept any liability for any damage or issues that may result from using Google Translate.

Who we are

HAE International is a global non-profit network of member organizations dedicated to raising awareness of hereditary angioedema and improving the lives of people with HAE.

Contact us

HAE International (HAEi)
10560 Main Street, Ste PS40
Fairfax City, VA 22030
United States of America
info@haei.org

Operations

HAE International (HAEi)
Vejlevej 16, 1.
8700 Horsens
Denmark
info@haei.org